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ABSTRACT 
 
The Role of p53 in Normal Development and Teratogen-Induced Apoptosis and Birth 
Defects in Mouse Embryos. (December 2008) 
Hiromi Hosako, B.S., Texas State University – San Marcos 
Co-Chairs of Advisory Committee,  Dr. Philip E. Mirkes 
                                                                          Dr. Stephen H. Safe 
 
In the studies described in this dissertation, we investigated the roles of p53 in 
normal development, teratogen-induced apoptosis, and birth defects.  In the first study, 
the activation of p53 and its target genes, p21, NOXA, and PUMA, were examined 
during neural tube closure in mouse embryos exposed to hyperthermia (HS) or 4-
peroxycyclophosphamide (4CP), teratogens known to induce neural tube defects 
(NTDs).  In the second study, using p53-deficient mice, we examined the expression of 
mRNAs and microRNAs (miRNAs) during neural tube closure.  In the third study, the 
incidence of NTDs was investigated in p53- and p21-deficient mouse embryos exposed 
to HS.  Finally, we examined the induction of apoptosis in p53-deficient mouse embryos 
exposed to HS.   
HS and 4CP induced the activation of p53 by phosphorylation and accumulation 
of the protein, leading to an increase in p21 proteins and mRNAs.  Although HS and 
4CP also induced the expression of Noxa and Puma mRNAs, no significant increases in 
NOXA and PUMA proteins were observed, suggesting a possible role of transcription-
independent apoptosis.  In the second study, we showed that the expression of 388 genes 
and 5 miRNAs were significantly altered in p53 -/- compared to p53 +/+ embryos.  
Finally, we showed that 10% of p53 -/- pups exhibit exencephaly, spina bifida, and/or 
preaxial polydactyly, whereas no malformations were observed among p21 -/- offspring 
in the absence of HS.  HS resulted in an increased incidence of exencephaly in both p53 
and p21 null mice indicating that these two proteins act as teratogen suppressors.   Our 
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preliminary data additionally showed that a decreased level of apoptosis was observed in 
HS-treated embryos lacking a p53 allele, suggesting that too little apoptosis may be 
causally linked to NTDs observed in embryos exposed to HS.  Taken together, these 
studies suggest that precise control of apoptosis and cell cycle arrest pathways are 
critical for neural tube development and the prevention of teratogen-induced NTDs.  
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1. INTRODUCTION 
 
1.1.   EMBRYONIC DEVELOPMENT 
1.1.1.   Human and Mouse Embryonic Development 
Development of the human embryo and fetus is an amazing but extremely 
complex process at both the tissue and cellular levels.  The gestational period in humans 
is approximately 38 weeks (266 days), and development of a zygote begins at 
fertilization about 14 days after the onset of the last menstrual period.  After fertilization 
occurs, the zygote undergoes cleavage as it passes along the fallopian tube toward the 
uterus, which results in the formation of a blastocyst.  Implantation of the blastocyst 
occurs at the end of the 1st week, leading to a rapid proliferation and differentiation in 
the 2nd week.  Conversion of a bilaminar to a trilaminar embryonic disk, called 
gastrulation, begins in the 3rd week with the formation of the primitive streak.  The 
period of 3rd to 8th weeks of development is called embryonic (organogenesis) period, 
during which all of the main organ systems begin to develop.  During organogenesis 
embryos are most vulnerable to various chemical and physical agents (for further 
discussion, refer to section 1.2), and teratogen exposure during this period may cause 
major congenital malformations.  By the end of the 8th week, the embryo has a distinct 
human appearance.  The interval from the 9th to the 38th week is referred to as the fetal 
period, and rapid body growth and differentiation of tissues, organs, and systems take 
place during this period (Moore and Persaud, 2003).            
The development of the human embryo and fetus have been observed and 
described since 1416 BC by Aristotle and Hippocrates (Bard, 1994).   In the early 19th 
century, experimental embryology first started (National Research Council, 2000), and 
the importance of “inductions,” which refers to the ability of one group of cells to 
influence the fate of another, was first recognized in the 1920s by the transplantation 
experiments for neural induction by Spemann and Mangold (1924).  Although in the 
____________ 
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1970s the movements and interactions of tissues and cells were described as 
developmental mechanisms, the advanced techniques of biochemistry, molecular 
biology, cell biology, and genetics that were required to understand the molecular 
mechanisms of embryonic development such as cell-cell signaling and transcriptional 
regulation were not yet available (National Research Council, 2000).  In the past 20 
years, the field of embryology has advanced remarkably thanks to these modern 
technologies, and it is now known that the trillions of cells of an adult animal arise from 
a single-celled zygote and all of the cells retain the same genetic content.  Much of the 
early molecular work on the development of the embryo was conducted on non-
mammalian species because embryos were more accessible and simple (Harkness and 
Baird, 1997).  However, studies of embryonic cells from echinoderms (e.g., sea urchins),  
nematodes (C. elegans), insects (Drosophila), and amphibians (Xenopus) have led to a 
discovery that developmental decisions are made based on which chemical signals they 
receive from other cells (Wolpert, 1969).  Subsequently, the signaling pathways 
involved in developmental decisions were elucidated, and currently seventeen 
intercellular signaling pathways have been identified (Table 1.1) (National Research 
Council, 2000).  These pathways are repeatedly used at different times and places in the 
embryo, from various developmental stages and even in the various proliferating and 
renewing tissues of the adult.    
The advancement in molecular techniques made it possible to study mammalian 
development, especially mouse embryonic development at the cellular level.  There are 
four main reasons why we now pay the greatest attention to one particular species, the 
mouse, as the developmental system of choice (Bard, 1994).  First, the ability to 
manipulate pre-implantation embryos and to culture early postimplantation embryos is 
well established.  Second, the molecular and cellular biology techniques required for the 
study of development in mice are now readily available.  Third, mouse embryogenesis is 
the best studied in terms of normal and abnormal human development.  Finally, mouse 
genetics, together with the ability to make custom mutations through transgenic 
methods, facilitates the investigation of how mutations and specific genes not only play 
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a role in normal and abnormal mouse development but also by extension the etiology of 
human congenital defects.        
 
 
 
1.1.2.   Neural Tube Development 
Formation of the neural tube, called neurulation, is an important process of 
embryogenesis in vertebrates that leads to the development of the cell precursors of the 
brain and spinal cord to form the central nervous system (CNS).  Neurulation is an 
extremely complicated process that requires neural crest cell migration, neuroepithelial 
proliferation, differentiation, programmed cell death, contraction of apical cytoskeletal 
microfilaments, and flexing at dorsolateral bending points in the developing neural tube 
Table 1.1 
The Seventeen Intercellular Signaling Pathways*  
Period During Development                    Signaling Pathway Used                                                              
Early development   1. Wingless-Int pathway 
(before organogenesis and  2. Transforming Growth factor β (receptor  
cytodifferentiation) and later       serine and threonine kinase) pathway 
(during growth and tissue renewal) 3. Hedgehog pathway 
      4. Receptor tyrosine kinase (small G   
              proteins) pathway 
      5. Notch-Delta pathway 
      6. Cytokine receptor (cytoplasmic tyrosine  
               kinases) pathway (STAT pathway) 
  
Middle and late development  7. Interleukin-1-Toll nuclear factor-kappa B 
(during organogenesis and       pathway 
cytodifferentiation) and later  8. Nuclear hormone receptor pathway 
(during growth and tissue renewal) 9. Apoptosis pathway 
                                       10. Receptor phosphotyrosine phosphatase  
              pathway 
 
Larval and adult physiology             11. Receptor guanylate cyclase pathway 
(after cell types have differentiated)      12. Nitric oxide receptor pathway 
        13. G-protein coupled receptor (large G proteins)    
      pathway 
                                       14. Integrin pathway 
                                        15. Cadherin pathway 
                                        16. Gap junction pathway 
                                        17. Ligand-gated cation channel pathway 
*From National Research Council, (2000). 
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to form a tube from flat sheet of epithelial cells (Blom et al., 2006).  Neurulation occurs 
in two distinct phases in mammalian embryos: primary neurulation that generates the 
brain and most of the spinal cord to the caudal neuropore, followed by secondary 
neurulation that forms the rest of the spinal cord including most of the sacral and all the 
coccygeal regions (Copp et al., 2003; Detrait et al., 2005; Kibar et al., 2007).  
Primary neurulation occurs during the third and fourth weeks of development in 
humans (Detrait et al., 2005) while in mice the neural tube forms during days 8 to 10 of 
gestation (Harris and Juriloff, 1999).  During primary neurulation the dorsal midline 
ectoderm of the embryo first thickens and differentiates into the neuroepithelium to form 
the neural plate (Colas and Schoenwolf, 2001; Detrait et al., 2005).  The neural plate first 
appears at the cranial end of the embryo and differentiates towards the caudal direction.  
Formation of the neural plate is the result of neural induction, and early studies using 
Xenopus embryos have shown that neural induction is regulated by endogenous bone 
morphogenetic protein (BMP) antagonists, including Chordin (Sasai et al., 1994), 
Noggin (Lamb et al., 1993), and Follistatin (Hemmati-Brivanlou et al., 1994).  BMP 
antagonists induce neural induction since ectodermal cells are, by default, programmed 
to become neuroepithelium, not to become the ectoderm, and this default state is 
normally inhibited by BMPs expressed throughout the ectoderm (Kibar et al., 2007; 
Padmanabhan, 2006).  In mammals, however, the formation of the neural plate appears 
to be a more complex process, in which BMP inhibition by fibroblast growth factors 
(FGFs) and Wnt (Wingless/Int-1) signaling pathways are also required as an early step in 
neural induction (Bainter et al., 2001; Wilson and Edlund, 2001; Wilson et al., 2001).  
Recent studies, however, have shown that BMP inhibition is a relatively late step and 
neural induction involves additional signaling events that need to be identified (Linker 
and Stern, 2004). 
The neural plate then begins to move upward forming the neural fold.  The neural 
plate becomes narrower and longer to form an elongated structure.  This movement is 
called convergent extension, and it occurs by cell movements elongating mediolaterally 
and by polarized cellular extensions that allow cells to move directionally and to 
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intercalate in the midline.  This change in shape and movement results in convergence 
toward the midline and extension of the tissue along the anteroposterior axis (Kibar et 
al., 2007).  Convergent extension is known to be regulated by the non-canonical 
Wnt/frizzled pathways (Lawrence and Morel, 2003).   
The neural plate becomes more pronounced and elevated, eventually bending 
longitudinally along the midline to form neural folds.  By day 23 in human embryos and 
day 8.5 in mouse embryos, the folds rise up dorsally, approach each other and merge 
together, forming a neural tube open at both ends (Detrait et al., 2005; Kaufman, 1992).  
Formation of two hinge points is critical for the neural plate bending.  The median hinge 
point (MHP) overlies the notochord along the rostrocaudal axis, and the paired 
dorsolateral hinge points (DLHPs) are situated at the lateral sides of the neural folds.  
The MHP, induced by signals from the notochord, is the only bending point at the upper 
spinal level whereas in the lower spine and cranial region DLHP forms as well as the 
MHP (Kibar et al., 2007).  Studies with cultured mouse embryos have shown that sonic 
hedgehog (SHH) induced by the notochord inhibits DLHP formation at the upper spinal 
region (Ybot-Gonzalez et al., 2002).  Mechanisms of conversion of columnar cells of the 
neural tube into wedge-shaped cells, termed apical constriction, are not well understood, 
but two actin-related genes, p190RhoGap, a negative regulator of Rho GTPase involved 
in actin dynamics (Brouns et al., 2000) and Shroom, which is an actin-binding protein 
(Hildebrand and Soriano, 1999; Martin, 2004), have been shown to mediate this process.  
Fusion of the neural folds eventually occurs by the lateral folds coming into 
contact at the dorsal midline and adhering to each other.  The fusion results in the 
formation of epidermal ectoderm and neuroepithelial and mesenchymal cells of the 
neural crest (Copp et al., 2003) as well as the breakdown of cells at contact sites by 
apoptosis (Lawson et al., 1999).  The important role of apoptosis in fusion of neural 
folds has been shown in chick embryos in which caspase inhibitors block neural tube 
closure (Weil et al., 1997).  For further information about apoptosis, refer to section 1.3.   
The fusion of neural folds was originally described to be initiated at a single site, 
extending bidirectionally in a zipper-like fashion to the rostral and caudal neuropores 
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(Purves and Lichtman, 1985).  Currently, several models of neural fold fusion have been 
proposed based on experimental observations in mice and observation and graphic 
reconstruction of human embryos from the Kyoto and Carnegie Collections.  These 
studies suggest that three to five and two to five multiple sites of initiation of neural fold 
fusion exist in mice and humans, respectively (Detrait et al., 2005; Padmanabhan, 2006).  
The neural fold fusion has been extensively investigated in several species including 
chick, mouse, rat, hamster, rabbit, and pig.  These studies show that although a certain 
degree of homology is observed between species, there are significant differences 
between species and even strains, e.g., the number of initiation sites, direction of fusion 
progression, and sequence and onset of fusion points.  The closure site 2, which starts at 
the prosencephalon-mesencephalon junction, varies in position among different mouse 
strains, and the position of the site may be associated with the susceptibility of the 
strains to neural tube defects (Fleming and Copp, 2000).  These defects are further 
discussed in section 1.1.3.2.   
Secondary neurulation begins after completion of primary neurulation at the most 
caudal level, and the neural tube is formed in the tail but without neural folding (Copp et 
al., 2003; Kibar et al., 2007).  The tail bud consists of stem cells from the remnant of the 
primitive streak, and these cells undergo proliferation and condensation to form the 
secondary neural tube, eventually fusing with the neural tube formed by primary 
neurulation (Catala, 2002; Copp et al., 2003).  Secondary neurulation forms most of the 
sacral and all of the coccygeal regions.   
As the formation of the neural tube progresses, the differentiation of cells in the 
CNS also takes place.  Neurons, astrocytes, and oligodendrocytes of the CNS arise from 
proliferating multipotent progenitor cells called neural stem cells (NSC) (Unsicker and 
Krieglstein, 2006).  In the neural tube, NSC are found in the polarized neuroepithelium.  
This neuroepithelium is referred to as the ventricular zone, the layer facing the lumen of 
the neural tube. These neural progenitors first produce neurons with gliogenesis 
following neurogenesis.  Neurogenesis proceeds in a rostral-to-caudal direction from the 
hindbrain to the spinal cord and in a caudal-to-rostral direction from the midbrain to the 
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forebrain.  The production of neurons requires precise control of balance between 
proliferation, differentiation, and survival by the integration of environmental and 
intrinsic cues.  There are well understood cellular pathways involved in this complex 
process, e.g., Notch genes are expressed in the proliferative regions at specific stages of 
nervous system development.  The Wnt family members stimulate stem cell proliferation 
not only during brain development, but also during spinal cord neurogenesis.  The most 
prominent member of the family, Wnt1, is expressed along the entire antero-posterior 
axis of the neural tube in the dorsal midline, and in a belt-like fashion at the midbrain-
hindbrain boundary (Gavin et al., 1990).  Wnt7a is also expressed in the germinal layer 
of the embryonic mouse cortex with several frizzled receptors (Grove et al., 1998; Kim 
et al., 2001a).  Wnt7b is expressed in the cortical plate, particularly by deep layer 
neurons (Kim et al., 2001b; Rubenstein et al., 1999).  Other signaling molecules and 
pathways involved in the development of CNS include SHH pathway for dorso-ventral 
patterning, FGF pathway for early neurogenesis, axon growth, neuroprotection, and 
synaptic plasticity, transforming growth factors-α (TGFα), neuregulins, and epidermal 
growth factors (EGF) for regulating the proliferation of precursor populations in the 
CNS, BMP for dorso-ventral patterning, specifying regional patterning within the 
developing neural tube, and neuronal and glial differentiation, and finally, neurotrophins 
for neuronal maturation (Unsicker and Krieglstein, 2006).   Taken together, neural tube 
development in mammals requires the precise control by numerous cell signaling 
pathways.    
 
1.1.3.   Congenital Malformations 
1.1.3.1.   Overview of Congenital Malformations 
Currently, approximately 2-3% of all live-born babies, which translates into 
120,000 every year in the United States, are born with major developmental defects 
(Holmes, 1997).  Those malformations that are life threatening, require major surgery, 
and present a significant disability account for approximately 70% of neonatal deaths 
occurring within the first month of age and 22% of the deaths in infants before 15 
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months of age (Marden et al., 1964).  Unfortunately, the causes of more than 50% of the 
birth defects remain unknown (Table 1.2) (Jelinek, 2005; The Teratology Society, 2005).  
However, it is known that 23-25% of all birth defects are related to genetic causes and 4-
5% are attributable to an exposure to drugs and environmental chemicals. Combined 
with multifactorial causes resulting from the exposure of genetically predisposed 
individuals to environmental factors, chemicals and physical agents may contribute to a 
significant number of developmental malformations (National Research Council, 2000).  
These agents causing congenital malformations are further discussed in section 1.2.     
 
 
 
Congenital malformations were already recognized in ancient Assyrian and 
Babylonian times, and until medieval time superstitious people believed that congenital 
malformations were supernatural phenomena, i.e., symbols of the devil or miracles.  
From the late 18th to early 19th century, descriptive studies of congenital malformations 
predominated.  Beginning with the studies of Isidore Geoffroy Saint-Hilaire, who coined 
the term teratology, the etiology of congenital malformations shifted from theological 
and metaphysical explanations to purely natural causes (Jelinek, 2005; Schumacher, 
2004).  During the 20th century, the Teratology Society was formed to promote research 
Table 1.2 
The Causes of Birth Defects in Humans* 
Known genetic transmission                    20 % 
 
Chromosomal aberrations           3 – 5 % 
 
Drugs and environmental chemicals           4 – 5 % 
 
Infections                2 – 3 % 
 
                             Maternal metabolic imbalances                     1 - 2 % 
 
                             Combinations and interactions                        ~25 %? 
 
                             Unknown             65 - 70 % 
 
*Modified from The Teratology Society, (2005) and National Research Council, (2000). 
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that reveals the causes and improves the diagnosis and treatment of birth defects (The 
Teratology Society, 2005; Wilson and Warkany, 1985).  Since then, the powerful 
techniques of molecular biology and genetics have been applied to identify teratogens 
and to understand the biological processes leading to abnormal development and birth 
defects. Despite enormous efforts and the development of diagnostic tests such as DNA 
probes, ultrasound devices, and microarrays, the overall incidence of birth defects has 
not declined.  For more than 20 years, major developmental malformations have been 
the leading single cause of infant mortality in the United States (Petrini et al., 1997).  
The most common birth defects associated with infant death are heart defects (31.4%), 
respiratory defects (14.5%), nervous system defects (13.1%), multiple defects associated 
with chromosomal aberrations (13.4%), and musculoskeletal defects (7.2%).  The 
estimated lifetime cost for children born with spina bifida in California alone exceeds 
$58 million and for those born with a conotruncal heart defect medical costs exceed 
$287 million every year, posing enormous emotional and fiscal costs (Waitzman et al., 
1994).  Therefore, birth defects are a serious health concern that needs to be addressed in 
our population, and more research is still necessary if we are to understand and prevent 
congenital malformations. 
To understand and prevent congenital malformations, James Wilson set forth six 
principles of teratogenesis (Wilson, 1973).  First published in 1973, these principles of 
teratogenesis were based upon the available research in developmental biology and 
experimental teratology, principles that remain valid even today (Jelinek, 2005; Kalter, 
2003).  These principles are: 
1. Susceptibility to teratogenesis depends on the genotype of the conceptus and the 
manner in which it interacts with adverse environmental factors. 
2. Susceptibility to teratogenesis varies with the developmental stage at the time of 
exposure to an adverse influence. 
3. Teratogenic agents act in specific ways (mechanisms) on developing cells and 
tissues to initiate sequences of abnormal developmental events (pathogenesis). 
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4. The access of adverse environmental influences to developing tissues depends on 
the nature of the influences (agent). 
5. The four manifestation of deviant development are death, malformation, growth 
retardation, and functional deficit. 
6. Manifestations of deviant development increase in frequency and degree as 
dosage increases, from the no-effect to the totally lethal level. 
Several mechanisms of congenital malformations were proposed; mutation, 
chromosomal nondisjunction, mitotic interference, altered nucleic acid functions, lack of 
substrates or precursors, lack of energy sources, enzyme inhibition, altered membrane 
characteristics, and osmolar imbalance (Wilson, 1973).  Recently, molecular 
mechanisms of teratogenesis, for example, free radicals, apoptosis, and inhibition of 
histone deacetylase have been proposed, and these mechanisms are discussed in section  
1.2.   
 
1.1.3.2.   Neural Tube Defects 
Neural tube defects (NTDs) are one of the most common congenital 
malformations in humans with the prevalence of approximately 1-2 in 1000 live births, 
and their incidence varies among different populations and geographic locations (Copp 
et al., 2003).  NTDs occur very early during pregnancy, and are caused by failure of the 
neural tube closure during embryogenesis at any level of the rostrocaudal axis.  The most 
common NTDs include anencephaly (a severe form of exencephaly) and spina bifida 
resulting from the failure of fusion in the cranial and spinal region of the neural tube, 
respectively.  Infants with anencephaly are stillborn or die shortly after birth, whereas 
infants with spina bifida can survive but often with severe and life-long physical and 
developmental disabilities (Botto et al., 1999).  Various types of spina bifida exist 
depending on the position of the spinal cord, and condition of vertebra and skin, e.g., 
spina bifida occulta, spina bifida with meningocele, meningomyelocele, or myeloschisis 
(Moore and Persaud, 2003; Rossi et al., 2004).  Most of these NTDs are due to the 
failure of primary neurulation, although spina bifida occulta results from the failure of 
secondary neurulation (Copp et al., 2003). Another rare form of NTD is 
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craniorachischisis, with a prevalence of approximately 1 in 100,000 births, that results 
from failure of neural tube closure over the entire body axis.  Iniencephaly presents with 
occipital bone defects, partial or total absence of cervicothoracal vertebrae, and fetal 
retroflexion (Botto et al., 1999; Moore et al., 1997; Tugrul et al., 2007).   
Studies suggest that genetic factors heavily contribute to the etiology of NTDs.  
The genetic component to NTDs include chromosomal abnormalities (such as trisomy 
13, 18, and 21), genetic syndromes (e.g. Meckel syndrome, Fraser syndrome, Gruber 
syndrome, Waardenburg syndrome, cerebrocostomandibular syndrome, and anal 
stenosis), ethnic and racial differences in incidence rates, increased risk for a second 
affected child for couples with one affected infant (3 – 5 fold) and for siblings of 
affected individuals compared to the general population (10 fold), and the occurrence of 
familial settings or distributions that do not follow mendelian inheritance (Chen, 2007; 
Kibar et al., 2007; Padmanabhan, 2006).  A recent study indicated that genetic factors 
for NTDs may be transmitted preferentially from the mother’s side of the family (Byrne 
and Carolan, 2006).  To date, however, no single gene has been implicated as a direct 
cause of NTDs in humans (Harris, 2001). 
A large number of experimental and epidemiological studies indicate that the 
etiology of NTDs also involves environmental factors. Geographic, epidemic, 
socioeconomic, and seasonal variations in the incidence of birth defects have implicated 
an important role for environmental factors in the etiology of NTDs (Frey and Hauser, 
2003; Mitchell, 2005).  In addition, these variations in frequency might point to possible 
gene-environment interactions at the time of neural tube closure (Padmanabhan, 2006).  
Animal and epidemiological studies on NTDs provide some evidence that the following 
agents are possible risk factors of NTDs in humans: physical agents (e.g. x-irradiation 
and hyperthermia), drugs (e.g. thalidomide, folate antagonists, androgenic hormones, 
and antiepileptics), substance abuse (e.g. alcohol), chemical agents (e.g. organic 
mercury, lead), maternal infections (e.g. rubella, cytomegalovirus, toxoplasmo gondii, 
syphilis), and maternal metabolic conditions (e.g. phenylketonuria, diabetes mellitus, 
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endemic cretinism) (Padmanabhan, 2006). Further discussion about the role of 
environmental factors in the etiology of NTDs is also found in section 1.2.2. 
The pathogenesis of NTDs is believed to involve inhibition of cellular 
proliferation, disturbance in the shaping of the developing neuroectoderm, or negative 
changes in vascular development supporting these cells (Bennett and Finnell, 1998).   
Currently, more than 190 mouse mutant models for NTDs have been utilized to study the 
mechanisms of NTDs (Harris and Juriloff, 2007).  Studies using these mutants show that 
there are probably different mechanisms specific to each type of NTD, as well as a few 
common mechanisms among particular types of NTDs (Harris and Juriloff, 1999).  In 
the curly tale (ct) model, in which spina bifida occurs in 15-20% of embryos (Embury et 
al., 1979), the defect appears to be in the adjacent tissue ventral to the posterior 
neuropore and not in the neural tube folds themselves.  In Cart1, Tcfap2a (Ap2), and 
Apob mutants, the neural tube fails to elevate because of abnormal and excessive cell 
death (Harris and Juriloff, 1999).  Defective lamina in surface ectoderm and broad 
floorplate and enlarged notochord also lead to the failure of neural tube closure in 
Lama5 and looptail (Lp) mutants, respectively (Greene et al., 1998; Hackett et al., 1997).  
The location and presence of the initiation site for neural tube closure also appear to be 
the key factors for the certain types of NTDs.  Mouse strains with a shift of initiation site 
2 towards the rostral direction have a greater predisposition to NTDs, and the 
exencephaly prone strain, SELH/Bc, even lacks the site (Fleming and Copp, 2000).  
Strain differences in the susceptibility to NTDs are also found following an exposure to 
certain agents (Finnell et al., 1986, 1988).   At the molecular level, mechanisms 
proposed include the failure of regulation of the arrangement of actin molecules, the 
signaling pathway that involves p300 for the regulation of apoptosis, and folic acid 
metabolism (Harris and Juriloff, 1999).   
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1.1.3.3.   Prevention of Neural Tube Defects 
It has been known for more than 20 years that maternal folic acid 
supplementation prior to and during early pregnancy can reduce the occurrence and 
recurrence of NTDs by as much as 70% (Czeizel and Dudas, 1992; Finnell et al., 2004; 
Smithells et al., 1980; Wald and Gilbertson, 1995).  Recent data also suggested the 
protective effects of folic acid for other congenital malformations such as conotruncal 
heart defects and craniofacial malformations (Berry et al., 1999; Czeizel and Dudas, 
1992; Wald et al., 2001).  The protective effect in the occurrence of NTDs was observed 
with 4 mg or 0.8 mg of folic acid supplementation per day in the largest trials, leading to 
the recommendation that all women who could become pregnant should receive 0.4 mg 
of folic acid per day (Czeizel and Dudas, 1992; Greene and Copp, 2005).  In the United 
States and subsequently other countries, governments now set health policies that 
mandate fortification of staple foods.  The effectiveness of folic acid fortification has 
already been shown with a significant reduction (15-50%) in the prevalence of NTDs in 
the United States, Canada, and Western Australia (Bower et al., 2002; Honein et al., 
2001; Persad et al., 2002).   
To understand the molecular mechanism of this protective effect of maternal 
folic acid supplementation, folate uptake, the folate cycles, and the closely-related 
homocysteine (Hcy) metabolism have been investigated (Fig. 1.1) (van der Linden et al., 
2006).  
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Figure 1.1. Simplified folate pathway and homocysteine metabolism. GAR, glycinamide 
ribonucleotide; FGAR, formyl glycinamide ribonucleotide; AICAR, 5-aminoimidazole-4-
carboxamide ribonucleotide; FAICAR, formyl 5-aminoimidazole-4-carboxamide ribonucleotide; 
THF, tetrahydrofolate; DHF, dihydrofolate; DHFR, dihydrofolate reductase; MTHFD, 
methylenetetrahydrofolate dehydrogenase; TS, thymidylate synthase; SHMT, serine 
hydroxymethyltransferase; MTHFR, methylenetetrahydrofolate reductase: MTR, methionine 
synthase; MTRR, methionine synthase reductase; BHMT, betaine-homocysteine 
methyltransferase; CBS, cystathionine β-synthase; RFC, reduced folate carrier; FR, folate 
receptor, AdoMet, S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; B6, pyridoxal 5’-
phosphate; B12, cobalamin; B2, riboflavin. Adapted from van der Linden et al., (2006). 
 
 
Mutations and polymorphisms in genes encoding proteins directly involved in 
folic acid uptake and metabolism were screened, and the causal relationship with the risk 
of NTDs was analyzed.  These genes include folate receptor alpha (FBα), reduced folate 
carrier (RFC), 5, 10-methylene-tetrahydrofolate reductase (MTHFR), cystathionine B-
synthase (CBS), methionine synthase (MS), methionine synthase reductase (MTR), and 
methylenetetrahydrofolate dehydrogenase (MTHFD) (Barber et al., 1998, 2000; Botto 
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and Yang, 2000; Brody et al., 1999; De Marco et al., 2000; Finnell et al., 1998; Hol et 
al., 1998; Lucock et al., 1997; Ou et al., 1996; Shields et al., 1999; van der Put et al., 
1995, 1997; Wilson et al., 1999).  One of the few polymorphisms that have been 
identified to be possibly related causally to the NTDs is the MTHFR polymorphism.  
One of the common polymorphisms that occurs is the change at nucleotide C677T, 
which results in a single amino acid substitution of alanine to valine, and individuals 
who are homozygous for this gene have 50 – 60% lower enzyme activity at high 
temperatures as it is a thermolabile form of the wild-type enzyme.  These individuals 
have slightly elevated homocysteine concentrations if their folic acid intake is low.  
Published studies have shown that infants who are homozygous for the C677T variant 
have a two to seven fold increased risk for NTDs (Botto and Yang, 2000; van der Put et 
al., 1995).  However, not all of the epidemiological studies found a positive association 
between this allele and an increased risk for NTDs.   Nevertheless, these studies have 
provided strong evidence that gene-nutrient interactions are significant risk factors for 
congenital malformations.   
Studies using mouse mutant models also suggest that folate metabolism is 
associated with the risk of NTDs.  Mouse models with disrupted folate transport, folic 
acid-binding protein 1 (Folbp1) and reduced folate carrier 1 (RFC1) knockouts, have 
NTDs.  However, mutant models for MTHFR, CBS, and MTR showed no NTD 
phenotype (Chen et al., 2001; Swanson et al., 2001; Watanabe et al., 1995).          
The protective effect of folic acid for NTDs has also been shown in animal 
studies.  Mouse mutants with NTDs including Cart1, splotch, and Cited2 showed 
reduced incidence of NTDs after folic acid supplementation by approximately 60%, 
65%, and 84%, respectively (Barbera et al., 2002; Fleming and Copp, 1998; Zhao et al., 
1996).  In addition to these NTDs that arise from gene mutations, it has been shown that 
the risk of NTDs induced by teratogenic agents can be also reduced by folic acid 
supplementation.  These agents include valproic acid, hyperthermia and fumonisin 
(Greene and Copp, 2005; Marasas et al., 2004; Padmanabhan and Shafiullah, 2003; 
Sadler et al., 2002; Shin and Shiota, 1999; Shiota, 1988).  The protective effect for 
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NTDs has also been shown for inositol, thymidine, arachidonic acid, methionine, and 
panthothenic acid (Greene and Copp, 2005).  
 
1.1.3.4.   Other Congenital Malformations 
 Cardiovascular defects are the most common defects above all other 
malformations affecting 1-2% of newborns, and congenital heart defects (CHDs) 
account for 25% of  all congenital malformations and are the leading cause of death in 
infants under one year of age (Nemer, 2008).  Limb defects are one of the most common 
and visible malformations.  They are therefore the most frequently reported phenotypic 
effects induced by toxicants (Holmes, 2002).  Limb malformations are of maltifactorial 
origin, and known environmental factors that increase the risk of limb defects include 
thalidomide, warfarin, phenytoin, and valproic acid.   
 Although not outwardly visible congenital defects, neurological disorders and 
associated behavioral alterations are now known to be caused by genetic factors and 
neurodevelopmental toxicants.   A variety of environmental chemicals and drugs, known 
to induce NTDs, are also recognized as neurotoxicants that cause neurodevelopmental 
problems.  These agents include alcohol, retinoic acids, antiepileptic drugs, methyl 
mercury, cadmium, lead, pesticides, and nicotine (Slikker and Chang, 1998).  Animal 
studies have been performed to understand diagnostic behaviors such as deficits in social 
interaction, autism, schizophrenia, and obsessive-compulsive disorder (Ridley, 1994).  
Deficits in social interaction are seen in animals exposed to lead, methylmercury, and 
maternal deprivation (Burbacher et al., 1990; Laughlin et al., 1991; Seay and Harlow, 
1965).  Together, the mechanisms of such neurological disorders may be closely related 
to the mechanisms of NTDs.   
 
 
1.2.   TERATOGENS 
1.2.1.   Overview of Teratogens 
 The term teratogen refers to any physical agent, chemical, drug, infectious 
disease, environmental agent, or maternal condition that produces permanent alterations 
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in morphology or function of the offspring during prenatal life (Shepard, 1995).   There 
are 65,000 chemicals in the general environment with hundreds or thousands of new 
chemicals being added every year (Schardein, 1993).  Of these, approximately 3,000 
have been tested in animals, 1,200 of which cause birth defects in animals, and only 40 
of which are known to be teratogenic to humans (Table 1.3) (Shepard, 1995).   Known 
teratogens account for roughly 5-10% of birth defects (Brent and Beckman, 1990; 
National Research Council, 2000).   
 
1.2.1.1.   Thalidomide 
From an historical perspective, the concept that chemical or physical agents 
could cause birth defects in humans is a relatively recent event.  The first human 
teratogen, rubella (German measles), was discovered by an Australian doctor Gregg in 
1941 (Schumacher, 2004).  Further teratological research was conducted on ionizing 
irradiation after atomic bombs were dropped on Hiroshima and Nagasaki, Japan, 
exposing more than 1,500 pregnant women to radiation (Wood et al., 1967a, 1967b, 
1967c).  These studies provided evidence that the placental barrier between mother and 
fetus does not fully protect the fetus from teratogens.    
Teratological research received significant attention from the general public after 
the thalidomide disaster (1959 – 1962).  This disaster led to the establishment of the 
Teratology Society and fostered an upsurge in teratological research as well as the 
establishment of strict safety testing guidelines during pregnancy (Bosch et al., 2008).   
Thalidomide, 1,3-dioxo-2-[2’,6’-dioxopiperidin-3’-yl]-isoindol, is a sedative, hypnotic, 
and anti-inflammatory medication that was developed by a German pharmaceutical 
company and was sold from 1957 to 1961 in almost 50 countries under at least 40 
different names, e.g., Distaval, Kevadon, Talimol, Nibrol, Sedimide, Quietoplex, 
Contergan, Neurosedyn, and Softenon (Bosch et al., 2008; Shepard, 1995).  Thalidomide 
was prescribed to pregnant women to avoid morning sickness and to help them sleep.   
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Unfortunately, consumption of thalidomide early in pregnancy caused the births 
of nearly 10,000 newborns with a severe limb malformation, phocomelia, and other 
associated defects including defects in external ears and facial hemangioma.  After this 
tragedy, the United States congress enacted laws in 1962, requiring tests for safety 
during pregnancy before any drug could be approved for use in humans, and, in addition, 
the FDA published guidelines for teratogenic testing of pharmaceuticals in 1966 (Bosch 
et al., 2008; Schumacher, 2004).   In addition, a pregnancy labeling system was put in 
place by FDA (FDA, 1979), a system that is currently being updated on the basis of 
information available since 1979 (Public Affairs Committee of the Teratology Society, 
2007).   Published studies later have suggested that the S-enantiomer of thalidomide was 
the main cause of the teratogenic effects (Blaschke et al., 1979), and thalidomide was not 
Table 1.3 
List of Teratogenic Agents in Humans* 
Radiation     Drugs and Environmental Chemicals 
 Atomic weapons     Aminopterin and methylaminopterin 
 Radioiodine      Androgenic hormones 
 Therapeutic      Busulfan 
Infections       Captopril (renal failure) 
 Cytomegalovirus (CMV)     Chlorobiphenyls 
 Herpes virus hominisis? I and II    Cocaine 
 Parvovirus B-19 (Erythema infectiosum)   Coumarin anticoagulants 
 Rubella virus      Cyclophosphamide 
 Syphilis       Diethylstilbestrol 
 Toxoplasmosis      Diphenylhydantoin 
 Varicella virus      Etretinate 
 Venezuelan equine encephalitis virus    Iodides and goiter   
Maternal Metabolic Imbalance     Lithium 
 Alcoholism      Mercury, organic 
 Chronic Villus Sampling (before day 60)   Methimazole and scalp defects 
 Cretinism, endemic     Methylene blue via intraamniotic  
Diabetes             injection 
 Folic acid deficiency (following gastric  Penicillamine 
     by-pass surgery)     13-cis-Retinoic acid (Isotretinoin and   
 Hyperthermia           Accutane) 
 Phenylketonurea     Tetracyclines  
 Rheumatic disease and Sjogren’s syndrome and Thalidomide 
    congenital heart block    Toluene abuse 
           Virilizing tumors     Trimethadione 
        Valproic acid 
*Modified from Shepard, (1995). 
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prescribed and sold for decades.  Nevertheless, this painful experience with thalidomide 
has led us to understand the vulnerability of unborn human life and established 
teratology as an important component of medicine and toxicology (Schumacher, 2004).  
More recently, the effectiveness of thalidomide against erythema nodusum leprosum as 
well as other diseases, including cancers and inflammatory diseases, e.g., multiple 
myeloma, has led the FDA to approve the reintroduction of thalidomide in 2006.  To 
prevent usage by pregnant women, this approval came with strict regulations and a 
requirement for extensive patient education (Bosch et al., 2008; Richardson et al., 2007). 
 
1.2.1.2.   Developmental Toxicity Testing 
 Currently, several testing methods are used to screen chemicals and other agents 
for teratogenic effects.  In vivo animal techniques have been used for developmental 
toxicity testing according to international guidelines, and they require pregnant animals 
such as mice, rats, and rabbits to assess toxic effects to the mother and offspring 
(Piersma, 2004). In this evaluation method, physiological effects including the 
morphology and function of the placenta, which is responsible for the exchange of 
metabolic and gaseous products between the mother and offspring, need to be 
considered.  Four segments of the prenatal development are tested using in vivo 
methods; preimplantation, organogenesis, fetal development, and lactation period 
(Schumacher, 2004).  Although these tests, along with human epidemiological studies 
and case reports, have been used by regulatory agencies (U.S. EPA guidelines on 
prenatal developmental toxicity testing in 1997, and risk assessment in development, 
reproduction, and neurotoxicology in 1991, 1996, and 1998, respectively) to characterize 
the potential human health risk in the area of developmental and reproductive toxicity, 
these approaches to assess human risk are limited because they are time consuming, 
expensive, and require large number of live animals (Kimmel, 1998; Webster et al., 
1997).           
 Alternative methods to in vivo testing have been developed since the early 1980s, 
and one of the methods is in vitro whole embryo culture system (WEC).  This system, 
which uses culture bottles to grow embryos in a serum-containing medium under a 
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steady oxygen level, was developed by New (New, 1978, 1990). This method has 
several advantages compared to in vivo testing (Webster et al., 1997).  Malformations 
resulting from WEC are directly related to the serum concentration of the agent tested 
and can be compared to the serum concentration in the human.  This comparison is not 
possible in vivo testing because of the possible pharmacokinetic differences between 
humans and experimental animals.  In vivo testing is also limited by the possibility that 
metabolites produced in humans and experimental animals may be different.  This 
problem can be bypassed in WEC by adding the metabolite directly.  The only major 
disadvantage in WEC, however, is that the types of malformations that can be induced 
are limited.  This may produce false-negative results for the compounds that exert their 
teratological effects in very early or late gestation, the period of embryogenesis that can 
not be tested in the culture system.  In addition to WEC, organ culture systems using 
parts of the embryonic body such as mandible, anlagen of extremities, endocrine organs 
or tooth buds, have also been used to screen teratogenic compounds (Schumacher, 
2004).   
 Some of the more recently developed in vitro approaches include micromass 
(MM) cultures of cells derived from dissociated embryos and the embryonic stem cell 
test (EST) (Faustman, 1988; Spielmann, 1997).  The MM technique uses primary cells 
from mammalian embryos, and the best documented examples include limb bud and 
brain micromass (Flint and Orton, 1984).  The EST approach has the advantage of using 
established cell lines that resemble early embryos without the necessity to sacrifice 
pregnant animals and embryos (Rohwedel et al., 2001; Scholz et al., 1999).  Alternative 
methods like WEC, MM, and EST have been used in the drug and chemical industry for 
screening new chemicals that are structurally related to known embryotoxic chemicals 
(Scholz et al., 1999), and validation of these methods for developmental toxicity testing 
have been conducted, including the study carried out by European Centre for the 
Validation of Alternative Methods (ECVAM) in 2002 (Genschow et al., 2002; Piersma 
et al., 2004).  These techniques, especially EST, therefore, have a great potential to meet 
a strong demand for alternative in vitro methods to screen a large number of chemicals 
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for their possible embryotoxicity (Festag et al., 2007).  However, it should be noted that 
these methods do not represent replacements for current animal tests for reproductive 
toxicity as a whole, although they could provide suitable means for reducing the use of 
animals in the context of testing strategies.     
 Although these advanced testing methods, including in vivo and various in vitro 
techniques, have been routinely used to screen chemicals and other agents for 
teratogenic effects, human epidemiologic surveillance is and will be our most powerful 
method to discover human teratogens and to identify the environmental causes of human 
birth defects (Brent, 2004).  The National Birth Defects Prevention Study (NBDPS) 
initiated by the Centers for Disease Control and Prevention (CDC) in 1997 covers an 
annual birth population of 482,000 and includes cases identified from birth defect 
surveillance registries in eight states (Yoon et al., 2001).  This study, assisted by 
clinicians and physicians as well as epidemiologists, abstractors, coordinators, and data 
managers (Lin et al., 2006), is designed to identify genetic and environmental factors 
important in the etiology of birth defects (Yoon et al., 2001).   However, epidemiologic 
studies also have some disadvantages, e.g., the occurrence of individual malformations is 
relatively rare, the fetus is exposed to an array of unknown genetic and environmental 
factors, the molecular mechanisms that cause most birth defects are unknown, and the 
defects identified at birth represent only the birth prevalence, not the true incidence of 
the condition, suggesting that these studies need to be examined carefully with the 
existing experimental data (Yoon et al., 2001). Together, the establishment of 
developmental toxicity testing as well as the well-thought experimental design is very 
important for the identification of teratogens.     
 
1.2.2.   Teratogens That Affect Central Nervous System 
1.2.2.1.   Hyperthermia 
 Hyperthermia (HS) refers to a body temperature that is above the upper limit of 
the normal range for the species. It was the first teratogen in animals that was 
subsequently proven to be teratogenic in humans (Edwards, 2006; Graham et al., 1998).  
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The normal body temperature range varies by species, e.g., the average temperature is 37 
ºC for humans (oral temperature), 38.3 ºC for mice (Shiota, 1988), 39 ºC for sheep and 
pigs, 39.5 ºC for goats (Blood and Radostits, 1989), and 39.5 ºC for guinea pigs 
(Edwards, 1969).  Therefore, the effects of hyperthermia can be only assessed by the 
elevation of body temperature above the normal body temperature of the species.    
Hyperthermia in humans can be caused by fever related to viral or bacterial 
illnesses, extreme exercise, saunas, hot tubs, heated beds, and electric blankets (Moretti 
et al., 2005).  Hyperthermia exposure during pregnancy can result in embryonic death, 
abortion, growth retardation, and various types of malformations, including NTDs 
(Edwards, 2006).   Although the most common outcomes in humans are usually prenatal 
losses due to an uncontrolled hyperthermia exposure such as a febrile illness, the 
development of the CNS is known to be particularly sensitive, and published studies 
have shown that maternal hyperthermia can account for 10-14% of NTD cases (Edwards 
et al., 2003; Graham et al., 1998; Kline et al., 1985; Shiota, 1982).  Epidemiological 
studies of children with maternal fevers have shown that a 2 ºC elevation for at least 24 
hr can result in a range of malformations, and most malformations observed in humans 
have been confirmed in experimental animals such as guinea pigs, mice, rats, rabbits, 
sheep, and monkeys (Edwards, 1986; Edwards et al., 2003; Finnell et al., 1992).   These 
defects include NTDs, microphthalmia, cataract, abdominal wall defects, heart defects, 
microcephaly, mental retardation, talipes, facial limb defects, midface hypoplasia, cleft 
lip and palate, hypodactyly, renal defects, Möbius syndrome, and arthrogryposis 
(Edwards, 2006).   
It has been questioned whether these defects are caused by metabolic changes in 
the mother due to the infection and fever and not by the direct action of elevated 
temperature.  This was mostly solved by studies using mouse WEC, showing the 
association of temperature with the defects observed (Cockroft and New, 1975, 1978; 
Kimmel et al., 1993; Mirkes, 1985, 1987; Walsh et al., 1987).    
Since the outbreak of abortions and congenital malformations found in guinea 
pigs in 1965 by Marshall J. Edwards (Edwards et al., 1995), studies using experimental 
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animals and cells have been conducted to understand the effects of hyperthermia in 
humans and animals, to investigate the pathogenic effects of hyperthermia and 
mechanisms of congenital malformations such as NTDs, and to identify other agents that 
might interact with hyperthermia. In earlier studies, thresholds and dose-response 
relationships for the induction of congenital malformations have been investigated.  In 
rats a 2.5 ºC elevation for 1 hr during early neural tube closure induced an increased 
incidence of cranio-facial defects, and an elevated temperature of 2-2.5 ºC for 1 hr 
during early neurogenesis in guinea pigs resulted in an increased incidence of 
microencephaly (Lary et al., 1983, 1986; Wanner and Edwards, 1983).  These studies 
show that in general, thresholds and dose-response relationship depend on the stage of 
development at which exposure occurs and vary between species and even between 
different strains of the same species (Edwards et al., 2003).  Finnell, et al. (1986) showed 
that 44.3% of fetuses of SWV mice exposed to hyperthermia for 10 min at 43 ºC 
exhibited exencephaly whereas less than 14% of fetuses from LM/Bc, SWR/J, 
C57BL/6J, and DBA/2J strains of mice were affected.   The sensitivity of SWV strain 
was lost in the offspring from crosses between the SWV and C57BL/6J strain.   
Different sensitivity among strains has been also reported for teratogens such as valproic 
acid (Finnell et al., 1988; Naruse et al., 1988), cadmium (Hovland et al., 1999), 2-ethyl 
hexanoate (Collins et al., 1992), 4-propyl-4-pentenoic acid (Finnell et al., 1988), and 
carbon dioxide (Collins et al., 1992).  
 Several possible mechanisms of hyperthermia have been studied, and these 
include disruption of the cellular processes essential for organogenesis such as cell 
proliferation, migration, differentiation, apoptosis, and damage to the embryonic 
vascular system (Edwards et al., 2003).  Of these, the best described pathogenic effects 
and mechanisms is cell death (apoptosis).  Further discussion about cell death is found in 
section 1.3.  Edwards was the first investigator to observe cell death in day 21 guinea-
pigs exposed to hyperthermia at 42 ºC for 1 hr, with up to 86% of mitotic cells showing 
damage in the form of nuclear clumping (Edwards et al., 1974).  Cell death and 
inhibition of mitotic activity were also observed in other animals (Shiota, 1988).  
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Subsequently, it was later shown that this hyperthermia-induced cell death occurs by a 
process termed apoptosis (Mirkes et al., 1997).  In addition, the increased resistance to 
hyperthermia-induced apoptosis by the induction of thermotolerance was also observed 
in rats (Mirkes et al., 1997).  This thermotolerance was achieved by exposing rat 
embryos to hyperthermia at 42 ºC for 15 min and then 1 hr later exposing them to 43 ºC 
for 15 min.  Furthermore, the acquisition of thermotolerance showed a correlation with 
the induction and nuclear translocation of a heat shock protein, Hsp72 (Thayer and 
Mirkes, 1997).  The induction of another heat shock protein, Hsp27, was also observed 
in embryos exposed to hyperthermia, and the heart of the exposed embryos, where 
Hsp27 is predominantly expressed, showed resistance to the cytotoxic effects of 
hyperthermia (Mirkes et al., 1996).  The apoptotic pathway observed in embryos 
exposed to hyperthermia was further examined at the molecular level, and the 
observation of DNA fragmentation, apoptotic bodies (Mirkes et al., 1997), cytochrome c 
release (Mirkes and Little, 2000), activation of caspase-3 (Umpierre et al., 2001) and 
caspase-9 (Little and Mirkes, 2002) have identified the mitochondrial apoptotic pathway 
(intrinsic pathway) as the main cell death pathway observed (detailed discussion found 
in section 1.3.4).  The upstream events of the mitochondrial apoptotic pathway induced 
by hyperthermia have been also examined, although it is still not well understood.  
Global gene analysis using microarrays have identified three p53 target genes that were 
upregulated by the treatment of hyperthermia, suggesting that p53 might play a role in 
the induction of apoptosis (Mikheeva et al., 2004).    
 Animal studies also revealed that some agents interact positively or negatively 
with hyperthermia to increase or decrease the incidence and severity of malformations.   
Agents that increase the incidence of malformations experimentally include alcohol 
(Graham and Ferm, 1985; Shiota, 1988), vitamin A (Ferm and Ferm, 1979), arsenic 
(Ferm and Kilham, 1977), lead (Edwards and Beatson, 1984), toxemia (Hilbelink et al., 
1986), and ultrasound (Angles et al., 1990).  Subteratogenic doses of these agents 
combined with normally harmless temperature can cause birth defects.  This might be of 
particular concern for febrile patients using ultrasound (Edwards, 2006).  In contrast, 
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clinical and experimental studies have shown that folate (Acs et al., 2005; Shin and 
Shiota, 1999) and multivitamin supplements containing folates (Botto et al., 2002) 
reduce the risk of damage.  Although aspirin and other antipyretic agents also showed 
protective effects, the experimental studies did not support the clinical studies (Acs et al., 
2005; Suarez et al., 2004; Tiboni et al., 1998).                     
 
1.2.2.2.   Cyclophosphamide 
 Cyclophosphamide (CP) is an alkylating agent used in the treatment of malignant 
tumors and autoimmune disorders (Fleming, 1997; Sladek, 1988).  CP is also a well 
studied teratogen that can produce malformations, including exencephaly, cleft palate, 
syndactyly and kinky tail in mice, and absence of toes and cleft palate in humans.  
Although the embryotoxicity of CP has been extensively studied in experimental 
animals, human studies are limited as the number of reported cases is rare and these 
patients were also exposed to X-ray treatment.  CP is a prodrug that needs to be 
metabolized to exert its therapeutic and embryotoxic effects (Fig. 1.2).  CP is mostly 
metabolized by cytochrome P450 via 4-hydroxylation and N-dechloroethylation, with 
only 10-30% of CP excreted in the urine as original parent compound (Moore, 1991; 
Sladek, 1988).  The P450 enzymes responsible for the 4-hydroxylation are CYP2B6, 
CYP3A4, and CYP2C, and the major metabolite of CP, 4-hydroxycyclophosphamide 
yields the active alkylating agent, phosphoramide mustard (PM), and the byproduct, 
acrolein (AC) (Chang et al., 1993; Huang et al., 2000; Roy et al., 1999).  Both PM and 
AC are active metabolites that interact with cellular macromolecules, and each cause 
unique teratogenic effects in day 10 rat embryos. PM-treated embryos exhibit 
abnormalities of the prosencephalon whereas embryos exposed to AC exhibit abnormal 
axial rotation (Little and Mirkes, 1990; Slott and Hales, 1988).  PM binds predominantly 
to DNA, damaging DNA by forming cross-links, whereas AC binds preferentially to 
embryonic proteins and does not cause DNA damage at embryotoxic concentrations 
(Little and Mirkes, 1987, 1990).  Subsequently it was shown that the DNA cross-links 
induced by PM are responsible for the teratogenic effects of CP (Little and Mirkes, 
1987). 
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Figure 1.2. Metabolism of cyclophosphamide. Modified de Jonge, et al., (2006) and Rodriguez-
Antona and Ingelman-Sundberg, (2006). 
 
One of the known early effects of CP is a perturbation of the cell cycle (Meyn 
and Murray, 1986).  In vitro studies showed that exposure of embryos to PM delayed 
cell cycle time, particularly the S phase (Mirkes et al., 1989).  Other studies have also 
described effects on the cell cycle after exposure to CP, PM, and AC (D'Incalci et al., 
1983; Marano and Puiseux-Dao, 1982; Millar et al., 1986).  Recently, the activated 
analog of CP, 4-hydroperoxycyclophosphamide (4CP), has been shown to activate 
apoptosis by inducing the mitochondrial apoptotic pathway in mouse embryos (Huang 
and Hales, 2002; Mirkes and Little, 1998, 2000).  In addition, a possible role of p53, a 
transcription factor that induces apoptosis or cell cycle arrest following a variety of 
stresses, has been suggested to play a role in apoptosis observed in embryos exposed to 
CP (Mikheeva et al., 2004; Pekar et al., 2007).           
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1.2.2.3.   Other Teratogens  
  As discussed in section 1.1.4, other well known teratogens that affect the CNS 
include, but are not limited to, alcohol, retinoic acid, and folate deficiency (folate 
metabolism discussed in section 1.1.4.4).  Maternal alcohol consumption has been the 
most common nongenetic cause of mental retardation and can cause a spectrum of 
physical and mental dysfunction (Abel and Sokol, 1987; Dunty et al., 2001).  Fetal 
alcohol syndrome (FAS), a collection of abnormalities caused by maternal alcohol 
abuse, occurs in approximately 1-7 in 1000 live births in the United States (Niccols, 
2007).  Individuals with FAS exhibit pre- and postnatal growth deficiencies, 
characteristic craniofacial dysmorphology, and varying degrees of CNS dysfunction 
such as changes in brain structure, cognitive impairments, and behavior problems (Dunty 
et al., 2001; Niccols, 2007).  Although the abnormalities of numerous cellular activities 
are well studied in animal models and in vitro studies, a large body of evidence indicates 
that apoptosis is an important pathogenic feature of the FAS (Smith, 1997; Sulik et al., 
1988).   
Retinoic acid (RA), a metabolite of vitamin A (retinol), is essential not only for 
the differentiation of progenitor cells to neurons and glia but also for organogenesis, cell 
proliferation, and apoptosis (Mark et al., 2006; McCaffery et al., 2003).   Precise 
regulation of RA level by controlled synthesis and catabolism is, therefore, essential for 
normal development.  This explains why both excess and deficiency in RA cause 
developmental malformations and why those areas in which RA signaling takes place 
are the most sensitive regions for its teratogenicity (Collins and Mao, 1999; McCaffery 
et al., 2003).  The malformations observed in experimental animals include exencephaly, 
spina bifida, cleft palate, eye defects, hydrocephaly, and shortening of the mandible and 
maxilla for excess RA and malformations in the eye, urogenital tract, diaphragm, heart, 
and lung for RA deficiency (Cohlan, 1954; Wilson and Warkany, 1950).   The most 
biologically active retinoids identified are all-trans retinoic acid and its 9-cis isomer.   
Extensive studies, including studies in vitro, have revealed that retinoid nuclear receptors 
such as retinoic acid receptor (RAR) and retinoid X receptor (RXR) transduce RA 
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signals during development, and specific heterodimers are involved in particular 
developmental processes.   
The molecular mechanisms of teratogens that induce NTDs as well as other 
teratogens have been extensively studied.   One of the mechanisms repeatedly identified 
is apoptosis, and the next section will discuss molecular pathways of apoptosis and 
apoptosis in normal and abnormal development.     
 
 
1.3.   APOPTOSIS 
1.3.1.   Molecular Pathways of Apoptosis 
Cell death in animals is classified into three types; apoptosis (type I), autophagy 
(type II), and necrosis (type III) (Krysko et al., 2008).  Apoptosis is an active and well 
controlled process that is important in the maintenance of tissue homeostasis and 
development.  Autophagy is a cytosolic degradation process by which intact organelles 
or large portion of cytoplasm are engulfed within autophagic vacuoles to ensure the 
physiological turnover of old and damaged organelles (Galluzzi et al., 2008).   Necrosis 
is distinct from apoptosis and defined as a passive and uncontrolled process that results 
from high level of physical stress such as injury.  During necrosis, rapid and large 
changes in essential ions, osmolarity, and pH lead to the lysis of the cell and activation 
of an inflammatory response (Penaloza et al., 2006).  Recent findings have changed our 
classical view of necrosis as a passive and accidental form of cell death to that of 
actively regulated process, and now it has been observed in parallel with apoptosis rather 
than as an alternative pathway to apoptosis (Henriquez et al., 2008).  In addition, the 
boundary between apoptosis and autophagy has not been completely clear, largely due to 
the intrinsic factors among different cell types and the crosstalk among organelles within 
each type (Lockshin and Zakeri, 2004).   In this section, the discussion will focus on 
molecular pathways of apoptosis and the importance of apoptosis in normal and 
abnormal development.  
Until some of the physiological effects of apoptosis were observed in 1972, cell 
death in general was believed to be a passive process of cells destined to disintegrate 
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(Kerr et al., 1972).  The observed physiological effects, including cell membrane 
blebbing, cell shrinkage, chromatin condensation, and DNA fragmentation suggested 
that cell death is actually an active process that is strictly controlled (Savill and Fadok, 
2000).   Subsequent studies have shown that chromatin condensation is associated with 
specific patterns of DNA fragmentation; fragmentation of DNA into large 300- and 50-
kb segments and subsequent cleavage between nucleaosomes, resulting in the generation 
of DNA fragments that are multiples of 185 bp (Ploski and Aplan, 2001; Wyllie, 1980).   
Concurrently, the cell membrane and the nuclear envelope are thrown into numerous 
vesicles called apoptotic bodies, which are subsequently engulfed by macrophages or 
neighboring cells to avoid inflammatory response in the surrounding tissues (Mirkes, 
2002; Savill and Fadok, 2000).   This process, complementary to mitosis, was termed 
apoptosis by Currie and colleagues (Kerr et al., 1972).       
Fundamental discoveries about the mechanisms of apoptosis at the molecular 
level were originally made using C. elegans, work which was later awarded the Nobel 
Prize in Medicine in 2002.  During the development of C. elegans, 1090 cells are 
generated, of which 131 undergo programmed cell death (programmed cell death is later 
discussed in section 1.3.2) (Kimble and Hirsh, 1979; Sulston and Horvitz, 1977; Sulston 
et al., 1983).  Genetic analyses of mutated C. elegans have identified the basic 
components of the cell death machinery, which turn out to be widely conserved from 
nematodes to humans (Metzstein et al., 1998).   Two genes that are largely responsible 
for the cell death were first discovered; ced-3 (caspase homologue) and ced-4 (Apaf-1 
homologue) (Ellis and Horvitz, 1986).  Subsequent screening studies using alleles of 
ced-3 and ced-4 identified another key gene, ced-9 (antiapoptotic Bcl-2 homologue), that 
is required to prevent cell death (Hengartner and Horvitz, 1994).  Another gene, egl-1 
(BH3 only member homologue), was found to serve as an upstream initiator of cell death 
(Conradt and Horvitz, 1998).  Current evidence suggests that the activation of egl-1 
protein is first induced by upstream death signals, which results in recruitment of ced-9 
to egl-1.   Following the binding of egl-1 to ced-9, ced-9 dissociates from ced-4 for its 
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activation, and the free ced-4 promotes the proteolytic cleavage of the proenzyme form 
of ced-3 (Fig. 1.3).  The activated ced-3 finally targets various cellular proteins for  
 
 
Figure 1.3. Comparison of cell death machinery in mammals to the C. elegans system.  
Modified Jin and El-Deiry, (2005). 
 
 
cleavage, which results in the structural features of the apoptotic cells.   Although the 
pathway of the apoptotic activation in mammals is analogous to that in C. elegans, 
apoptotic pathways in mammals are much more complex.  For example, 14 caspases, the 
homologues of ced-3, have been identified in mammals, of which 7 caspases are known 
to play critical roles in apoptosis (Mirkes, 2002).  Caspases are synthesized as inactive 
proenzymes (procaspases) that must be proteolyticaly processed to become activated.  
Caspases that are essential for the regulation and activation of apoptosis are classified 
into two groups according to their functions and the length of their N-terminal 
prodomain (Launay et al., 2005; Mirkes, 2002).  Caspase-2, -8, -9, and -10, called 
initiator caspases activate effecter caspases, caspase-3, -6, and -7.   Multiple homologues 
of ced-9 and egl-1, which are antiapoptotic Bcl-2 proteins and proapoptotic BH3 only  
proteins, respectively, as well as proapoptotic Bcl-2 proteins are also found in mammals.   
In mammals, two major apoptotic pathways, the extrinsic pathway (death 
receptor pathway) and the intrinsic pathway (the mitochondrial pathway), are activated 
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by a variety of external signals (Fig. 1.4) (Jin and El-Deiry, 2005).   The death receptor 
pathway is activated by extrinsic signals that bind to cell surface receptors whereas the 
intrinsic pathway is initiated following intrinsic signals such as DNA damage induced by 
irradiation or chemicals, growth factor deprivation or oxidative stress.  These signals 
activate apoptosis via the interaction with mitochondria (Leist and Jaattela, 2001).   
 
 
Figure 1.4. Simplified two major apoptotic pathways.  Adapted from Shiozaki and Shi, (2004). 
 
 
The extrinsic pathway is activated by ligand-bound death receptors including 
Fas, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) 
receptors (Thorburn, 2004).   Apoptosis induced through the extrinsic pathway is critical 
in several disease processes and has been a major focus in cancer research.   The known 
death receptors all contain an intracellular globular protein interaction domain called a 
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death domain (DD). Binding of death ligand to the death receptors results in 
oligomerization of the receptors and recruitment of an adopter protein called Fas-
associated death domain (FADD) (Chinnaiyan et al., 1995).  FADD contains two 
domains: DD and a death effector domain (DED).  FADD binds to the receptors through 
interactions between DDs and to procaspase-8 through DED interactions to form a 
death-inducing signaling complex (DISC).  Caspase-8 is auto-cleaved and activated at 
the DISC, which then leads to the activation of effecter caspases, including caspase-3, -
6, and -7 and the subsequent induction of apoptosis (Ashkenazi and Dixit, 1998).      
The intrinsic pathways are triggered by various apoptotic signals and initiated 
inside the cells.  The most central regulator of these pathways is mitochondria, and 
critical event in the intrinsic pathway is mitochondrial outer membrane permeabilization 
(MOMP) (Jin and El-Deiry, 2005).   MOMP is mediated and regulated by Bcl-2 family 
proteins, and MOMP leads to the release of molecules from mitochondria such as 
cytochrome c, which is involved in the activation of caspases.   Approximately 20 Bcl-2 
family proteins have been identified in mammals.   They are divided into three groups, 
but they all contain at least one Bcl-2 Homology (BH) domain.   Antiapoptotic members, 
including Bcl-2, Bcl-Xl, Bcl-w, A1, and Mcl-1 contain four BH domains (BH1, BH2, 
BH3, and BH4) and prevent cell death by binding to proapoptotic members such as Bax, 
Bak, and Bok.   These proapoptotic proteins also contain three domains (BH1, BH2, and 
BH3), and present a similar 3D structure with antiapoptotic proteins (Fesik, 2000; 
Hengartner, 2000).   The third group consists of eight proapoptotic proteins that only 
contain the BH3 domain.   These BH3 only proteins include Bid, Bad, Bik, Bim, Bmf, 
Hrk, Noxa, and Puma.   Both proapoptotic groups are necessary for the induction of 
apoptosis, although BH3 only proteins apparently lie upstream of Bax/Bak because 
when cells lack Bax and Bak, they fail to induce apoptosis (Cheng et al., 2001; Zong et 
al., 2001).   Death signals first activate BH3 only proteins, which subsequently induce 
oligomerization of the other proapoptotic group proteins such as Bax and Bak to insert 
into the outer mitochondrial membrane (OMM).   BH3 only proteins can also function to 
release Bax and Bak from the antiapoptotic Bcl-2 family proteins (Cory and Adams, 
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2002; Huang and Strasser, 2000).  Bax and Bak then induce MOMP, leading to the 
release of molecules from the mitochondrion through either permeability transition (PT) 
-dependent or –independent processes.  MOMP then leads to the release of soluble 
mitochondrial proteins, the best studied of which is cytochrome c, a key component of 
the electron transport chain (Liu et al., 1996).   The release of cytochrome c into the 
cytosol results in the interaction of cytochrome c with Apaf-1, procaspase 9, and 
ATP/dATP to form a complex called the apoptosome (Li et al., 1997).   The apoptosome 
dimerizes and activates caspase-9.   Caspase-9 then activates effector caspases, caspase-
3, -6, and -7 leading to the induction of apoptosis.   Other proteins released, for example, 
Smac/DIABLO, HtrA2/Omi, and GSPT1/eRF3, bind inhibitors of apoptosis (IAPs) to 
neutralize the inhibitory activity of IAPs to promote cytochrome c-dependent caspase 
activation (Shiozaki and Shi, 2004).   IAPs act as a brake for apoptosis by inhibiting 
activated caspases.   A different group of proteins are also released from mitochondria to 
promote caspase-independent apoptosis.   For example, apoptosis inducing factor (AIF) 
translocates to the nucleus and induces chromatin condensation and large-scale DNA 
fragmentation (Susin et al., 1999).   Another protein, endonuclease G protein (Endo G), 
is also released in response to apoptotic stimuli and is responsible for the induction of 
oligonucleosomal DNA fragmentation (Li et al., 2001).  
Although these two apoptotic pathways are initiated through different processes, 
they converge on the activation of effector caspases (Danial and Korsmeyer, 2004).   In 
addition, the death receptor pathway signaling can activate the mitochondrial pathway 
through the BH3 only protein, Bid.  In this pathway, the activated caspase-8 cleaves 
cytosolic Bid, cleaved Bid (tBid) then translocates to the mitochondria, which leads to 
cytochrome c release (Li et al., 1998; Luo et al., 1998).   Crosstalks between the two 
pathways also occur at the initiation level.  For example, in p53-mediated apoptosis, p53 
not only activates the intrinsic apoptotic proteins such as BAX and PUMA leading to the 
activation of mitochondrial pathway but also upregulates the death receptor pathway 
proteins like FASL and KILLER/DR5 (Kasibhatla et al., 1998; Wu et al., 1997).  
Detailed discussion about p53 is found in section 1.4.          
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1.3.2.   Apoptosis in Normal Development (Programmed Cell Death) 
 Apoptosis occurs in various tissues at different times during development, and 
the genetically controlled sequence leading to cell death in development is referred to as 
programmed cell death (PCD) (Mirkes, 2008).   Examples of PCD include the neural 
tube, eye and ear development, cardiovascular development, limb development, deletion 
of mullerian/wolffian ducts, and kidney development. These widely recognized 
examples of PCD can be classified into several categories based on their functions; (1) 
sculpting structures; (2) deleting unwanted structures; (3) controlling cell numbers; and 
(4) producing differentiated cells without organelles (Jacobson et al., 1997).           
 The best studied role of PCD is sculpting parts of the body.  This includes well-
studied limb development, the formation of preamniotic cavity, and fusion of epithelial 
sheets for the formation of neural tube and lens vesicle.   PCD during limb development 
has been observed in chick and mouse embryos (Ballard and Holt, 1968; Hurle and 
Colombatti, 1996; Zakeri and Ahuja, 1997).   PCD during limb development in chick 
embryos is observed at the anterior edge of the limb bud and then at the posterior 
junction of the limb bud and the body wall.  At a later stage, PCD is observed in the 
interdigital mesenchyme.   At the molecular level, published studies have identified 
effecter caspases that are activated and that cytochrome c is released from mitochondria 
in limb PCD (Umpierre et al., 2001; Zuzarte-Luis et al., 2006).  Subsequent studies 
showed that caspase-2 functions as its initiator caspase and that proapoptotic factor AIF 
translocates from mitochondria to the nucleus during interdigital PCD, suggesting that 
PCD during limb development occurs through multiple apoptotic pathways including 
both caspase-dependent and –independent pathways (Grossmann et al., 2001; Zuzarte-
Luis et al., 2006).  The role of PCD in the formation of neural tube has been also studied.   
Inhibition of apoptosis by caspase inhibitors results in the increased incidence of neural 
tube defects (Weil et al., 1997).  The spatial and temporal distribution of PCD in the 
dorsal midline of the developing chick hindbrain has shown that PCD plays a significant 
role in morphogenetic thinning during roof plate development (Lawson et al., 1999).  It 
has also been shown that the development of lens vesicle involves PCD of the cells 
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between the surface ectoderm and the optic vesicle to help trigger invagination and to 
facilitate separation from the ectoderm (Mohamed and Amemiya, 2003).  Furthermore, 
PCD shapes the inner ear structure in day 5 chick embryo (Avallone et al., 2002).  In 
cardiovascular development, PCD is also essential in creating the four-chambered 
architecture of the heart (Abdelwahid et al., 2002).    
 In embryonic development, a number of extra structures are formed that are later 
eliminated by PCD.   Such structures include ones that are needed only at one stage of 
development, ones that are required only in one sex but not in the other, and ones that 
were required in an ancestral species but not in extant species (Jacobson et al., 1997).   
Subplate neurons that are required only during the development of the mammalian 
cerebral cortex are subsequently removed by PCD.  In addition, the Műllerian duct and 
the Wolffian duct, which develop into female and male reproductive system, 
respectively, are formed in both sexes.  Later, the unnecessary duct for each sex is 
removed by PCD.   Pronephric tubules that function as kidneys in fish and amphibian 
lavae are formed in mammals but later eliminated by PCD. 
 In certain organs, cells are produced excessively and then later the number of 
cells is adjusted by PCD.  Neurons and oligodendrocytes, for example, are produced in 
numbers greater than those in the adult, and are subject to PCD (de la Rosa and de Pablo, 
2000).  It has been estimated that approximately 50% of the neurons generated are 
eliminated by PCD (Oppenheim, 1991). The best hypothesis for the biological 
significance of this pruning process is that neuronal competition for their target serves to 
adjust the number of neurons and oligodendrocytes to the size of the target (Barres et al., 
1992; Oppenheim, 1991).   
In the developing lens, the nucleus is removed in the process called nuclear 
death, leaving the rest of the cell to function as a mature lens cell.  A similar 
phenomenon is observed in mammalian red blood cells and skin keratinocytes, 
suggesting an involvement of PCD in these processes (Gao et al., 1997; Jacobson et al., 
1997). Together, all these examples of PCD clearly indicate that cell death in 
development is an indispensable part of normal development.           
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1.3.3.   Apoptosis in Abnormal Development 
 Because of the important role of PCD in normal development, there is a 
possibility that animals lacking gene(s) critical for PCD develop abnormally.   Using 
knock out mice, it was tested whether any of the apoptotic proteins are essential for the 
PCD occurring during development.   Loss of caspase-9 and Apaf-1 resulted in abnormal 
development, e.g., mouse embryos lacking caspase-9 showed reduced apoptosis in the 
developing brain and died around day 11 – 12.5, and embryos lacking Apaf-1 showed 
brain defects (e.g. exencephaly) and died on day 16.5 (Cecconi et al., 1998; Hakem et 
al., 1998; Yoshida et al., 1998).   These results suggest that caspase-9 and Apaf-1 are 
critical for some of the PCD observed in the developing brain (Mirkes, 2008).   In 
contrast, deletion of proapoptotic genes, either Bax or Bak, showed no effect in 
development.   However, the loss of both Bax and Bak showed interdigital webbing in 
the paws, indicating that Bax and Bak together play a role in PCD occurring in the 
formation of digits (Lindsten et al., 2000).   Although all these genes are likely to play 
critical roles in PCD, caspase-9 and Apaf-1 are essential for at least some PCD in the 
brain and not in the limbs whereas Bax and Bak play essential role in limb PCD but 
appear to play no essential role in brain PCD (Mirkes, 2008).  These differences could be 
because these apoptotic proteins are tissue specific.   Another possibility is that there are 
strain-specific effects. Strain differences to abnormalities in knock out mice or 
abnormalities induced by teratogens have been reported (Finnell et al., 1986; Zheng et 
al., 1999).   Deletion of genes that are not involved in apoptosis also result in abnormal 
patterns of cell death and development (Zakeri and Ahuja, 1997).   Dominant hemimelia 
(Dh) mutant mice lacked the features of physiological cell death in their limbs and 
developed a preaxial polydactyly (Rooze, 1977).  Hemimelic extra toes (Hx) mutant 
exhibited altered patterns of cell death and polydactyly in all four feet (Knudsen and 
Kochhar, 1981).   Together, these studies suggest that many but not all abnormalities in 
PCD are causally linked to the development of abnormal development.     
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1.3.4.   Teratogen-Induced Apoptosis 
 As mentioned in section 1.2, more than 1,200 agents have been known to induce 
malformations in experimental animals (Shepard, 1995).   Although the mechanisms by 
which these teratogens result in abnormal development are still not well understood, it is 
known that a number of teratogens induce cell death in tissues that subsequently develop 
abnormally and give rise to structural and/or functional malformations (Knudsen, 1997; 
Scott, 1977).   Teratogens known to induce cell death include HS, CP (or 4CP), sodium 
arsenite, staurosporine, retinoic acid (Ali-Khan and Hales, 2003; Okano et al., 2007), 
folate deficiency (Gu et al., 2002b), cadmium (Fernandez et al., 2003), fumonisin B1 
(Jones et al., 2001), ethanol (Dunty et al., 2001), 2-deoxyadenosine (Gao et al., 1994), 
pentostatin, and N-acetoxy-2-acetyl aminofluorene (Knudsen et al., 1992; Thayer and 
Mirkes, 1995).                     
 The discussion of teratogen-induced apoptosis, however, will focus on two well 
known teratogens, HS and CP (please refer to section 1.2.2 for information about these 
teratogens).  These teratogens have been chosen to investigate the molecular 
mechanisms of teratogen-induced apoptosis because: 1) they represent both chemical 
and physical teratogens that are well studied, 2) they are both human and animal 
teratogens, and 3) there is an extensive literature on the biochemistry of HS- and CP-
induced cell death. 
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Figure 1.5. Activation of the mitochondrial apoptotic pathway in day 9 mouse embryos exposed 
to HS and 4CP.  Adapted from Mirkes, (2002). 
 
 
To determine whether HS and CP induce the terminal events of apoptosis, such 
as the activation of caspase-3, inactivation of the caspase-3 target, poly (ADP-ribose) 
polymerase (PARP), and DNA fragmentation, day 9 mouse embryos were exposed to 
these two teratogens in vitro (Fig. 1.5) (Mirkes and Little, 1998; Umpierre et al., 2001).  
In untreated embryos, caspase-3 exists in an inactive form, procaspase-3, which is 
approximately 32 kDa. Following HS and 4CP exposure (also sodium arsenite), 
procaspase-3 was cleaved to a larger fragment of approximately 19 kDa (p19) and a 
smaller fragment of approximately 17 kDa (p17), indicating that caspase-3 is activated 
by these teratogens.  These studies also showed that the enzyme PARP, which is 
approximately 116 kDa (p116), is cleaved to produce an inactive fragment of 
approximately 85 kDa (p85).  In addition, internucleosomal DNA degradation is 
observed as a ladder of DNA fragments.   Activation of caspase-3 by these teratogens 
was observed between 2.5 and 5 hr after the exposure whereas the inactivation of PARP 
and DNA fragmentation occurred 5 hr after the exposure, indicating that apoptotic 
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signaling pathway occurs within 5 hr after the exposure and that these teratogens activate 
the terminal portion of the apoptotic pathway.   To investigate whether these teratogens 
activate upstream events in the apoptotic pathway, cytochrome c release from 
mitochondria was examined (Mirkes and Little, 2000).  Results show that all three 
teratogens induced the release of cytochrome c between 2.5 and 5 hr after the initiation 
of exposure.   To further investigate upstream events in this apoptotic pathway, the 
activation of caspase-9 was studied (Little and Mirkes, 2002).   Results show that in 
untreated day 9 mouse embryos, caspase-9 exists as its inactive form, procaspase-9, 
which is approximately 49 kDa (p49).  Following the exposure of embryos to HS and 
4CP (also staurosporine), the level of procaspase-9 decreased and its cleaved fragments 
that are approximately 39 kDa (p39) and p37 kDa (p37), increased. Because the 
generation of p37 fragment occurs through the interaction of cytochrome c and Apaf-1, 
whereas p39 is generated through a feedback loop involving caspse-3, these results 
indicate that HS, CP, and staurosporine trigger an apoptotic signal that converges on the 
mitochondria to induce cytochrome c release.   Cytochrome c in cytosol presumably then 
activates Apaf-1, which, in turn, activates caspase-9.  Caspase-9 subsequently activates 
the key effector caspase, caspase-3.   Recent studies have also shown that caspase-3 not 
only inactivates PARP and promotes DNA fragmentation but also activates caspase-6 
and -7 (Little et al., 2003).   These studies suggest that intrinsic apoptotic pathway is a 
critical part of apoptosis induced by some teratogens.   Other studies using CP or 4CP 
have shown that the integral part of the extrinsic pathway, caspase-8 is also activated in 
the brain and liver of embryos (Torchinsky et al., 2002).   In contrast, Huang and Hales 
(2002), observed the activation of caspase-3, but not caspse-9 and -8 in mouse 
embryonic limbs cultured with 4CP.   These results suggest that the apoptotic signaling 
induced by teratogens might be tissue specific.    
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Figure 1.6. Activation of the mitochondrial apoptotic pathway in heads, hearts, and trunks 
isolated from day 9 mouse embryos exposed to HS.  Adapted from Mirkes, (2002). 
 
Published studies also indicate that teratogens induce apoptosis in some cells of 
the embryos but not others (Fig. 1.6) (Gao et al., 1994; Mirkes, 1985; Mirkes et al., 
1985, 1991; Thayer and Mirkes, 1995).   Umpierre et al. (2001) has shown using vital 
dyes and TUNEL staining that teratogen-induced apoptosis is cell specific: some cells in 
the mouse embryo die, particularly in areas of PCD, whereas other cells survive.   Their 
study revealed that neuroepithelial cells are particularly sensitive to teratogen-induced 
apoptosis, mesenchymal cells surrounding the neuroepithelium are less sensitive, and 
cells of the heart are completely resistant (Umpierre et al., 2001).   Because none of the 
terminal events such as cytochrome c release, activation of effector caspases, PARP 
cleavage, and DNA fragmentation, were observed in the cells of the embryonic heart, 
these studies indicate that the mitochondrial pathway is disrupted in heart cells upstream 
of cytochrome c release (Fig. 1.6).   The differential sensitivity of embryonic cells to 
teratogen-induced apoptosis has been also observed following the exposure to N-
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acetoxy-2-acetylaminofluorene (Thayer and Mirkes, 1995), ethanol (Dunty et al., 2001), 
and 2-deoxyadenosine (Gao et al., 1994).   Differential sensitivity might be the key to 
the regulation of teratogen-induced apoptosis.          
 
   
1.4.   TRANSFORMATION RELATED PROTEIN 53  
1.4.1.   Overview of p53 
 Transformation related protein 53 (p53), known as the “guardian of the genome,” 
was first identified in 1979 as a cellular protein tightly associated with a DNA tumor 
virus, simian virus 40 large T protein (SV40LT) (Kress et al., 1979; Lane and Crawford, 
1979; Linzer and Levine, 1979; Vogelstein et al., 2000).   The early research on the role 
of p53 in viral transformation unexpectedly revealed the critical role of p53 in all major 
types of human cancers.   Almost 30 years later, p53 is now recognized as a potent tumor 
suppressor, whose alteration is found in more than 50% of human cancers (Hollstein et 
al., 1994).  Frequently, even cancers without the mutation of p53 still have the p53 
pathway inactivated by alterations of genes that regulate p53 or by the localization of 
p53 in the cytoplasm (Levine, 1997).   In addition, germline mutations of p53 lead to Li-
Fraumeni syndrome, which is a rare cancer predisposition syndrome in humans (Diller 
and Friend, 1992).   Therefore, the role of p53 as a tumor suppressor has been the focus 
of numerous studies, encompassing over 35,000 publications in Pubmed under the query 
“p53 and cancer.”     
p53 functions biochemically as a sequence-specific transcription factor that is 
essential for maintaining genomic integrity and preventing inappropriate cell 
proliferation following a variety of stresses that induce cellular damage (Janus et al., 
1999).   The protein is present at very low levels in unstressed cells because of its fast 
turnover, which is regulated mainly by the binding of E3 ubiquitin ligase, mouse double 
minute 2 (MDM2) (Lohrum and Vousden, 1999).   In response to cellular stresses such 
as DNA damage, hypoxia, oncogene overexpression, and nucleotide depletion, p53 is 
rapidly stabilized and activated by extensive post-translational modifications such as 
phosphorylation, acetylation, and ubiquitination (Vogelstein et al., 2000; Vousden and 
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Lu, 2002).  The activation of p53 results in the translocation of the protein to the nucleus 
where it transcriptionally activates its target genes such as p21, Noxa, Puma, Bax and 
Fas (transcription-dependent pathway).  Active p53 also translocates to the mitochondria 
or cytosol and interacts with proapoptotic or antiapoptotic proteins (transcription-
independent pathway).   Both the transcription-dependent and –independent pathways of 
p53 activate an array of biological responses including apoptosis, cell cycle arrest, 
senescence, DNA repair, and differentiation (Albrechtsen et al., 1999; Lane, 1992; 
Levine, 1997; Vogelstein et al., 2000).      
The p53 family members p63 and p73 are both structurally and functionally 
similar to p53 (Stiewe, 2007).   Increasing evidence indicates that these homologs may 
act in concert with p53 in response to DNA damage and the subsequent  induction of 
apoptosis and cell cycle arrest (Jost et al., 1997; Yang et al., 1998).   In addition, 
isoforms of p63 and p73 that lack the N-terminal transactivation domain, ∆Np63 and 
∆Np73, were found to be naturally occurring inhibitors of p53 (Fillippovich et al., 2001; 
Pozniak et al., 2000; Yang et al., 2000).   These studies indicate that the interaction and 
communication of p53 with other p53 family proteins are also important for 
understanding the function of p53.  
 The p53 protein also plays roles in normal development.  p53 mutant mice 
exhibit birth defects such as exencephaly and have a high mortality rate in utero in 
addition to the high cancer predisposition (Armstrong et al., 1995; Donehower et al., 
1992; Sah et al., 1995).   Published studies have shown that p53 is altered by teratogens 
such as cadmium and 4CP (Pekar et al., 2007; Sarkar and Sharma, 2003; Yu et al., 2008).   
Detailed discussion of teratogen-induced activation of p53 is the focus of the study 
presented in this dissertation.        
 
1.4.2.   Molecular Structure of p53 
Knowledge of molecular structure of the p53 protein is important to understand 
how p53 is regulated and activated as well as how it activates various biological 
pathways.   The protein consists of 393 amino acids and contains three functional 
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domains (Fig. 1.7) (Bode and Dong, 2004).   The N-terminus transactivation domain of 
p53 interacts with a number of proteins, which are required for transactivation activity.   
For example, a negative regulator of p53, MDM2, interacts with the transactivation 
domain of p53 to inhibit the transcription activity of p53 (Chen et al., 1995).   In humans, 
the N-terminal portion contains Src homology 3-like (SH3) domain.   The SH3 domain 
is a proline-rich domain that interacts with SIN3, which protects p53 from degradation.    
 
 
Figure 1.7.  Functional domains of p53.  Adapted from Bode and Dong, (2004). 
 
The central core DNA-binding domain of p53 is required for the sequence-specific 
interaction of p53 with its target proteins.   DNA-protein binding is facilitated by the 
four evolutionally conserved regions within the central core domain (Cho et al., 1994) as 
well as by the binding of proteins such as p53 binding protein 1 and 2 (p53BP1 and 
p53BP2) to the domain (Derbyshire et al., 2002; Gorina and Pavletich, 1996).  The C-
terminal portion contains the nuclear localization signal motifs (NLS), which regulate 
nuclear translocation of p53 from the cytoplasm to the nucleus following DNA damage.   
In addition, the C-terminus contains an oligomerization domain that promotes the 
formation of p53 tetramers, nuclear export signals (NES), and the regulatory domain that 
regulates the core DNA-binding domain.           
 Because p53 is maintained at low levels in unstressed condition, the stabilization 
and activation of p53 is essential for the activation of p53-regulated biological pathways.   
The binding of p53 to other proteins, especially the binding of MDM2 to p53 at the N-
terminal transactivation domain, play important roles in the stabilization and activation 
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of p53.   In addition, the alteration of the DNA-binding domain as well as other domains 
by post-translational modifications is also critical (Cuddihy and Bristow, 2004) (for 
detailed discussion of post-translational modifications, please refer to section 1.4.3.3).    
Mutation of the p53 often alters the function and structure of p53 or inactivates 
the gene (Braithwaite et al., 2005).  The most frequent mutations identified in p53 (75%) 
are missense, and these mutations are most often found in the tetramerization domain 
(3.4%) and the SH3 domain (2.3%) (Hofseth et al., 2004; Olivier et al., 2004).   However, 
90% of the mutations that inactivate p53 function in cancer cells can be observed in the 
DNA-binding domain, and these mutations generate a protein that lacks the ability to 
transcribe p53 target genes.  Common polymorphisms of p53 also have been studied, 
although a great number of these natural variants are found in non-coding regions of the 
gene (Pietsch et al., 2006).   Polymorphisms in codon 47 and 72, however, may play a 
role in p53-dependent apoptosis and cancer progression (Bulavin et al., 1999; Okamura 
et al., 2001; Sanchez-Prieto et al., 2000; Storey et al., 1998; Takekawa et al., 2000). 
 
1.4.3.   Stabilization and Activation of p53 
1.4.3.1.   Types of Stress That Stabilize and Activate p53 
 p53 is stabilized and activated by a variety of stresses.   A well studied group of 
agents that increase the level of p53 includes a variety of DNA damaging agents.  DNA 
is often the main target of environmental genotoxins such as ultraviolet light (UV), 
ionizing radiation, polycyclic aromatic hydrocarbons, and alkylating compounds (Table 
1.4) (Roos and Kaina, 2006).    
Following DNA damage, ataxia telangiectasia mutated (ATM) or the 
homologous A-T and Rad3-related (ATR) protein initiate the activation of downstream 
pathways through phosphorylation of a number of proteins, including p53, MDM2, 
H2AX, checkpoint kinase 2 (CHK2), and p53BP1 (Ackermann and El-Deiry, 2008).    
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Table 1.4 
Agents That Stabilize and Activate p53 Protein* 
Type  Agent 
DNA damaging agents  
 Irradiation UV 
  Gamma rays 
  
X-rays 
Alpha particles 
 Carcinogens Polycyclic aromatic hydrocarbons 
  Mycotoxins 
  Heavy metals (Cadmium) 
 Oxidative/nitrosative stress Hydrogen peroxyde 
  Nitric oxide donors 
 Cytotoxic drugs Platinum compounds 
  Alkylating agent 
  Antimetabolites 
  5-FU 
  PALA 
  Methotrexate 
  Tumor antibiotics 
  Mitomycin C 
  Antinomycin D 
  Bleomycin 
  Anthracyclins (doxorubicin) 
 Topoisomerase inhibitors Camptothecin 
Non-genotoxic agents  
 Anti-microtubule agents Taxanes 
  Nocodazole 
 Ribonucleotide depletion  
 Hypoxia/anoxia  
 Cell adhesion  
 Oncogene activation Overexpression of E1A 
 Cytokines TNF-alpha 
 Hyperthermia  
 Proteasome inhibitors  
 
Senescence/telomere 
erosion  
 Polyamine analogues  
*Adapted from Pluquet and Hainaut, (2001). 
 
Upon phosphorylation, p53 is stabilized and initiates cell cycle arrest or 
apoptosis.   It is believed that low levels of DNA damage triggers the transcription of 
cell-cycle related genes such as p21 whereas high levels of DNA damage activate pro-
apoptotic genes including Bax, Puma, and Fas receptor (Roos and Kaina, 2006).                
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In contrast, exposure to agents that do not induce any detectable level of DNA 
damage such as hypoxia also results in the accumulation of p53 (Hammond et al., 2002).   
Hypoxic stress induces p53 protein accumulation and p53-dependent apoptosis.   The 
stabilization and accumulation of p53 occur through the decreased level of MDM2 and 
possible interaction of p53 with hypoxia inducing factor 1 alpha (HIF1α) (Hammond and 
Giaccia, 2005).  p53-dependent apoptosis is associated with cytochrome c release and 
the activation of Apaf-1 and caspase-9, suggesting the involvement of the mitochondrial 
apoptotic pathway (Alarcon et al., 2001).   Unlike DNA damaging agents, hypoxia does 
not induce p53-dependent cell cycle arrest.   In addition, hypoxia-induced p53 does not 
seem to activate well known proapoptotic genes such as Bax, Noxa, and Puma and 
instead acts almost entirely as a transrespressor to induce apoptosis, suggesting that 
hypoxia-induced p53 activates apoptosis differently from DNA damaging agents 
(Hammond and Giaccia, 2005).     
Oncogenic stimuli such as c-myc and RAS induce p19ARF, which associates 
with MDM2, to allow p53 to be stabilized and activated (Pomerantz et al., 1998; Zhang 
et al., 1998).   Depletion of ribonucleotides (Linke et al., 1996), cytokine stimulation, 
anchorage, cell-to-cell contact, viruses and various metabolic changes are also known to 
stabilize and activate p53 (Braithwaite et al., 2005).          
    
1.4.3.2.   p53-MDM 2 
 In the absence of cellular stress, an E3 ubiquitin ligase MDM2 binds to p53 and 
transports p53 to the cytoplasm for its degradation by the 26S proteasome.   MDM2, 
thus, maintains p53 at very low steady-state levels under unstressed condition and 
regulates the stabilization and activation of p53.   In response to stress, MDM2 itself is 
ubiquitinated and degraded, releasing p53 and allowing it to be stabilized and activated 
(Alarcon-Vargas and Ronai, 2002; Fang et al., 2000).   MDM2 is also phosphorylated in 
an ATM-dependent manner, which decreases its ability to interact with p53, thus, 
stabilizing p53 (Khosravi et al., 1999).   Furthermore, MDM2 has the ability to inhibit 
acetylation of p53 mediated by CREB-binding protein (CBP) or by the p300 protein (Ito 
et al., 2001; Kobet et al., 2000).  Activation of p53 leads to the transactivation of 
47 
 
MDM2, ensuring the autoregulatory feedback loops between Mdm2 and p53 (Harris and 
Levine, 2005).  Loss of Mdm2 leads to embryo lethal phenotypes that are completely 
rescued by concomitant deletion of p53.   These studies indicate that Mdm2 is an 
important negative regulator of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995; 
Parant et al., 2001).   Other ubiquitin ligases, PRH2 and COP1 have been also shown to 
interact with p53 and promote its ubiquitination independent of MDM2 (Harris and 
Levine, 2005; Leng et al., 2003).    
 Another Mdm2 family protein, Mdmx is also a key regulator of p53.   Recent 
studies have shown that MDMX also interacts with p53, but controls p53 not by 
ubiquitinating it but by inhibiting its transactivation activity (Finch et al., 2002).   
Interestingly, MDM2 and MDMX interact with each other to protect p53 from 
undergoing MDM2-mediated degradation (Jackson and Berberich, 2000) although 
MDMX can also stabilize MDM2 by preventing its self-ubiquitination.  MDM2 and 
MDMX are functionally dependent in controlling p53.   In the absence of MDMX, 
MDM2 still retains the ability to control p53 but the capacity of MDM2 to control p53 is 
reduced due to its shorter half-life (Gu et al., 2002a).  MDMX, on the other hand, is 
dependent on MDM2 to inhibit p53 function (Li et al., 2002).   These studies show that 
both MDM2 and MDMX are critical regulators of p53.                  
 
1.4.3.3.   Post-Translational Modifications 
 Other than the modification of MDM2 and other proteins, post-translational 
modifications of p53 also play critical roles in the regulation of p53 stabilization and 
activation (Appella and Anderson, 2001).  These modifications are known to enhance 
the DNA-binding activity of p53 as well as influence the interaction between p53 and 
MDM2 (Harris and Levine, 2005; Lavin and Gueven, 2006). The types of post-
translational modifications include phosphorylation, acetylation, methylation, 
ubiquitination, neddylation, and sumoylation (Appella and Anderson, 2001).   The most 
common modification is phosphorylations, and it accounts for all modifications observed 
in the N-terminal portion as well as the majority of modifications in the central core and 
C-terminal portion (Table 1.5).  The p53 protein is phorphorylated by a variety of 
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protein kinases that are activated by different stresses.   Published studies have shown 
that protein kinases that phosphorylate p53 include ATM, ATR, CHK1, CHK2, Jun 
NH2-terminal kinase (JNK), p38, and others (Lavin and Gueven, 2006).  The most well 
described phosphorylation site is ser-15 (ser-18 in mouse) carried out by ATM, which 
occurs in response to double stranded breaks (DSBs) induced by ionizing radiation 
(Saito et al., 2002).   ATM phosphorylates p53 at multiple sites, including ser-6, 9, 15, 
20, 46, and thr-18.   The most frequently phosphorylated sites are ser-15, 20, 33, and 46.   
In contrast, phosphorylation at thr-81 is only observed after exposure to UV or H2O2.   
JNK is the only protein kinase identified that phosphorylates p53 at thr-81, a 
modification that stabilizes and activates p53 (Buschmann et al., 2001).    
Phosphorylation of p53 in the N-terminal portion generally influences the affinity 
of p53 with MDM2.  Ser-376 and ser-378 are phosphorylated in resting cells, and are 
dephosphorylated in response to radiation (Waterman et al., 1998).   Dephosphorylation 
of p53 at ser-376 generates a binding site for 14-3-3 proteins, which then enhances the 
DNA-binding activity of p53.   Modifications at C-terminal region allow the region to 
unfold, increasing the affinity of p53 for sequence-specific DNA-binding (Selivanova et 
al., 1998).    
Acetylation of lysine at the C-terminal region also enhances DNA-binding 
activity.   The well described acetylation of p53 occurs by binding of the histone 
acetylase family members p300/CBP (Gu and Roeder, 1997), and the acetylation of p53 
by p300/CBP has been shown to enhance its transcriptional activity (Avantaggiati et al., 
1997).  Generally acetylation stabilizes the p53 protein by preventing ubiquitylation.   
Ubiquitylation of p53 by MDM2 leads to the degradation of p53, and the ubiquitylation 
sites are also targets of acetylation.  Acetylation of p53, therefore, prevents 
ubiquitylation and degradation of p53 (Juan et al., 2000; Luo et al., 2000, 2001; Vaziri et 
al., 2001).  Whether acetylation stabilizes and activates p53 remains controversial 
(Espinosa and Emerson, 2001; Nakamura et al., 2000), and it is believed that this could 
be due to the differences in the experimental protocols or animals or cell type used.    
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Table 1.5 
Post-Translational Modifications of p53* 
Domain Amino acid/location Modification Modifier proteins 
T
ra
ns
ac
tiv
at
io
n 
do
m
ai
n 
S 6 P CK1, ATM, ATR, DNA-PK, SMG1, mTOR 
S 9 P 
CK1, ATM, ATR, DNA-PK, SMG1, 
mTOR, CHK2 
S 15 (S 18) P 
DNA-PK, ATM, ATR, mTOR, SMG1, p38, 
ERK, CHK2, RSK2, AMPK 
T 18 P CHK2, VRK1, CK1, ATM 
S 20 (S 23) P 
CHK2, JNK, MAPKAPK2, CHK1, PIk3, 
ATM 
S 33 (-) P p38, CAK,  GSK3β, CDK9, CDK5 
(S 34) P JNK 
S 37 P ATR, p38, GSK3β, CAK, DNA-PK, CHK2 
S 46 (-) P HIPK2, p38, CHK2, CDK5, PKC, ATM 
T 55 P TAF1, ERK2 
SH
3 (T76/86) ---  --- 
T 81 (-) P JNK 
D
N
A
-b
in
di
ng
 
do
m
ai
n 
K 120 A  Tip60, hMOF 
S 149 P CSN 
T 150 P CSN 
T 155 P CSN 
S 215 P STK15, Aurora-A 
N
L
S 
K 305 A  p300 
S 313, 314 P CHK1, CHK2 
S 315 P CDK2, AURKA, GSK3β, CDK9, STK15 
K 320 (K 317) A, Nd PCAF 
C
-t
er
m
in
al
 re
gu
la
to
ry
 d
om
ai
n 
S 366 P CHK2 
K 370 (K 367) 
A, Ub, Nd, 
M MDM2, CBP/p300, SMYD2 
K 372, 373 (K 369, 
373) 
A, M, Ub, 
Nd 
CBP/p300, MDM2, PCAF, SET9, HCP 
core protein 
S 376 (S 373) P PKC, CHK1, CHK2 
T 377 P CHK1, CHK2, PKC 
S 378 (S 375) P PKC, CHK1, CHK2 
K 381, 382 (K 378, 
379) A, Ub, M CBP/p300 
K 386 (K 383) S, Ub Sumo1, CBP/p300, MDM2 
T 387 P Chk1, Chk2 
S 392 (S 389) P PKR, CK2, FACT, p38, Cdk9 
*Combined Apella and Anderson, (2001); Bode and Dong, (2004); Lavin and Gueven, (2006); 
Xu, (2003). 
 
Recent studies have further revealed that neddylation of p53 by MDM2 may also 
repress the activation of p53 (Xirodimas et al., 2004).  Frequently the target sites of 
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neddylation are also targeted by ubiquitylation.  Ubiquitylation refers to the modification 
of lysine residues in the C-terminal by ubiquitin-like protein called NEDD8 conjugated 
to MDM2. It is not known whether neddylation competes with acetylation or 
ubiquitylation (Bode and Dong, 2004).     
 Sumoylation of p53 has been also shown to alter p53 transcriptional activity 
(Melchior and Hengst, 2002). Sumoylation regulates the formation of promyelocytic 
leukaemia (PML) tumor suppressor protein localized in the nucleoplasm or in subnuclear 
structures referred to as nuclear bodies (NBs).  This protein is implicated in the 
pathogenesis of acute promyelocytic leukaemia (APL), but the role of sumoylation is not 
clear.   Sumoylation, similar to ubiquitylation, forms an isopeptide bond between the 
small ubiquitin-like protein SUMO1 and lys-386 of the p53 protein (Gostissa et al., 
1999; Rodriguez et al., 1999). Recent studies have shown that MDM2 and ARF-
mediated nuclear targeting regulate this modification (Chen and Chen, 2003).   Whether 
sumoylation activates or repress p53, however, remains controversial. 
 The p53 protein is also altered by ubiquitylation, leading to its degradation.   The 
addition of ubiquitin molecules to p53 marks the protein to be degradated by the 26S 
proteasome. Studies have shown that MDM2 is involved in the localization and 
degradation of p53 and that different levels of MDM2 can induce both mono- and poly-
ubiquitylation of p53 (Li et al., 2003).                
 The same modification sites are targeted by different enzymes in response to 
variety of cellular stresses.  Extensive studies have shown that these redundancies of p53 
modifications could be that specific stress leads to a distinct modification pattern, or a 
unique combination of modifications is required for further modifications, which leads 
to maximal level of activation (Bode and Dong, 2004). The example includes 
phosphorylation of ser-15 followed by the phosphorylation of thr-18.   Phosphorylations 
at ser-15, thr-18, and ser-20 recruit other factors such as p300, CBP, and P/CAF for its 
acetylation. It is generally accepted that the functional responses of p53 by its 
stabilization and activation of p53 are highly orchestrated by phosphorylations at 
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multiple sites combined with other forms of modifications such as acetylation, 
deacetylation, ubiquitylation, and neddylation.     
    
1.4.4.   Activation of p53 Pathways 
1.4.4.1.   Transcription-Dependent Pathway 
 p53 is a transcription factor that activates or represses a significant number of 
genes related to cell cycle regulation and apoptosis in response to cellular stresses.  p53 
directly activates the expression of genes through binding to specific DNA sequences 
containing two adjacent copies of the consensus sequence 5’-RRRCWWGYYY (N=0-
13)RRRCWWGYYY-3’ (R=G or A, W=T or A, Y=C or T, N=any base), located in the 
promoter or introns of the downstream target genes (el-Deiry et al., 1992; Kern et al., 
1991).  Identification of the p53 target genes have been attempted by using three 
different methods (Yu and Zhang, 2005).   The first approach is the identification of 
genomic DNA fragments that are bound to p53 based on the reasoning that p53 
promotes the activation of the target genes by interacting at their promoter region or 
introns (Nakamura, 2004; Tokino et al., 1994).  The second approach is to systematically 
identify genes that show different expression in the presence or absence of p53 (el-Deiry, 
1998b; Polyak et al., 1997; Sax et al., 2003; Yu et al., 1999; Zhao et al., 2000).   The 
third approach is to identify basic components of p53-regulated pathways through genes 
that are already known to play roles in these pathways.   For example, investigation of 
the apoptotic pathway showed that p53 transactivates caspase-6 in response to DNA 
damage (MacLachlan and El-Deiry, 2002).   These approaches have identified several 
hundred possible genes, although further verification of each gene is necessary to 
confirm the association (Wei et al., 2006).          
 Cells undergo growth arrest by the transactivation of cell cycle-related genes 
induced by p53.   For example, well described genes that are activated include the CDK 
inhibitor p21, GADD45, 14-3-3σ, cyclin G, and placenta transforming growth factor 
beta (PTGF-β) (Sax et al., 2003).  p21 is required for the induction of a G1 arrest 
whereas GADD45 and 14-3-3σ regulate G2/M phase in response to ionizing radiation 
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(Brugarolas et al., 1995, 1999; Deng et al., 1995).   These studies show that p53 can 
transcriptionally activate cell cycle arrest by preventing both G1/S and G2/M 
progression.    
 Apoptosis is another process induced by the activation of p53 after cellular 
damage.   Both the mitochondrial apoptotic pathway and death receptor pathway can be 
mediated by transactivation of p53 target genes.   The p53 target genes involved in the 
mitochondrial apoptotic pathway includes Bax, Noxa, Puma, p53AIP1, p53-induced 
genes (PIGs), and Apaf-1.   Bax is the first proapoptotic Bcl-2 family member identified 
to be regulated by p53, and loss of Bax accounted for approximately half of the tumor 
growth observed in a brain tumor model that lacks the p53 gene (Miyashita and Reed, 
1995; Symonds et al., 1994; Yin et al., 1997).   p53 also transactivates BH3 only proteins, 
Noxa and Puma, which function upstream of Bax for the induction of apoptosis.   Puma 
has been shown to be a critical mediator of p53-dependent apoptosis following DNA 
damage (Han et al., 2001; Nakano and Vousden, 2001; Yu et al., 2001).  Noxa also 
activates p53-dependent apoptosis but to a lesser extent than Puma (Oda et al., 2000a; 
Shibue et al., 2003; Villunger et al., 2003).   Studies have also shown that another BH3 
only protein Bid and a mitochondrial protein encoded by p53AIP1 are activated by p53 
(Oda et al., 2000b; Sax et al., 2002).   PIGs were originally identified following p53 
overexpression (Polyak et al., 1997), and the activation of PIGs suppresses tumor 
formation and induces apoptosis (Gu et al., 2000; Lehar et al., 1996).   Studies have 
shown that PIGs induce apoptosis by generating or recognizing reactive oxygen species 
(ROS) (Polyak et al., 1997).    
The death receptor pathways are activated through the transactivation of 
Killer/DR5, DR4, Fas/Apo-1, and Pidd by p53 (Sun, 2006). In response to 
chemotherapeutic agents and TRAIL, the extrinsic pathway is activated by the 
transactivation of DR 4 and DR 5 (Liu et al., 2004; Sheikh et al., 1998).   Pidd also leads 
to apoptosis through the extrinsic pathway, and it is transactivated by p53 following 
ionizing radiation in MEFs (Lin et al., 2000).   Although Fas is also activated by p53, the 
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induction of Fas is tissue specific and often does not require p53 (Bouvard et al., 2000; 
Muller et al., 1998).           
 p53 can also transcriptionally represses genes for the induction of apoptosis,    
such as Igfr, Bcl-2, and survivin, which are cell survival genes (Levine, 1997; Vogelstein 
et al., 2000).  There are three known mechanisms for the activation of apoptosis by 
repression of these genes (Ho and Benchimol, 2003).  First, p53 interferes with the 
function of DNA-binding transcriptional activators.   Second, p53 interferes with the 
basic components of the transcriptional machinery.  Third, p53 alters chromatin structure 
by recruiting chromatin-modifying factors such as histone deacetylases (HDAC) to 
reduce promoter accessibility to the transcriptional machinery and activator proteins.         
 
1.4.4.2.   Transcription-Independent Pathway 
 Although p53 is a transcription factor that activates an ever-increasing number of 
target genes, transcription-independent activity of p53 has been receiving increasing 
attention (Moll et al., 2005).   The initial evidence that p53 might promote transcription-
independent apoptosis was discovered in 1994 by using cells expressing a temperature-
sensitive mutant p53 protein (Val135) (Caelles et al., 1994).   In this study, cells that 
undergo p53-dependent apoptosis upon the shift of temperature, exhibited apoptosis 
even after the cells were treated with drugs that inhibit transcription of p53 target genes.   
Additional studies using cells with transcriptionally inactive mutant p53 proteins have 
confirmed the transcription-independent apoptosis activated by p53 (Chen et al., 1996; 
Haupt et al., 1995; Wagner et al., 1994).  However, because of an initial lack of any idea 
about how p53 activates apoptosis through a transcription-independent mechanism, these 
studies were neglected until recently (Moll et al., 2005). Subsequently, Moll and 
colleagues (Marchenko et al., 2000; Sansome et al., 2001) showed that translocation of 
wildtype p53 to mitochondria induces p53-dependent apoptosis in vivo.  They also 
showed that mitochondrial p53 binds to BCL-2 and BCL-XL to inhibit their 
antiapoptotic activity (Chipuk et al., 2004; Mihara et al., 2003).  Another group also 
observed the localization of p53 to the mitochondria (Dumont et al., 2003) and 
discovered the ability of p53 to bind to proapoptotic protein BAK (Leu et al., 2004).   
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Other studies have shown that wildtype p53 can also directly activate apoptosis in the 
cytoplasm by binding to BAX (Chipuk et al., 2004).  Furthermore, a proapoptotic protein 
PUMA, which is transactivated by p53, also binds to p53 to release BCL-XL from p53, 
suggesting that nuclear and cytoplasmic proapoptotic function of p53 are coupled by 
PUMA (Chipuk et al., 2005).  Interestingly the kinetics of both transcriptional-dependent 
and –independent apoptosis induced by γ irradiation in vivo have revealed that the 
apoptotic response occurs in two waves (Erster et al., 2004); the first apoptotic response 
induced by translocation of p53 to mitochondria occurred within 30-60 min after the 
initial stress response followed by the second apoptotic response induced by 
transcription of p53 target genes.  Another study has suggested that transcription-
dependent response induced by low dose irradiation is primarily responsible for the 
induction of cell cycle arrest whereas the transcription-independent response activated 
by high dose irradiation leads to the induction of apoptosis (Speidel et al., 2006).   Taken 
together, these studies show that transcription-independent function of p53 is also 
critical in the induction of apoptosis.  Whether p53 is activated in response to teratogen 
exposures and whether the induction of apoptosis is through transcription-dependent or –
independent response is the focus of the research presented in this dissertation (section 
2).                         
 
1.4.5.   p53 Pathways 
1.4.5.1.   Apoptosis 
 This topic is discussed in detail in sections 1.3, 1.4.1, 1.4.4, and 5.   Please refer 
to these sections. 
  
1.4.5.2.   Cell Cycle Arrest 
 The cell cycle consists of a series of events by which a cell duplicates its genetic 
material and divides into two identical daughter cells.   The orderly sequence of events 
consists of four distinct phases.   The genetic material is duplicated only once in the S 
(synthesis) phase, and the cell with duplicated chromosomes is divided equally to the 
two daughter cells in the M (mitosis) phase.   The phase preceding the S phase is called 
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G1 (gap 1) phase, and phase between the S and M phase is called G2 (gap 2) phase.   
Most of the terminally differentiated cells in the body of adults, however, are maintained 
in a phase called G0, which is a non-dividing, resting stage that branches out from the 
early G1 stage (Tessema et al., 2004).   G1 and G2 are critical for the regulation of cell 
cycle.   The shift from one phase to another is strictly controlled by certain classes of 
cellular proteins.   Cyclin dependent kinases (CDKs) are serine/threonine protein kinases 
bound and activated by cyclins that appear and disappear strictly during the cell cycle 
phases (Sherr, 1996).  Currently 16 cyclins and 9 CDKs have been identified in 
mammals although not all of them have a defined function in cell cycle regulation 
(Johnson and Walker, 1999).   In addition, the progression of the cell cycle is controlled 
at several points of cell cycle termed cell-cycle checkpoints (Tessema et al., 2004).   
Checkpoints ensure the proper DNA replication and chromosome segregation as well as 
halt the cell cycle in case of DNA damage or errors.  The cell cycle is arrested to prevent 
genomic instability that results from defects in the cell cycle.   Cell cycle arrest at the 
G1/S checkpoint prevents cells from duplicating defective or damaged chromosomes 
while G2/M checkpoint ensures properly replicated DNA/chromosomes before cells 
enter into mitosis.   The final checkpoint exists at the metaphase of mitosis, which is 
before the separation of sister chromatid occurs.   The checkpoints in the gap phases are 
mediated by the two families of cyclin kinase inhibitors (CKIs), INK4 family (p15INK4b, 
p16INK4a, p18INK4c, and p19INK4d) and/or the CIP/KIP family (p21CIP1, p27KIP1, and 
p57KIP2).   The INK4 family members only function at G1 checkpoint whereas the 
CIP/KIP family serves at both checkpoints as well as in all the four cell cycle phases 
(Sherr, 2000).                           
 In response to genotoxic stress such as ionizing radiation ATM and ATR can 
induce cell cycle arrest.   ATM and ATR activate checkpoint kinases, CHK1 and/or 
CHK2 (Chaturvedi et al., 1999; Sanchez et al., 1997), which in turn phosphorylates and 
inhibits CDK1 (Vermeulen et al., 2003). ATM, ATR, CHK1, and CHK2 also 
phosphorylate and activate p53.   Three proteins, p21, 14-3-3σ, and GADD45 are the 
main cell cycle-related target genes of p53.  p21 has the ability to induce cell cycle arrest 
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at both G1 and G2 checkpoint.  It binds and inactivates CDK4, 6/cyclin D and 
CDK2/cyclin E complexes, resulting in pRB hypophosphorylation and cell cycle arrest 
at G1 phase (Stewart and Pietenpol, 2001).   p21 also arrests cells at G2 checkpoint by 
inhibiting CDK1/cyclin B1 (Flatt et al., 2000; Innocente et al., 1999).   14-3-3σ binds to 
CDC25C, which is a phosphatase responsible for the activation of CDKs, or to 
CDK1/cyclin B complex, which induces export of this complex to the cytoplasm and 
inhibits the function of these proteins (Abraham, 2001; Furnari et al., 1997; Stewart et al., 
2003).   The transactivation of 14-3-3σ activates cell cycle arrest only at G2 phase 
(Nurse, 2002).   GADD45 also induces a G2 arrest by altering the expression of cyclin 
B1 or CDC25C (Wang et al., 1999).  
  
1.4.5.3.   Factors That Decide Which Pathway is Activated 
How does p53 decide whether cells undergo cell cycle arrest or apoptosis?   How 
does p53 know which genes to turn on or off to achieve the desirable cell fate, for 
example, apoptosis for cell death or cell cycle arrest for cell survival?   This question has 
been a focus of intensive research (Aylon and Oren, 2007; Harris and Levine, 2005; 
Laptenko and Prives, 2006), and three important mechanisms for deciding cell fate have 
been elucidated (Fig. 1.8).   Recent studies indicated that different affinities of p53 
toward different p53 response elements may affect promoter choice and cell fate 
(Laptenko and Prives, 2006). Generally growth arrest related genes tend to contain high 
affinity sites whereas proapoptotic genes seem to contain low affinity sites (Inga et al., 
2002), which indicates that cells make a maximum attempt to retain cells for survival.   
In addition, several co-factors and transcription factors have been discovered that guide 
p53 to promoters of specific genes in order to induce a particular pathway (Aylon and 
Oren, 2007).   For example, recently discovered apoptosis-stimulating protein of p53 
(ASPP) family proteins, ASPP1 and ASPP2, bind to the DNA binding domain of p53 
upon cellular damage and specifically enhance p53-induced apoptosis by directing p53 
to the promoters of proapoptotic genes such as Bax and PIG3, but not to the promoters 
of cell cycle genes and regulatory genes such as p21 and Mdm2 (Sullivan and Lu, 2007).   
Transcription factor BRN3b also binds to p53 to promote the activation of proapoptotic 
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genes such as Bax selectively (Budhram-Mahadeo et al., 2006).  In contrast, several 
different proteins including BRN3a, YB1, and Hzf selectively stimulate cell survival by 
transcriptionally activating cell cycle related genes such as p21 and 14-3-3σ (Aylon and 
Oren, 2007).   Finally, the pattern of post-translational modifications of p53 may well 
control the promoter choice and cell fate.   For example, phosphorylation of ser-46 has 
been observed to specifically induce p53 proapoptotic genes such as Noxa, p53AIP1, and 
p53RFP (Nakamura et al., 2006).   The life-death decision is also made at lys-320 as 
well as other lysines located in the C-terminal section of p53 (Le Cam et al., 2006).   
Acetylation of lys-320 leads to apoptosis whereas ubiquitylation at this site directs cell 
fate toward growth arrest by activating p21 and cyclin G1.  These studies beautifully 
illustrate how cells decide upon a certain cell fate in response to a variety of stimuli and 
how strictly p53 is regulated and controlled so as to achieve the desired outcome.                  
 
 
Figure 1.8. Differential regulation of p53 target genes.  Adapted from Aylon and Oren, (2007). 
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1.4.6.   p53 and MicroRNAs 
1.4.6.1.   Overview of MicroRNAs 
 The recent discovery of small RNA molecules, known as microRNAs (miRNAs), 
has quickly expanded our view of gene regulation and  revealed further complicated 
mechanisms of gene regulation in eukaryotes (Ambros, 2004; Bartel, 2004; He and 
Hannon, 2004).  miRNAs are small 18- to 24-nucleotide long RNAs that bind to mRNAs  
and regulate gene expression largely by inhibiting their expression either by interfering 
with translation or by destabilizing the target mRNAs (Meister and Tuschl, 2004; Pillai 
et al., 2007).   Currently, nearly 800 miRNA have been predicted to exist in humans 
(Bartel, 2004; Bentwich et al., 2005).   A series of steps are involved in the biosynthesis 
of miRNAs.   A long primary miRNA (pri-miRNA) is first translated from non-coding 
polycistronic regions of the genome by polymerase II (Pol II) (Zhou et al., 2007).   These 
pri-miRNA transcripts, which can exceed 1 kb and give rise to a number of different 
miRNAs (Du and Zamore, 2005), are then cleaved by the nuclear ribonuclease III 
(RNase III) Drosha and transported from the nucleus to the cytosol by exportin5.   The 
pre-miRNA, that is now a 70 – 100 nt stem loop, is processed by a second RNase III 
Dicer to produce a mature miRNA duplex (Du and Zamore, 2005; Kosik, 2006).   The 
duplex unwinds and the single strand is incorporated into the RNA-induced silencing 
complex (RISC). RISC complex then binds to its target mRNA and silences its 
expression. 
It is now clear that miRNAs play important regulatory roles in developmental 
timing and patterning, cellular differentiation, proliferation, organogenesis, and 
apoptosis (Alvarez-Garcia and Miska, 2005; Ambros, 2004).  In mouse embryos, 
miRNAs are expressed in stage- and tissue-specific manner (Mineno et al., 2006; 
Schulman et al., 2005).  In addition, exposures that induce developmental anomalies, 
such as folate deficiency and sodium arsenite, are known to increase global miRNA 
expression in human lymphoblastoid cells (Marsit et al., 2006).   Furthermore, recently 
another group of small RNAs called germline-specific PIWI-interacting RNAs 
(piRNAs), which play roles in spermatogenesis, have been discovered and have been 
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implicated in the inheritance of epigenetic information.   The importance of miRNA in 
cellular responses to teratogens/xenobiotics as well as in disease pathology, particularly 
cancer, will be a focus of intensive research. Prediction of target genes using 
computational algorithms as well as experimental identification of target genes have 
been also extensively investigated, and a number of on-line sites are publicly available.   
        
1.4.6.2.   Regulation of MicroRNAs by p53 
Several recent studies have shown that the miR-34 family miRNAs are induced 
by p53 and mediate apoptosis in response to DNA damage and oncogenic stress.   Using 
adriamycin as a DNA damaging agent, Chang et al. (2007) showed in colon cancer cells 
(HCT116) that miR-34a exhibited p53-dependent upregulation, and the characterization 
of the miR-34a primary transcript and promoter confirmed that miR-34a is directly 
transactivated by p53.   Tarasov et al., (Tarasov et al., 2007) utilized massively parallel 
sequencing and observed that miR-34a is differentially expressed in a p53-dependent 
manner.   In addition, two other studies have further confirmed independently that the 
transcriptional activation of miR-34a promotes p53-mediated apoptosis in vivo (Bommer 
et al., 2007; Raver-Shapira et al., 2007).  More studies followed and supported the 
previous studies as well as the identification of other miR-34 family, miR-34b and miR-
34c as the transcriptional target of p53 (Corney et al., 2007; He et al., 2007; Tazawa et 
al., 2007).    
 
1.4.7.   Expression of p53 in Mouse Embryos 
The importance of p53 in embryonic development was first suggested in 1980 
when protein expression of p53 was observed in primary embryo cells of day 12 – 14 
mouse but not those in cells of day 16 embryos (Mora et al., 1980).  Subsequently, a 
significant decrease in the level of p53 protein was observed in cells of day 11 embryos, 
indicating a functional role of p53 in embryogenesis (Chandrasekaran et al., 1981).  
Decrease in the level of p53 protein was also observed in the similar stage of rat and 
hamster embryos, suggesting that the expression pattern of p53 in embryos is 
evolutionary conserved (Chandrasekaran et al., 1981).  Decreased level of p53 mRNA in 
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mouse and chick was also observed at similar stages (Louis et al., 1988), and further 
examination of p53 mRNA using in situ hybridization revealed that in day 8.5 post-
coitum (p.c.) and 10.5 p.c. mouse embryos, expression level of p53 mRNA remains high 
and is detected ubiquitously (Schmid et al., 1991).  As differentiation of cells progresses, 
the expression of p53 mRNA becomes more pronounced in specific tissues including the 
brain, liver, lung, thymus, intestine, salivary gland and kidney.  The level of p53 mRNA, 
then, decreases significantly and rapidly when cells are in the terminal differentiation 
stage beginning on day 11 in the mouse (Rogel et al., 1985).  Overall, these studies have 
shown that in developing embryos the level of p53 protein and mRNA expression both 
decrease significantly at a certain stage, suggesting an important functional role for the 
protein during these proliferative stages.       
Although the expression levels of p53 differ among embryonic stages and may 
suggest a functional role of p53 during embryogenesis, the expression of p53 is not 
always correlated with the activation of p53.  In unstressed cells, p53 is believed to be 
biochemicaly inactive, and post-translational modification and translocation of p53 are 
often necessary for the activation of p53 (Eizenberg et al., 1996, refer to section 1.4.4).  
Using lacZ transgenic mice in which a bacterial lacZ marker gene is regulated by a 
promoter with a p53 DNA response element, three studies have shown that in early 
stages (day 8.5 – 12.5) most of the expressed p53 is inactive, suggesting a post-
translational control on the activity of p53.  Weak but pronounced expression of active 
p53, however, was observed in the branchial arches and the periphery of the somites in 
day 8.5 embryos, branchial arches, the tips of the limb buds, and the midbrain-hindbrain 
boundary in day 10.5 embryos, and in the forebrain and in the hair follicles of the 
sensory vibrissae in day 12.5 embryos (Gottlieb et al., 1997).  Other studies have also 
shown that active p53 is expressed in the brain of day 8, 10, 11 embryos and at all later 
stages (day 15, 17, 19 embryos and newborn mice) (Komarova et al., 1997; MacCallum 
et al., 1996).  These studies using lacZ transgenic mice have all shown that although p53 
protein and mRNA are highly expressed during early embryogenesis, most of this p53 is 
inactive, suggesting that p53 protein level is not always correlated well with its 
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functional activity (Lutzker and Levine, 1996).  However, in the early stage of 
embryogenesis the highest level of p53 expression is in the developing nervous system.  
Thus, this particular organ may be most susceptible to maldevelopment in the absence of 
p53 because of an inability to induce apoptosis or arrest cell cycle in neuronal precursor 
cells at the time of neural tube closure (Choi and Donehower, 1999).  Therefore, this 
temporal and spatial regulation of p53 in embryogenesis supports the idea that p53 may 
have an important role in the process of embryonic development (Almog and Rotter, 
1997).  The role of p53 in normal development and gene and miRNA expression 
differences in p53-deficient mouse embryos are the focus of the research presented in 
this dissertation (section 3). 
 
1.4.8.   p53 Transgenic Mice 
 Further insight into the role of p53 in embryonic development came through the 
observation of p53 knockout mice.   The first abnormality in p53-deficient mice was 
reported by two independent research groups in 1995 (Armstrong et al., 1995; Sah et al., 
1995).   Although mice lacking p53 alleles are viable, 2-6% of the offspring exhibit 
exencephaly resulting from the abnormal neural tube closure.  In addition, some p53-
deficient pups exhibited ocular, limb and tooth defects.  Significantly increased mortality 
in utero or soon after birth was also observed.  These studies also revealed that the p53-
deficient mice exhibiting NTDs are predominantly females, a situation also found in 
human exencephaly cases as well as in other mouse mutants, e.g., 1/Hipk2, Efna5, 
Marcks, Nif1, and xn mutants (Harris and Juriloff, 2007; Seller, 1987, 1995).   
 
1.4.9.   p53 as a Teratogen Enhancer or Suppressor 
Although mice lacking p53 alleles exhibit NTDs, embryos exposed to certain 
teratogens show the activation of p53. Whether p53 plays a role as a teratogen 
suppressor or inducer has been controversial, although the role of p53 as a suppressor 
has been more favored based on the protective role of p53 following a variety of 
environmental stresses (Choi and Donehower, 1999).  Recent studies have shown that 
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p53 functions as a teratological inducer (Boreham et al., 2002; Narai et al., 2006; Wang, 
2001), as well as a teratogen suppressor (Baatout et al., 2002; Bekaert et al., 2005; 
Moallem and Hales, 1998).  For example, it has been shown that the loss of p53 alleles 
increase the incidence of fetal resorption and developmental anomalies in mouse 
embryos exposed to benzo[a]pyrene (Nicol et al., 1995).   It was also shown that p53 -/- 
embryos showed higher incidence of structural anomalies and fetal death and a fewer 
number of apoptotic cells than that of p53 +/+ embryos exposed to radiation (Baatout et 
al., 2002; Norimura et al., 1996).  Others have also shown that the absence of p53 
resulted in the increased limb defects but no signs of apoptosis (Moallem and Hales, 
1998).   These studies suggest that p53 acts as a teratological suppressor.   In contrast, 
eye defects in mouse embryos exposed to 2-chloro-2’-deoxyadenosine (2CdA) was 
mediated by p53-dependent apoptosis, suggesting that p53 acts as a teratogen inducer 
(Wubah et al., 1996).  Other studies have also shown that the lack of p53-dependent 
apoptosis resulted in reduced the incident of limb defects and cleft palate (Boreham et 
al., 2002; Narai et al., 2006; Wang, 2001).   Examination of these studies suggests that 
the role of p53 differs by the type of teratogen as well as the type of malformations 
evaluated.  Most studies that have identified p53 as a teratogen suppressor have 
examined multiple types of malformations as well as resorptions (Baatout et al., 2002; 
Bekaert et al., 2005; Nicol et al., 1995; Norimura et al., 1996) whereas studies that have 
identified p53 as a teratological inducer have investigated specific malformations such as 
eye defects, limb malformations, or cleft palate (Boreham et al., 2002; Narai et al., 2006; 
Wang, 2001; Wubah et al., 1996).  The role of p53 in teratogen-induced maldevelopment 
is the focus of the research presented in this dissertation (section 4).  
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2.  TERATOGEN-INDUCED ACTIVATION OF P53 IN EARLY 
POST-IMPLANTATION MOUSE EMBRYOS* 
 
2.1.   OVERVIEW 
HS and 4CP activate the mitochondrial apoptotic pathway in day 9 mouse 
embryos. Previous microarray analyses revealed that several p53 target genes are 
upregulated after exposure to HS or 4CP, suggesting a role for p53 in teratogen-induced 
apoptosis. To explore the role of p53, we assessed the activation of p53 in day 9 mouse 
embryos exposed to HS or 4CP in vitro.    
Both teratogens induced the accumulation of p53 and phosphorylation of p53 at 
ser-15, two hallmarks of p53 activation.   HS and 4CP also induced an increase in Noxa 
and Puma mRNAs, transcripts of two known proapoptotic p53 target genes; however, 
these two teratogens did not induce significant increases in NOXA and PUMA proteins, 
suggesting that p53 does not activate the mitochondrial apoptotic pathway by 
transcriptionally upregulating the expression of NOXA and PUMA proteins. HS and 
4CP also induced the expression of p21 mRNA and protein, suggesting a role for p53 in 
teratogen-induced cell cycle arrest. Previously, we also showed that HS and 4CP activate 
the apoptotic pathway in the embryo proper (head and trunk) but not in the heart. We 
now show that HS and 4CP induce a robust activation of p53 in the embryo proper but 
an attenuated induction in the heart. HS and 4CP induce the expression of p21 protein in 
majority of the cells in the embryo; however, expression of NOXA and PUMA proteins 
were not significantly induced in heads, hearts, or trunks of day 9 embryos. Overall, our 
results suggest that p53 may play a transcription-dependent role in teratogen-induced 
cell cycle arrest but a transcription-independent role in teratogen-induced apoptosis in 
day 9 mouse embryos exposed to HS or 4CP. 
____________ 
*Reprinted with permission from “Teratogen-induced activation of p53 in early 
postimplantation mouse embryos” by Hiromi Hosako, Sally A. Little, Marianne Barrier, 
and Philip E. Mirkes, 2007. Toxicological Sciences, 95(1), 257-269, Copyright 2007 
Oxford University Press.  
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2.2.   INTRODUCTION 
Over 1,200 chemical and physical agents are known to cause structural and/or 
functional congenital anomalies in experimental animals (Shepard, 2001). Although the 
mechanisms by which these agents disrupt normal development are often not well 
understood, it is known that many teratogens induce cell death in tissues that 
subsequently develop abnormally and give rise to structural malformations (Knudsen, 
1997; Scott, 1977).  In addition, teratogens often induce cell death in areas of normal 
PCD suggesting a mechanistic link between PCD and teratogen-induced cell death 
(Menkes et al., 1970; Milaire, 1983; Sulik et al., 1988). Finally, mouse mutants, in which 
genes known to play a role in apoptosis have been deleted, exhibit abnormal levels of 
apoptosis associated with abnormal development often culminating in structural birth 
defects (Boya and de la Rosa, 2005).  Taken together, available data indicate that the 
dysregulation of apoptosis is consistently correlated with embryo/fetal lethality and/or 
birth defects.   
Previously, we showed that HS, 4CP, and staurosporine, known animal 
teratogens, induce apoptosis in early postimplantation rodent embryos by activating the 
mitochondrial apoptotic pathway. Activation of this pathway is characterized by the 
release of cytochrome c and the subsequent activation of caspases, cleavage of poly 
ADP-ribose polymerase, and DNA fragmentation (Little et al., 2003; Little and Mirkes, 
2002; Mirkes and Little, 1998, 2000). Thus, at least for this small sampling of 
teratogens, teratogen-induced apoptosis in early postimplantaion mouse embryos 
involves activation of the mitochondrial apoptotic pathway.  
Using vital dyes and TUNEL staining, we have also shown that teratogen-
induced cell death is cell specific, that is, some cells in the mouse embryo die, 
particularly in areas of normal PCD, while other cells, often neighboring cells, survive 
(Mirkes and Little, 1998; Umpierre et al., 2001). For example, cells of the embryonic 
nervous system (neuroepithelial cells) are particularly sensitive to teratogen-induced cell 
death, whereas mesenchymal cells surrounding the neuroepithelium are less sensitive 
(Umpierre et al., 2001). In contrast, cells of the embryonic heart are resistant to cell 
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death induced by a variety of teratogens (Gao et al., 1994; Umpierre et al., 2001). We 
have also shown that although teratogens activate the apoptotic pathway in sensitive 
cells, these hallmarks of apoptosis are not activated in cells of the heart (Mirkes and 
Little, 1998; Umpierre et al., 2001). These results indicate that the mitochondrial 
apoptotic pathway is blocked in heart cells at the level of the cytochrome c release from 
mitochondria or at some point upstream of cytochrome c release.  
The rapid induction of the mitochondrial apoptotic pathway in teratogen-
sensitive neuroepithelial cells and the failure to activate this pathway in teratogen-
resistant heart cells suggest that the embryo must possess factors that regulate the efflux 
of cytochrome c and thereby the activation of the mitochondrial apoptotic pathway. To 
begin to identify proteins and signaling pathways that regulate cytochrome c release, we 
compared gene expression patterns in HS- or 4CP-treated and –untreated mouse 
embryos before and during the activation of the mitochondrial apoptotic pathway, using 
DNA microarray gene expression profiling. Our studies identified five candidate 
‘‘apoptosis-related’’ genes (Mikheeva et al., 2004). Three of these genes, Mdm2, Gtse1, 
and Cyclin G, are coordinately upregulated by both HS and 4CP during the first 5 hr 
after embryos are exposed to these teratogens. Because these three genes are all p53-
regulated genes, our microarray data suggested that HS and 4CP both activate p53.  
p53 is essential for preventing inappropriate cell proliferation and maintaining 
genomic integrity following a variety of stresses (Harris and Levine, 2005). The level of 
p53 is maintained at a low level because of its rapid turnover through proteolysis. 
Following DNA damage, hypoxia, oncogene expression, and nucleotide depletion, p53 
undergoes extensive posttranslational modifications. These modifications result in the 
accumulation of p53, its translocation into the nucleus, enhanced binding to DNA, and 
transcriptional activation of its target genes. The protein products of these target genes 
subsequently regulate a number of cellular processes, the most well studied being cell 
cycle arrest and apoptosis.  
The objectives of the current studies were (1) to assess the kinetics of p53 
activation in day 9 embryos exposed to HS or 4CP, (2) to determine whether key p53 
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proapoptotic or cell cycle arrest genes/proteins are induced by HS and/or 4CP, (3) to 
assess whether p53 is activated in cells sensitive and resistant to teratogen-induced 
apoptosis, and (4) to determine whether key p53 proapoptotic or cell cycle arrest 
genes/proteins are induced by HS and/or 4CP in cells sensitive and resistant to teratogen-
induced apoptosis. Our data show that p53 is rapidly activated in day 9 mouse embryos 
exposed to HS or 4CP and suggest that once activated, p53 plays an important role in 
teratogen-induced apoptosis and cell cycle arrest. 
 
 
2.3.   MATERIALS AND METHODS 
In Vitro Whole-embryo Culture: Primigravida Swiss-Webster mice were 
obtained from a local supplier. The morning following copulation was designated day 0 
of gestation. On the morning of day 9, conceptuses from multiple litters were explanted 
using the whole rodent embryo culture system established by New (1978) with the 
following modifications. Embryos from all litters were equally distributed among the 
different treatment groups. For each treatment group, 10–12 embryos were cultured in 
12 ml of media containing 80% heat-inactivated rat serum, 20% Hanks’ balanced salt 
solution (HBSS), 50 U/ml penicillin, 50 µg/ml streptomycin; gassed with a mixture of 
20%  O2, 5% CO2, 75% N2; and cultured for 1 hr prior to treatment. 
Embryo Exposure Conditions: Treatment of the embryos with 4CP, a 
preactivated analogue of cyclophosphamide (a gift of Michael Colvin, Johns Hopkins 
University), was initiated by direct addition of freshly prepared 250X solution of 4CP (in 
HBSS) to the culture medium resulting in a final concentration of 40 µM 4CP. HS-
treated embryos were exposed to 43 ºC for 15 min and then returned to 37 ºC (Mirkes, 
1985). Embryos were continued in culture with drug or following heat shock for up to 5 
hr.  
Embryo Collections: At indicated times, treated and control embryos were 
removed from culture, dissected free of associated membranes and rinsed in cold HBSS. 
Embryos from each treatment group were pooled prior to the preparation of embryo 
lysates. For those experiments requiring embryo parts, groups of embryo were further 
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dissected into heads, hearts, and trunks using a fine lancet and forceps. The dissected 
head consisted of the prosencephalon and mesencephalon and the trunk consisted of the 
remainder of the embryo minus the heart. Dissected heads, hearts, and trunks were 
separately pooled prior to the preparation of head, heart, and trunk lysates.  
Western Blot: Following treatment, washed embryos or embryo parts were 
sonicated in RIPA lysis buffer (10mM HEPES, pH 7.4, 42 mM KCl, 5 mM MgCl2, 0.1 
mM EDTA, 0.1 mM EGTA, 1% Triton-X100 plus 1 mM PMSF, 1 mM DTT, 1 µg/ml 
pepstatin A, 1 µg/ml leupeptin, and 5 µg/ml aprotinin). Aliquots were taken for protein 
quantification using Bicinchoninic Acid (BCA) assay and equal amounts of protein of 
each sample in 2X laemmli buffer were applied to 12.5% PAGE (Laemmli, 1970) and 
transferred to PVDF membranes. Immunoblot analysis was carried out as previously 
described (Mirkes and Little, 1998) using 3% nonfat dry milk in tris-buffered saline 
(TBS)/0.5% Tween-20 (TW) for blocking and antibody dilutions. The primary 
antibodies used were mouse monoclonal anti-Pan p53 at 1:500, rabbit polyclonal anti-
human phosphoserine-6, -9, -15, -20, -37, -46, -392 specific p53 (Cell Signaling, 
Beverly, MA) at 1:1000– 1:2000 (note: human ser-15 is equivalent to mouse serine-18), 
mouse monoclonal anti-p21 at 1:625 (Santa Cruz Biotechnology, Santa Cruz, CA), 
rabbit polyclonal anti-NOXA at 1:1000 (Ingenex, San Diego, CA), rabbit polyclonal 
anti-a PUMA at 1:5000 (Oncogene Science, San Diego, CA), mouse monoclonal anti-
GAPDH at 1:1,200,000 (Chemicon, Temecula, CA), and mouse monoclonal anti-actin at 
1:300,000 (Sigma, St Louis, MO). Membranes were incubated overnight with primary 
antibodies and then washed four times with TBS/TW. HRP linked anti-mouse or anti-
rabbit secondary antibodies (Amersham Life Sciences, Arlington Heights, IL) were used 
at 1:3000 for 2 hr, and membranes were washed twice with TBS/TW and three times 
with TBS. Antigen-antibody complexes were visualized by development with ECL Plus 
(Amershan Life Sciences) and autoradiography. For image analysis, antigen antibody 
complexes were detected using the KODAK Image Station 440, and quantification of 
protein band densities was determined using ImageQuant (Molecular Dynamics, 
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Sunnyvale, CA). Differences in levels of particular polypeptides were assessed using t-
test (Statview 512).  
Real-Time PCR: Embryos for real-time PCR were quick-frozen and stored at - 
80 ºC. Total RNA was isolated from embryos using the RNeasy mini kit 
(Qiagen,Valencia, CA) according to the manufacturer’s instructions. After treatment 
with 1 U DNase (Promega, Madison, WI) at 37 ºC for 30 min, followed by incubating 
with stop solution at 65 ºC for 10 min, 2 µg total RNA was reverse transcribed using 
0.025 µlg/µl oligo-d(T)15 primer and 0.5 mM dNTP mix (Roche Applied Science, 
Indianapolis, IN) by heating at 70 ºC for 5 min, followed by cooling on ice. The 
mRNAwas then copied into cDNA by diluting 10-fold with first-strand buffer containing 
100 U SuperScript II (Gibco, Rockville, MD), 10 mM DTT and 1 U/µl RNasin 
(Promega) and incubated at 45 ºC for 1 hr. The reaction was terminated by placing at 70 
ºC for 15 min and then brought to 4 ºC and stored at - 80 ºC until analyzed by real-time 
PCR. Fluorogenic 5’ nuclease assays (TaqMan) were carried out in Functional 
Genomics Laboratory in the Center for Ecogenetics and Environmental Health at the 
University of Washington, Seattle, WA, using the ABI PRISM 7500 Sequence Detection 
System (Applied Biosystems Inc., Foster City, CA). Statistical differences of control to 
HS or 4CP samples were determined by ANOVA analysis followed by Dunnett’s post 
hoc test. 
Immunohistochemistry: Following treatment and embryo collections, embryos 
were immediately fixed in 4% paraformaldehyde for 2 hr at 4 ºC. The embryos were 
then dehydrated in several changes in ethanol, embedded in paraffin, sectioned at 5 µm, 
and mounted on glass slides. Tissue sections were heated at 58 ºC for 20 min, 
deparaffinized in histoclear, and rehydrated. Sections were then boiled for 20 min with 
sodium citrate buffer (pH 6.0) for antigen unmasking. Endogenous peroxidase activity 
was blocked by placing slides in 3% H2O2 in dH2O for 10 min. Slides were briefly rinsed 
in distilled water and in TBS/TW. Sections were blocked with 1% BSA in TBS for 1 hr.  
Primary antibody solutions, diluted in blocking solution, were placed on the sections 
overnight. The ser-15 p53 antibody (Cell Signaling) was prepared against a synthetic 
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phosphopeptide corresponding to residues surrounding ser-15 of human p53, and the 
dilution used was 1:50. To confirm the specificity of ser-15 p53, the primary antibody 
was incubated with the blocking peptide (Cell Signaling) for 30 min at room temperature 
and then the adsorbed primary antibody was placed on tissue sections and incubated 
overnight at room temperature. The p21 antibody (Santa Cruz Biotechnology) was 
prepared against amino acids 1–159 representing full-length p21 of mouse, and the 
dilution used was 1:50. Slides were washed three times in TBST for 5 min each. 
Biotinylated donkey anti-rabbit or sheep anti-mouse IgG secondary antibodies 
(Amersham) were placed at 1:200 for 30 min. The slides were washed as before and 
incubated in Vectastain Universal Elite ABC Reagent (Vector Laboratories, Burlingame, 
CA) for 30 min. Antigen-antibody complexes are visualized as brown staining. Slides 
were then rinsed in water, dehydrated, counterstained with hematoxylin, and 
coverslipped. 
 
 
2.4.   RESULTS 
To investigate the activation of p53, we measured two different but related 
aspects of teratogen-induced activation of p53, that is, p53 accumulation and site-
specific phosphorylation, in day 9 embryos exposed to HS or 4CP. To study p53 
accumulation, we used commercially available antibodies that recognize both 
unphosphorylated (Pan p53) and phosphorylated p53. To determine the kinetics of p53 
activation, we assessed total p53 accumulation at 1, 2.5, and 5 hr after initiation of 
exposure to HS or 4CP (Fig. 2.1). Figure 2.1A is a representative western blot showing 
that HS induces an apparent increase in total p53 as early as 2.5 hr after exposure. 
Densitometric analysis of western blots from three independent experiments shows that 
HS induces a statistically significant increase in total p53 at the 2.5- and 5-hr time points 
(Fig. 2.1B). We next determined whether another known teratogen, 4CP, also induced 
the activation of p53 in day 9 mouse embryos. Figure 2.1C shows that 4CP, like HS, 
induces an apparent increase in total p53 as early as 2.5 hr after exposure to 4CP; 
however, densitometric analysis of western blots from three independent experiments 
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indicates that a statistically significant increase is only observed at the 5-hr time point as 
shown in Figure 2.1D.  
 
 
Figure 2.1 Western blot analysis of the time course of total p53 (Pan p53) accumulation in 
cultured day 9 mouse embryos receiving no treatment (CT), a HS of 43 ºC for 15 min (A), or 
continuous exposure to 40 µM of 4CP (C). Densitometric analysis of three independent 
experiments is presented for HS- (B) and 4CP-treated embryos (D). * Indicates a significant 
difference from CT (p < 0.05). 
 
To study site specific phosphorylation of p53, we initially used commercially 
available antibodies that recognize p53 phosphorylated at specific serine residues (ser-6, 
-9, -15, -20, -37, -46, -392) and western blot analysis to determine which, if any, sites are 
phosphorylated in response to HS. Although phospho-specific antibodies to ser-6 (Fig. 
2.2, lanes 3 and 4), ser-9 (Fig. 2.2, lanes 5 and 6), ser-20 (Fig. 2.2, lanes 9 and 10), ser-
37 (Fig. 2.2, lanes 11 and 12), and ser-46 (Fig. 2.2, lanes 13 and 14) p53 failed to detect 
an increase in phosphorylated p53, the phospho-specific ser-15 p53 antibody (Fig. 2.2, 
lanes 7 and 8) detected a HS-induced increase in ser-15 p53. In addition, there may be a 
slight increase in ser-392 p53 (Fig. 2.2, lanes 15 and 16) induced by HS.  
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Figure 2.2. Western blot analysis of phosphorylation of p53. Lysates from control and heat-
shock–treated (HS, 43 ºC for 15 min) cultured day 9 mouse embryos were applied to 12.5% 
PAGE, transferred to PVDF membranes, and probed with Pan p53, ser-6 p53, ser-9 p53, ser-15 
p53, ser-20 p53, ser-37 p53, ser-46 p53, or ser-392 p53 antibodies. 
 
On the basis of these preliminary results, we next assessed the kinetics of HS- 
and 4CP-induced increases in ser-15 p53. Figure 2.3A is a representative western blot 
showing that HS induces an apparent increase in ser-15 p53 as early as 2.5 hr after 
exposure. Densitometric analysis of western blots from three independent experiments 
shows that HS induces a statistically significant increase in ser-15 p53 (Fig. 2.3B) at the 
2.5- and 5-hr time points. Figure 2.3C shows that 4CP, like HS, also induces an apparent 
increase in ser-15 p53; however, densitometric analysis of western blots from three 
independent experiments indicates that a statistically significant increase is only 
observed at the 5-hr time point (Fig. 2.3D).  
 
 
Figure 2.3. Western blot analysis of the time course of ser-15 p53 phosphorylation in cultured 
day 9 mouse embryos receiving no treatment (CT), a HS of 43 ºC for 15 min (A), or continuous 
exposure to 40 µM of 4CP (C). Densitometric analysis from three independent experiments is 
presented for HS (B) - and 4CP-treated embryos (D). * Indicates a significant difference from 
CT (p < 0.05). 
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Having shown that HS and 4CP both activate p53, we next sought to determine 
whether these two teratogens activated both arms of the p53 pathway, that is, one 
leading to cell cycle arrest and the other to apoptosis. To do this, we used real-time 
PCR and western blot analysis to quantitate the levels of p21, a major p53 target gene 
involved in cell cycle arrest, and Noxa and Puma, two ‘‘proapoptotic’’ p53 target genes.  
With respect to the cell cycle arrest arm of the p53 pathway, both HS and 4CP 
induce a significant increase in p21 mRNA but only at the 5-hr time point (Figs. 2.4A 
and B). Using western blot analysis, we show that p21 protein levels mirror p21 mRNA 
levels, with a significant increase in HS- and 4CP-induced p21 levels at the 5-hr time 
point (Fig. 2.4C and D, respectively).  
 
 
Figure 2.4. p21 mRNA (A and B) and protein expression (C and D) in cultured day 9 mouse 
embryos receiving no treatment (CT), a HS (43 ºC for 15 min), or continuous exposure to 40 µM 
of 4CP. Densitometric analysis from three independent western blot experiments is presented for 
HS(B)- and 4CP-treated embryos (C). * Indicates a significant difference from CT (p < 0.05). 
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With respect to the apoptosis arm of the p53 pathway, HS and 4CP induce 
apparent increases in Noxa mRNA at the 2.5- and 5-hr time points; however, only the 
HS- and 4CP-induced increases at the 5-hr time point are statistically significant (Fig. 
2.5A). Similarly, HS and 4CP also induce apparent increases in Puma mRNA at the 2.5- 
and 5-hr time points; however, only the HS-induced increase at 5 hr and 4CP-induced 
increase at 2.5 and 5 hr are statistically significant (Fig. 2.5B).  
Although HS and 4CP induced increases in Noxa and Puma mRNAs at the 5-hr 
time point, western blot analysis did not show significant increases in NOXA or PUMA 
protein at any of the time points studied (Fig. 2.6A–H). It should be noted that although 
other studies have identified several isoforms of PUMA (α, β, γ, and δ), only PUMA α is 
expressed in the day 9 mouse embryo. 
 
 
Figure 2.5. Noxa (A) and Puma (B) mRNA expression in cultured day 9 mouse embryos 
receiving no treatment (CT), a HS (43 ºC for 15 min), or continuous exposure to 40 µM of 4CP. 
* Indicates a significant difference from CT (p < 0.05). 
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Figure 2.6. Western blot analysis of the time course of NOXA (A–D) and PUMA (E–H) protein 
expression in cultured day 9 mouse embryos receiving no treatment (CT), a HS of 43 ºC for 15 
min (A and E), or continuous exposure to 40 µM of 4CP (C and G). Densitometric analysis from 
three independent experiments is presented for HS (B and F)- and 4CP (D and H)-treated 
embryos. 
 
Published research from our laboratory has shown that although HS and 4CP 
activate the mitochondrial apoptotic pathway leading to apoptosis in day 9 mouse 
embryos, activation of this pathway does not occur in cells of the embryonic heart, 
which are resistant to teratogen-induced apoptosis. On the basis of this information, we 
next compared the activation of p53 in day 9 mouse embryo hearts (resistant tissue) and 
the day 9 mouse embryo head and trunk (sensitive tissues). Figure 2.7A presents a 
representative western blot showing HS-induced increases in total p53 in heads and 
trunks but not hearts. Densitometric analysis of western blots from three independent 
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experiments shows that HS induces a statistically significant increase in total p53 in 
heads and trunks (Fig. 2.7B). In the heart, HS appears to induce a modest increase in 
total p53; however, this increase is not statistically significant. The results for total p53 
are mirrored by those for ser-15, that is, significant increases in ser-15 p53 in heads and 
trunks and a modest but not a significant increase in ser-15 p53 in hearts (Fig. 2.7C and 
D).  
 
 
Figure 2.7. Western blot analysis of Pan p53 accumulation (A) and ser-15 p53 phosphorylation 
(C) in cultured day 9 embryo heads, hearts, and trunks receiving HS exposure. Lysates of heads, 
hearts, and trunks were prepared from cultured day 9 mouse embryos at 5 hr after receiving no 
treatment (CT) or HS (43 ºC for 15 min). Densitometric analysis from three independent 
experiments is presented for Pan p53 (B) and ser-15 p53 (D). * Indicates a significant difference 
from CT (p < 0.05). 
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Although the western blot data clearly show that HS induces a robust activation 
of p53 in the day 9 mouse embryo head and trunk but only a modest increase in the 
heart, this approach does not provide any information concerning HS-induced activation 
of p53 in specific cells/tissues of the head and trunk. To obtain such data, we used an 
anti–ser-15 p53 antibody and immunohistochemistry (Fig. 2.8). Figure 2.8A is a 
parasagittal section from a day 9 control embryo. Occasional p53-positive cells (brown 
staining) are observed in the neuroepithelium (arrows in Fig. 2.8B) but not in the heart 
(Fig. 2.8C) or trunk (Fig. 2.8D). In contrast, many more p53-positive cells are observed 
in a comparable parasagittal section from a day 9 embryo exposed to HS and harvested 5 
hr after exposure (Fig. 2.8E). Although p53-positive cells are present in all tissues of the 
embryonic head and trunk, for example, outer epithelium, neuroepithelium, loose 
mesenchyme, and somites, the majority of cells in any one tissue are unstained. Higher 
magnification photomicrographs of the prosencephalon (Fig. 2.8F) and the trunk region 
(Fig. 2.8H) show robust staining in cells and different tissues, for example, epithelial, 
mesenchymal, and neural cells in the head. Even higher magnification photomicrographs 
show that this staining is nuclear (data not shown). In contrast, heart cells exhibit either 
no apparent staining or much reduced staining intensity (Fig. 2.8G). The lack of staining 
in Figure 2.8I–L, in which an adjacent section was stained with the anti–ser-15 p53 
antibody that had been adsorbed with the peptide used to make the primary antibody, 
confirms the specificity of the primary antibody. Overall, these immunohistochemical 
data confirm the western blot data showing that HS-induced activation is robust in some 
cells of the embryo proper but attenuated in cells of the heart.  
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Figure 2.8. Immunohistochemical detection of ser-15 p53 in cultured day 9 mouse embryos 
receiving no treatment (CT) or a HS of 43 ºC for 15 min. Magnified images of the head (B), 
heart (C), and trunk (D) of the control embryo (A) are presented. The arrows indicate 
immunoreactive cells. Magnified images of the head (F), heart (G), and trunk (H) of HS-treated 
embryo (E) are presented. To show the specificity of the antibody, section of the HS-treated 
embryo was stained with an anti–ser-15 p53 antibody that had been incubated with the peptide 
(I). Magnified images of the head (J), heart (K), and trunk (L) are presented. 
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A western blot analysis of the effects of 4CP exposure on p53 activation in day 9 
mouse embryo head, heart, and trunk shows that 4CP induces a statistically significant 
increase in total p53 (Fig. 2.9A and B) and ser-15 p53 (Fig. 2.9C and D) in heads and 
trunks. Unlike the situation in HS-treated embryos, 4CP induced an attenuated but 
statistically significant increase in total and ser-15 p53 levels in the heart (Fig. 2.9B and 
D).  
 
 
Figure 2.9. Western blot analysis of Pan p53 accumulation (A) and ser-15 p53 phosphorylation 
(C) in cultured day 9 embryo heads, hearts, and trunks receiving 4CP exposure. Lysates of 
heads, hearts, and trunks were prepared from day 9 mouse embryos at 5 hr after receiving no 
treatment (CT) or continuous exposure to 40 µMof 4CP. Densitometric analysis from three 
independent experiments is presented for Pan p53 (B) and ser-15 p53 (D). * Indicates a 
significant difference from CT (p < 0.05). 
 
Having shown that HS and 4CP induce a robust activation of p53 in the head and 
trunk and a more attenuated activation in the heart, we next sought to determine the 
extent to which these two teratogens activated both arms of the p53 pathway, that is, one 
leading to cell cycle arrest and the other to apoptosis. The induction of p21 in heads, 
hearts, and trunks is presented in Figure 2.10. HS-induced activation of p53 in the heads 
and trunks (Fig. 2.7) is correlated with a statistically significant induction of p21 (Figs. 
2.10A and B). Similarly, 4CP-induced activation of p53 in the heads and trunks (Fig. 
2.9) is correlated with a statistically significant induction of p21 (Fig. 2.10C and D). 
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Although there is no apparent activation of p53 in the heart (Fig. 2.7) and an attenuated 
but significant activation of p53 in heart cells from 4CP-treated embryos (Fig. 2.9), HS 
and 4CP both induced a statistically significant induction of p21 in the heart (Fig. 2.10B 
and D).  
 
 
Figure 2.10. Western blot analysis of p21 (A and C) in cultured day 9 embryo heads, hearts, and 
trunks. Lysates of heads, hearts, and trunks were prepared from cultured day 9 mouse embryos at 
5 hr after receiving no treatment (CT), a HS of 43 ºC for 15 min (A), or continuous exposure to 
40 µM 4CP (C). Densitometric analysis from three independent experiments is presented for p21 
(B and D). * Indicates a significant difference from CT (p < 0.05). 
 
To confirm the increased mRNA and protein expression levels of p21 in day 9 
mouse embryos after the exposure to HS, and to provide information concerning HS-
induced activation of p21 in specific cells/tissues of the head and trunk, 
immunohistochemistry was used to stain p21 protein in embryos (Fig. 2.11). Figure 
2.11E is a parasagittal section from a day 9 embryo taken 5 hr after exposure to HS and 
probed with an anti-p21 antibody. Many cells throughout all regions including the heart 
cells are uniformly stained. Higher magnification photomicropraphs of the 
prosencepahalon (Fig. 2.11F), heart (Fig. 2.11G), and the trunk region (Fig. 2.11H) show 
distinct staining in many cells and different tissues. Control embryos (Fig. 2.11A) 
stained with p21 showed an absence of staining in the head (Fig. 2.11B), heart, (Fig. 
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2.11C), and trunk (Fig. 2.11D), except for the specific staining of a subset of cells in 
somites. Overall, these immunohistochemical data show that HS-induced activation is 
robust in cells of the embryo, including heart cells, and confirm the western blot data.  
 
 
Figure 2.11. Immunohistochemical detection of p21 in cultured day 9 mouse embryos receiving 
no treatment (CT) or a HS of 43 ºC for 15 min. Magnified images of the head (B), heart (C), and 
trunk (D) of the control embryo (A) are presented. The arrow indicates immunoreactive cells in 
somites. Magnified images of the head (F), heart (G), and trunk (H) of the HS-treated embryo 
(E) are presented. 
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We next determined whether HS- and 4CP-induced activation of p53 was 
accompanied by an increased expression of NOXA and PUMA proteins, two 
proapoptotic proteins known to be transcriptional target genes of activated p53, in heads, 
hearts, and trunks of day 9 mouse embryos (Fig. 2.12). Western blot analysis (Figs. 
2.12A and E) showed that HS does not induce a significant increase in NOXA (Fig. 
2.12B) or PUMA (Fig. 2.12F) protein expression in either heads, hearts, or trunks; 
however, our results do show that NOXA and PUMA proteins are constitutively 
expressed in heads, hearts, and trunks of unexposed embryos. Similar results were 
obtained when embryos were exposed to 4CP (Figs. 2.12C, D, G, and H). 
 
 
Figure 2.12. Western blot analysis of NOXA (A and C) and PUMA (E and G) in cultured day 9 
embryo heads, hearts, and trunks. Lysates of heads, hearts, and trunks were prepared from day 9 
mouse embryos at 5 hr after receiving no treatment (CT), a HS (43 ºC for 15 min), or continuous 
exposure to 40 µM 4CP. Densitometric analysis from three independent experiments is presented 
for NOXA (B and D) and PUMA (F and H). 
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2.5.   DISCUSSION 
Previously published gene expression profiling studies revealed that three known 
p53 target genes, Mdm2, Gtse1, and Cyclin G, were significantly upregulated in day 9 
mouse embryos after exposure to HS or 4CP, thus implicating p53 as an important 
regulator of teratogen-induced apoptosis (Mikheeva et al., 2004). Called the ‘‘guardian 
of the genome,’’ p53 is known to play a key role in regulating whether a cell will arrest, 
undergo apoptosis, senesce, or differentiate in response to various stresses. To achieve 
this regulatory role, p53 must be activated by a variety of posttranslational 
modifications, for example, phosphorylation, acetylation, and ubiquitination (Brooks and 
Gu, 2003). Using a panel of phospho-specific p53 antibodies directed against human ser-
6, -9, -15, -20, -37, -46, and -392 p53, we have now shown that p53 is phosphorylated at 
ser-15 after exposure to HS or 4CP. Phosphorylation at this serine is known to regulate 
apoptosis because p53- mediated apoptosis is significantly impaired when ser-15 is 
mutated to alanine (Chao et al., 2003; Sluss et al., 2004). Using an antibody that 
recognizes phosphorylated and nonphosphorylated p53 (Pan p53), we also showed that 
the increase in ser-15 p53 is correlated with an increase in total p53. Finally, using ser-
15 p53 antibodies and immunohistochemistry, we have shown that activated p53 
localizes to the nucleus of stained cells. Together, these results show that HS and 4CP, 
two teratogens that induce apoptosis in day 9 mouse embryos, also activate p53, a 
known regulator of apoptosis.  
Our data also show that p53 is rapidly activated by both HS and 4CP, with 
activation occurring between 1 and 2.5 hr after exposure. Thus, p53 is activated before 
HS- and 4CP-induced release of mitochondrial cytochrome c and activation of the 
caspase cascade, which occur between 2.5 and 5 hr after exposure to these two 
teratogens (Little and Mirkes, 2002; Mirkes and Little, 1998, 2000). Although not 
definitive, the kinetics of p53 activation are consistent with a regulatory role for p53 in 
teratogen-induced apoptosis. We are currently using p53 mutant mice to determine 
whether p53 is required for teratogen-induced apoptosis.  
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Although our data are consistent with a regulatory role for p53 in teratogen-
induced apoptosis, the mechanisms by which p53 activates the mitochondrial apoptotic 
pathway in the day 9 mouse embryo are unclear. One known mechanism, elucidated 
from cell culture studies, is the transcription-dependent expression of proapoptotic 
genes. Two of the major downstream targets of p53-mediated apoptosis are Noxa and 
Puma, transcripts of proapoptotic genes belonging to the Bcl-2 family. At least in some 
settings, NOXA protein is an essential mediator of p53-dependent apoptosis (Yakovlev 
et al., 2004) and activates the mitochondrial apoptotic pathway by interacting with Bcl-2 
family members resulting in the release of cytochrome c and the activation of caspase-9 
(Oda et al., 2000a; Seo et al., 2003). Other studies suggest that PUMA protein interacts 
with BCL-2 and BCL-XL and thereby induces mitochondrial membrane potential 
change, cytochrome c release, and caspase activation (Chipuk et al., 2005; Yu and Zhang, 
2003; Yu et al., 2001).  
Our results indicate that although HS and 4CP both induce increased expression 
of Noxa and Puma mRNAs, the increased expression of these mRNAs is not coupled 
with an increased expression of NOXA and PUMA proteins. Although we cannot 
explain the apparent disconnect between mRNA and protein levels, the explanation may 
involve a timing issue. Our data show that the increases in Noxa and Puma mRNA levels 
are significant at the 2.5- and 5-hr time points, latter being the latest time point studied in 
terms of NOXA and PUMA protein levels. Thus, there may not have been sufficient 
time for the increases in Noxa and Puma mRNAs to be translated into increases in their 
respective proteins that could be detected by western blot analysis. Had we measured 
NOXA and PUMA protein levels at some later time point, we may have observed the 
expected increases. Nonetheless, even if this were observed, increases in NOXA and 
PUMA proteins at times later than 5 hr would not be relevant to the initial activation of 
the mitochondrial apoptotic pathway, which is activated at some time between 2.5 and 5 
hr after exposure to these teratogens.  Thus, our data suggest that p53-mediated 
upregulation of NOXA and PUMA proteins is not involved in HS- and 4CPinduced 
activation of the mitochondrial apoptotic pathway.   
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Although upregulation of NOXA and PUMA proteins may not be required, these 
proteins may still play a role in the activation of the mitochondrial apoptotic pathway. Of 
interest, our data show that NOXA and PUMA proteins are constitutively expressed in 
the day 9 embryos in the absence of any teratogenic exposure. The function of these 
proteins in mouse development is unknown but do not appear to be required for normal 
development because Noxa and Puma null mice are born at the expected frequency and 
exhibit a normal phenotype (Villunger et al., 2003). How the proapoptotic activity of 
NOXA and PUMA is blocked is also unknown; however, it may be that these proteins 
are sequestered in an inactive form that is then activated in response to appropriate 
apoptotic stimuli. The constitutive expression of proapoptotic Bcl-2 family members that 
are sequestered and then activated in response to various apoptotic stimuli is well 
documented. Examples include binding to other proteins (BIM and BMF binding to 
dynein motor complex), cleavage (inactive BID cleaved to active tBID by caspase-8), 
and phosphorylation-induced binding of BAD to 14-3-3 (Gross et al., 1999; Li et al., 
1998; Puthalakath et al., 1999, 2001; Zha et al., 1996). However, we are not aware of 
any published data showing that NOXA or PUMA proteins are sequestered in the 
absence of an apoptotic stimulus and then activated after an appropriate cell death signal.  
Even if p53-mediated upregulation of NOXA and PUMA proteins does not play 
a role in activating the mitochondrial apoptotic pathway in teratogen-exposed mouse 
embryos, p53 is known to upregulate other proapoptotic proteins, for example, BAX, 
p53AIP, and PIGs. Whether any of these or other p53 target genes play a role in HS- and 
4CP-induced activation of the mitochondrial pathway is unknown; however, our studies 
have shown that there is no significant increase in BAX protein levels in mouse embryos 
exposed to HS or 4CP (unpublished data). Although p53 may regulate teratogen-induced 
apoptosis in the mouse embryo by transcriptionally upregulating proapoptotic target 
genes, we presently do not have any data to support this possibility.  
Alternatively, recent evidence has uncovered a transcription independent role for 
p53 in the regulation of apoptosis. Early studies, using cancer cell lines, reported that 
apoptosis occurred in the presence of inhibitors of transcription and translation or in cells 
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expressing p53 mutants with abrogated transactivation activity (Caelles et al., 1994; 
Jimenez et al., 2000). Subsequent studies have shown that after apoptotic stimuli, 
activated p53 rapidly translocates to mitochondria where it physically interacts with 
BCL-2 and BCL-XL to antagonize their antiapoptotic activities or BAX and BAK to 
promote their proapoptotic activities (Chipuk et al., 2004; Leu et al., 2004; Marchenko et 
al., 2000; Mihara et al., 2003; Schuler et al., 2000). Current studies are underway to 
determine whether p53 may have a transcription- independent role in inducing apoptosis 
in mouse embryos exposed to HS or 4CP.  
Our data also show that HS and 4CP induce the upregulation of cyclin-dependent 
kinase p21 mRNA and protein. Moreover, results from our immunohistochemical 
analysis indicate that p21 protein is upregulated in most, if not all, cells of the day 9 
mouse embryo after exposure to HS. Because p21 is a known p53 target that plays a 
central role in arresting the cell cycle after various genotoxic stresses (Harris and Levine, 
2005; Taylor and Stark, 2001), our results suggest that cells of the day 9 mouse embryo 
have activated the cell cycle arrest arm of the p53 pathway in response to teratogenic 
exposures. Although we have not shown that HS induces cell cycle arrest in early 
postimplantation rodent embryos, we have shown that phosphoramide mustard, the 
major teratogenic metabolite of 4CP, induces alterations in the cell cycle in 
postimplantation rat embryos (Little and Mirkes, 1992; Mirkes et al., 1989). In addition, 
Chernoff et al. (1989) and Francis et al. (1990) have shown that cyclophosphamide 
induced a dose-dependent increase in the percentage of limb bud cells in the S phase of 
the cell cycle. Together, these results demonstrate that cyclophosphamide 4CP induce 
alterations in the cell cycle in early postimplantation mouse embryos exposed in vitro or 
in vivo.  
Published data consistently show that teratogens induce apoptosis in some cells 
of the embryos and not others (Gao et al., 1994; Mirkes, 1985; Mirkes et al., 1985, 1991; 
Thayer and Mirkes, 1995). With respect to HS- and 4CP-induced apoptosis, cells within 
the neuroepithelium and neural crest cells that have migrated from the neuroepithelium 
are the most sensitive to teratogen-induced cell death, whereas surrounding 
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mesenchymal cells as well as epithelial cells are less sensitive. In contrast, cells of the 
heart are completely resistant to teratogen-induced apoptosis (Umpierre et al., 2001). In 
addition, activation of the mitochondrial apoptotic pathway, characterized by 
cytochrome c release, activation of caspases, and the induction of DNA fragmentation, is 
completely blocked in heart cells from day 9 mouse embryos (Little and Mirkes, 2002; 
Mirkes and Little, 1998, 2000). In the present studies, we now show that heart cell 
resistance is associated with significant attenuation of the activation of p53 in heart cells. 
Despite the attenuated activation of p53 in heart cells in response to teratogenic 
exposures, our data indicate that both HS and 4CP induce increased levels of p21 in 
heart cells. These results suggest that p53 is activated in the heart and when activated 
subsequently upregulates the expression of p21, thereby arresting heart cells. One 
caveat, however, is that p21 expression can also be induced via p53- independent 
mechanisms (O'Reilly, 2005). Using p53 null mice, we are currently determining 
whether HS- and 4CPinduced upregulation of p21 is p53-dependent.  
Our results showing robust activation of p53 in cells sensitive to teratogen-
induced apoptosis and attenuated activation of p53 in cells resistant to teratogen-induced 
apoptosis, leads to the hypothesis that high levels of activated p53 induce apoptosis, 
whereas low levels of activation lead to cell cycle arrest. This hypothesis is supported by 
studies showing that high amounts of ectopic p53 induce apoptosis, whereas lower 
amounts result in cell cycle arrest (Chen et al., 1998; Lokshin et al., 2005; Ronen et al., 
1996). More recently, Speidel et al. (2006) showed that low levels of UV-irradiation, 
which led to a relatively low-level activation of p53, induced temporary cell cycle arrest, 
whereas high levels of UV-irradiation, which induced a more robust activation of p53, 
led to apoptosis. Although our results are consistent with the cell culture data suggesting 
that low levels of p53 activation culminate in cell cycle arrest whereas more robust 
activation of p53 results in apoptosis, additional research will be required to determine 
whether the sensitivity/resistance of specific cells to teratogen induced apoptosis in the 
day 9 mouse embryo is determined by the extent to which p53 is activated. 
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3.   GENE AND MIRNA EXPRESSION IN P53-DEFICIENT DAY 8.5  
MOUSE EMBRYOS* 
 
3.1.   OVERVIEW 
NTDs are one of the most common human birth defects in the United States.  In 
animal studies, deletion of p53 leads to a significant increase in embryos that exhibit 
exencephaly.  To study the molecular-level alternations in p53-deficient embryos, we 
identified genes and miRNAs whose expressions were modified by deletion of p53 in 
day 8.5 mouse embryos.  Mouse embryos from p53 heterozygous crosses were collected, 
genotyped, and embryos of similar genotype (+/+; +/-; -/-) were pooled.  RNA from the 
pooled samples was isolated to determine mRNA and miRNA expression levels using 
Whole Genome Bioarrays and Low Density Arrays, respectively.  In p53 -/- embryos, 
388 genes showed statistically significant alteration in gene expression of more than 2 
fold compared to p53 +/+ embryos.  Expression of p53 and p53 target genes, such as p21 
and cyclin G1, were significantly down-regulated in p53 -/- embryos.  In contrast, 
expression of other p53 target genes, Mdm2, Noxa, and Puma, were unchanged.  We 
have also shown that 6 genes, known to cause NTDs when deleted, were down-regulated 
in p53 -/- embryos.  Finally, 5 miRNAs also showed statistically significant alterations in 
expression levels in p53 -/- embryos compared to p53 +/+ embryos.  Combined analysis 
of the experimental data and two publicly available algorithms identified putative target 
genes of these miRNAs.   Our data have identified genes and miRNAs that may be 
involved in the mechanisms underlining NTDs and begin to define the developmental 
role of p53 in the etiology of NTDs.      
  
 
 
____________ 
*Reprinted from “Gene and miRNA Expression in p53-Deficient Day 8.5 Mouse 
Embryos” by Hiromi Hosako, Gail S. Martin, Marianne Barrier, Yian A. Chen, Ivan V. 
Ivanov, and Philip E. Mirkes. Birth Defect Research A. Accepted.  
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3.2.   INTRODUCTION 
NTDs represent a group of serious congenital malformations resulting from 
failure of neural tube closure during early development and are one of the most common 
human birth defects, with a prevalence of approximately 1 in 1000 live births in the 
United States (Copp et al., 2003).  Of these, the most common NTDs are 
anencephaly/exencephaly and spina bifida resulting from the failure of neural tube 
closure in the cranial and spinal region, respectively.  The etiology of NTDs is complex 
and is known to involve both genetic and environmental factors.  In humans, genetic 
factors such as chromosomal abnormalities and single-gene disorders, including Fraser 
syndrome and Waardenburg syndrome, are associated with NTDs (Padmanabhan, 2006).  
Although no single gene mutation has been shown to be solely responsible for human 
NTDs, animal studies have identified more than 190 genes that cause NTDs when 
deleted (Harris and Juriloff, 2007).  Examples of environmental factors that contribute to 
NTDs include geographic and temporal variations as well as physical and chemical 
agents, such as x-irradiation, hyperthermia, antiepileptic drugs, thalidomide, and folate 
antagonists (Mitchell, 2005; Padmanabhan, 2006).  In addition, gene-environment and 
gene-gene interactions are also known to play a role in the etiology of NTDs.  For 
example, maternal folic acid supplementation interacts with the presence of gene 
variants directly involved in folic acid metabolism and uptake in determining the risk of 
NTDs (Cabrera et al., 2004).  Mutation in methylene tetrahydrofolate reductase 
(MTHFR) 677C à T, which plays a critical role in homocysteine metabolism, is 
associated with decreased MTHFR activity, low plasma folate, and high plasma 
homocysteine; dietary and supplemental folate have been reported to modify the 
penetrance of this polymorphism (Koch et al., 1998; Shaw et al., 1998; Volcik et al., 
2003).   
Animal studies have also shown that the transcription factor p53 plays a role in 
the etiology of NTDs (Harris and Juriloff, 2007).  Early studies (Armstrong et al., 1995; 
Sah et al., 1995) reported that although mice lacking p53 are viable, a significant portion 
of p53 -/- mice (2~6%) exhibit abnormal neural tube closure resulting in exencephaly as 
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well as a significant increase in mortality in utero or soon after birth.  In addition, these 
studies revealed that the p53 -/- mice exhibiting NTDs are predominantly females, which 
is also found in human exencephaly cases as well as in other mouse mutants, e.g., 
1/Hipk2, Efna5, Marcks, Nif1, and xn mutants (Harris and Juriloff, 2007; Seller, 1987, 
1995).  It should be noted, however, that the penetrance of exencephaly in p53 -/- 
embryos is not complete.   
Called “the guardian of the genome”, p53 is essential for preventing 
inappropriate cell proliferation and maintaining genomic integrity.  Activation of p53 
can lead to apoptosis, cell cycle arrest, DNA repair, senescence, and differentiation 
following a variety of stresses (Hofseth et al., 2004; Lane, 1992; Levine et al., 2006).  To 
be stabilized and activated, p53 undergoes either a single or series of post-translational 
modifications, including methylation, acetylation, phosphorylation, ubiquitylation, 
sumoylation, and neddylation (Harris and Levine, 2005; Xirodimas et al., 2004).  
Interaction of p53 with other proteins, for example, MDM2 (Lakin and Jackson, 1999) 
and PIN1 in the N-terminal transactivation domain of p53 (Ryan and Vousden, 2002; 
Zacchi et al., 2002) also influence the stabilization and activation of p53.  Once 
activated, p53 translocates to the nucleus and activates numerous target genes that 
involve multiple pathways.  Some of the genes activated by p53 are transcription factors, 
which further activate multiple genes (Levine et al., 2006).  Although the list of p53 
target genes now contains several hundred genes (Wei et al., 2006), only selected sets of 
genes are activated to achieve the desirable outcome in a specific situation.  Recent 
studies indicated that promoter choice and cell fate may well depend on the level of 
activated p53 protein, indicating that different affinities of p53 exist toward different p53 
response elements (Laptenko and Prives, 2006).  Moreover, several binding proteins, 
including ASPP, BRN3, and YB1, which guide p53 to the promoters of specific genes in 
order to induce a particular pathway, have been discovered (Budhram-Mahadeo et al., 
2006; Homer et al., 2005; Sullivan and Lu, 2007).   In addition, recent studies revealed 
that p53 can also translocate to mitochondria, where it directly binds to anti-apoptotic 
proteins BCL2 and BCL-XL, and the pro-apoptotic proteins, BAX, BAK, and BAD to 
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activate the mitochondrial apoptotic pathway, suggesting further complexity of 
molecular functions of p53 (Chipuk et al., 2004; Jiang et al., 2006; Leu et al., 2004; 
Mihara et al., 2003). 
In mouse embryos, both p53 mRNA and protein are ubiquitously expressed until 
mid gestation (Louis et al., 1988; Rogel et al., 1985; Schmid et al., 1991).  At later 
organogenesis stages, however, the expression levels decrease rapidly and only specific 
differentiating tissues show the expression of p53.  Although p53 is expressed in 
developing embryos, most p53 protein in embryos is relatively inactive, suggesting post-
translational control of p53 activity (Gottlieb et al., 1997; Komarova et al., 1997; 
MacCallum et al., 1996).   Weak but pronounced expression of active p53, however, is 
observed in the brain of day 8 - 11 embryos, suggesting that the developing brain may be 
most susceptible in the absence of p53 given the importance of apotosis, cell 
proliferation, and differentiation in the process of neural tube closure (Choi and 
Donehower, 1999).  In addition, it is not well understood which p53 target genes are 
regulated and the extent to which they are activated by p53 in the developing brain.  
Although it is well known that mRNA transcription and post-transcriptional 
processing are key determinants in the regulation of gene expression, a recently 
discovered class of small RNA molecules, known as microRNAs (miRNAs), have been 
shown to regulate gene expression in mammals, with about 800 miRNAs currently 
predicted to exist in humans (Bartel, 2004; Bentwich et al., 2005).  These 18-24 nt RNAs 
bind to mRNAs and inhibit their expression either by interfering with translation or by 
destabilizing the target mRNAs (Meister and Tuschl, 2004; Pillai et al., 2007).  Although 
little is known about the biological function of miRNAs in mammals, recent studies have 
suggested that miRNAs play important regulatory roles in developmental timing and 
patterning, cellular differentiation, proliferation, organogenesis, and apoptosis (Alvarez-
Garcia and Miska, 2005; Ambros, 2004).  In mouse embryos, miRNAs are expressed in 
stage- and tissue-specific manner (Mineno et al., 2006; Schulman et al., 2005).  In 
addition, exposures that induce developmental anomalies, such as folate deficiency and 
sodium arsenite, are known to increase global miRNA expression in human 
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lymphoblastoid cells (Marsit et al., 2006).  Moreover, the miR-34 family has been 
recently shown to be induced by p53 and to mediate apoptosis in response to DNA 
damage and oncogenic stress (Bommer et al., 2007; Chang et al., 2007; Raver-Shapira et 
al., 2007; Tarasov et al., 2007).  
To begin to dissect the mechanistic links between loss of p53 and the etiology of 
NTDs, we set forth three objectives.  First, we used DNA whole genome microarrays to 
compare mRNA expression profiles in day 8.5 p53 +/+, +/-, and -/- mouse embryos.  
Second, we used miRNA low density arrays to compare miRNA expression profiles in 
day 8.5 p53 +/+, +/-, and -/- mouse embryos.  Finally, we ran a stepwise regression using 
our experimental data and used two computational algorithms to examine potential 
involvement of specific miRNAs in the alteration of mRNAs that are disregulated in p53 
-/- embryos. 
 
 
3.3.   MATERIALS AND METHODS 
Experimental Animals: All animals were maintained in accordance with animal 
use protocol approved by the Institutional Animal Care and Use Committee at Texas 
A&M University.  A pair of p53 +/- mice (a gift of Lawrence A. Donehower, Baylor 
College of Medicine) with C57BL6-Tyrc-Brd background (Zheng et al., 2002) was used 
for breeding.  Mice were kept with freely available pellet food and water at 21-23 ˚C and 
12-h light/dark cycle (6:00-18:00).  Virgin p53 +/- females were cohabited with p53 +/- 
males and checked the following morning for the vaginal plug.  Upon detecting a plug, 
12 a.m. was designated GD 0.   
Embryo Collections and Genotyping PCR: Embryos were explanted and their 
yolk sac was separated in ice-cold Hanks’ balanced salt solution on GD 8.5.  Each 
embryo was placed in a separate PCR tube with RNAlater (Ambion, Austin, TX) and 
stored at -20 °C.  The yolk sac dissected from each embryo was put in a PCR tube with 
7.5 µl of tail lysis buffer (25 mM NaOH and 0.2 mM EDTA), and heated at 95 °C for 20 
min. The same volume of Tris-HCl (40 mM) was added to the tube, and 3 µl of the yolk 
sac sample was used for p53 genotyping of its matching embryo.  Primers used for PCR 
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genotyping were: p53 forward primer (in the intron 1): 5’-
GTGTGTGAAATGGTGGATGG-3’, p53 reverse primer (in the intron 3/4): 5’-
AGGTGATGGCTGTGGATG-3’, puro forward primer: 5’-
ATGACCGAGTACAAGCCCAC-3’, and the puro reverse primer: 5’- 
GCGTGAGGAAGAGTTCTTGC-3’.  The expected length of each band was 1147 bp 
for p53 and 166 bp for puro gene.  The PCR program consisted of one cycle of 2 min at 
95 ˚C, 40 cycles of 40 s at 95 ˚C, 40 s at 65 ˚C, and 60 s at 72 ˚C, followed by one cycle 
of 7 min at 72 ˚C.  Samples were visualized on a 1.5% agarose electrophoresis gel after 
staining with ethidium bromide. 
Total RNA Preparation: Based on the PCR results, 3-7 embryos of similar 
genotype from multiple litters were pooled in RNAlater to obtain quadruplicate samples 
of each of three genotypes.  Total RNA was extracted from each sample using 
mirVana™ miRNA Isolation Kit (Ambion) according to the manufacturer’s instructions.  
Concentration and quality of the total RNA were assessed using a Nanodrop (Nanodrop, 
Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, 
Germany), respectively.  The RNA samples were stored at -80 ˚C until analyzed.      
Codelink Mouse Whole Genome Bioarray: Microarray hybridization and 
scanning were performed by the Genomics Core Facility of the Center for 
Environmental and Rural Health at Texas A&M University.  Quadruplicate total RNA 
samples of each genotype were used to generate biotin-labeled cRNA via a modified 
Eberwine RNA amplification protocol.  Labeled cRNA was applied to the CodeLink 
Mouse Whole Genome Bioarray, which contains 34,967 unique probe sequences, for 18 
hr (GE Healthcare, Waukesha, WI).  After incubation, the slide was washed, stained, and 
scanned.  Array images were processed using CodeLink system software.  Raw 
CodeLink data output were imported into GeneSpring GX 7.3. (Agilent Technologies) 
and normalized by setting all measurements <0.01 to 0.01, normalized to the 50th 
percentile of all measurements on each array, and to the median of all measurements on 
each gene.  The twelve data sets were then assigned to three genotypes.  To remove 
unreliable measurements, quality control on gene level was performed for 1) data 
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identified as present or marginal in at least 6 of the 12 samples, 2) no unknown flag 
designation in more than 4 of the 12 samples, 3) signal intensity greater than background 
in at least 4 of the 12 samples, and 4) control signal in at least 3 in 4 samples per 
genotype group greater than the ratio of the fixed error to proportional error for that 
genotype group.  Lists of genes that showed alterations in expression in p53 +/- and -/- 
embryos compared to p53 +/+ embryos were created using fold change filters (x>2 fold 
and 2>x>1.5 fold). To identify statistically altered genes in p53 +/- and -/- embryos 
compared to p53 +/+ embryos, a one-way Welch t-test (p<0.05) was used.  Gene 
annotations were acquired using the accession numbers provided with the arrays and the 
GeneSpider function in GeneSpring.  Our microarray data have been deposited in Gene 
Expression Omnibus (GEO), with the accession number GE11321.  Genes with p53 
consensus DNA binding sites in the list of genes with significant alteration were 
identified according to the directory catalogue of putative p53 DNA-binding elements in 
the laboratory of Statistical Genetics at Rockefeller University (Hoh et al., 2002). 
Quantitative Real-Time PCR: To confirm changes in the gene expression 
detected by microarray analysis, real-time PCR was performed.  Of the quadruplicate 
total RNA samples used for microarray, three replicates of each genotype were used.  
Total RNA (1-10 µg) was reverse-transcribed using 25 ng/µl oligo(dT)15 primer and 9.6 
µM random hexamers by heating at 65 °C for 5 min, followed by cooling on ice.  The 
mRNA was then copied into cDNA by 300 U SuperScript II RNase H¯ reverse 
transcriptase, 1st strand buffer, 10 mM DTT (Invitrogen, Carlsbad, CA), and 30 U RNase 
block (Qiagen, Valencia, CA) and incubated at 37 °C for 1 hr.  The reaction was 
terminated by placing at 90 °C for 5 min and then brought to 4 °C and stored at -80 °C 
until ready to use.  Subsequently, 1 µl cDNA was added to 96-well fast plate with master 
mix (Applied Biosystems, Foster City, CA) and TaqMan probe to carry out fluorogenic 
5’ nuclease assays (TaqMan) using 7500 Fast Real-Time PCR System (Applied 
Biosystems).  Pre-designed probes of the selected genes were purchased from Applied 
Biosystems, and relative quantification was performed using ∆∆Ct method.   
94 
 
miRNA TaqMan® Low Density Array (LDA): Of the quadruplicate total RNA 
samples used for microarray, three replicates of p53 +/+ and -/- samples were used.  
Total RNA (50 ng) was reverse-transcribed using TaqMan MicroRNA RT kit and 
Multiplex RT human primer pool (Applied Biosystems) according to the manufacturer’s 
instructions.  Diluted cDNAs (62.5 fold) were added to master mix (Applied 
Biosystems) and applied to miRNA TaqMan LDA human panels (Applied Biosystems) 
for the simultaneous quantification of 368 miRNAs.  miRNA TaqMan assays were 
carried out using 7900 HT Fast Real-Time PCR System (Applied Biosystems).  Relative 
quantification was performed using ∆∆Ct method, and the data were normalized using a 
miRNA with the least changes between samples.  Statistical analysis of the alterations of 
miRNA expression between p53 +/+ and -/- samples was performed using t-test 
(p<0.05).   
Putative miRNA Target Gene Analysis: To examine potential involvement of 
specific miRNAs in the alteration of mRNAs that are disregulated in p53 -/- embryos, 
significantly down-regulated or up-regulated miRNAs in p53 -/- embryos compared to 
p53 +/+ embryos were first identified based on the experimental data.  Potential targets 
of the selected miRNAs were predicted by two publicly available computational 
techniques, PicTar (http://pictar.bio.nyu.edu/) and miRBase 
(http://microrna.sanger.ac.uk/sequences/).  These two algorithms use independent 
computational approaches to identify common targets of miRNAs.  PicTar uses 
experimental results to define probabilities for a mRNA sequence to be a binding site for 
a given miRNA and requires that the free energy of the entire miRNA:mRNA duplex be 
below a cutoff value (Krek et al., 2005), whereas miRBase scans sequence database 
against 3’-untranslated regions predicted from all available species in Ensembl 
(Griffiths-Jones et al., 2006).  We adopted a conservative approach and selected the 
common predicted targets detected by both algorithms.  To compare these predicted 
targets for the possible interactions that could be specific to our study, we performed a 
stepwise regression using our experimental mRNA and miRNA data to determine which 
miRNA or genotype might be responsible for the regulation of the significantly 
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expressed mRNAs (p<0.05).  Finally, the predicted target genes identified by both 
computational methods were compared to the sets of genes identified by our regression 
model.    
 
 
3.4.   RESULTS 
Differentially Expressed Genes Identified by Codelink Bioarray: To examine 
the expression patterns and identify genes that are expressed differentially among p53 
+/+, +/-, and -/- day 8.5 mouse embryos, microarray gene profiling was used.  Data from 
four independent experiments show that deletion of both p53 alleles results in a 
significant alteration of embryonic gene expression, whereas deletion of only one p53 
allele leads to altered expression of only a few genes.  Figure 3.1 shows the number of 
genes with statistically significant changes in expression in p53 +/- and -/- compared to 
p53 +/+ day 8.5 mouse embryos.  At the 2-fold cut off, only 2 genes showed a 
significant increase in gene expression and no gene showed a significant decrease in 
gene expression in p53 +/- compared to p53 +/+ embryos.  In p53 -/- embryos, however, 
17 genes showed increased gene expression and 371 showed decreased gene expression 
compared to p53 +/+ embryos.  When the cut off fold change is decreased to 1.5-fold, a 
similar trend is observed: only 14 genes showed significant alteration in p53 +/- 
embryos, whereas in p53 -/- embryos 232 genes showed a significant increase in gene 
expression and 785 genes showed a significant decrease in gene expression.  These data 
show that a significant number of genes are altered when both p53 alleles are deleted, 
and among those altered genes at the 2-fold cut off, the majority (77%) are down-
regulated in the absence of p53.   
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Figure 3.1. p53-regulated gene expression in day 8.5 mouse embryos.  Number of genes 
showing statistically significant increase or decrease in gene expression more than 1.5 fold in 
deletion of p53 allele was identified by microarray.  Genes with 1.5<x<2 fold change are shown 
in grey and 2<x fold change are shown in white. 
 
Table 3.1 lists 17 genes that showed increased gene expression of more than 2-
fold in p53 -/- embryos.  Supplemental Table 3.2 shows 371 genes with more than 2-fold 
decrease in gene expression in p53 -/- embryos.  To examine how many of these genes 
whose expression levels were altered in p53 -/- embryos are possibly up- or down-
regulated directly by p53, we attempted to identify genes that contain putative p53 
DNA-binding sites.  These genes are shown in Tables 3.1 and 3.2.  Out of 388 genes, 43 
genes were identified as possible p53 target genes.  Thus, about 11% of the disregulated 
genes could be directly regulated by p53, whereas most of the genes altered in p53 -/- 
embryos are indirectly affected by p53.          
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 Table 3.1 
Genes Whose Expression Was Increased in p53 -/- day 8.5 Embryos  
by More Than Two Fold* 
                                          Fold   Putative 
Symbol   Description              change   site(s) 
Pp11r Placental protein 11 related 5.5  
Ezh1 Enhancer of zeste homolog 1 (Drosophila) 3.93  
AI852444 Expressed sequence AI852444 3.64  
2210019E14Rik RIKEN cDNA 2210019E14 gene 3.59  
Plxna1 Plexin A1 3.44  
Ccr9 Chemokine (C-C motif) receptor 9 2.53  
Baiap1 BAI1-associated protein 1 2.4  
Rock1 Rho-associated coiled-coil forming kinase 1 2.24 X 
 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833411N21 product:unclassifiable, full insert sequence 2.23  
Rbm16 RNA binding motif protein 16 2.14  
Grip1 Glutamate receptor interacting protein 1 2.07  
3110001N23Rik RIKEN cDNA 3110001N23 gene 2.07  
Ssbp3 Single-stranded DNA binding protein 3 2.06  
 
Adult male corpora quadrigemina cDNA, RIKEN full-length 
enriched library, clone:B230209D03 product:unknown EST, full 
insert sequence 
2.06 
 
Gnas RIKEN cDNA A930027G11 gene 2.06  
Laf4 Hypothetical protein A730046J16 2.05  
Adcyap1r1 Adenylate cyclase activating polypeptide 1 receptor 1 2.01  
* Significant difference between day 8.5 p53 +/+ embryos and p53 -/- embryos. p<0.05. 
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Table 3.2                 
Genes Whose Expression Was Decreased in p53 -/- day 8.5 Embryos  
by More Than Two Fold* 
                    Fold   Putative 
Symbol   Description              change   site(s) 
Trp53bp1 Transformation related protein 53 binding protein 1 23.50  
Pabpc4 Poly(A)-binding protein, cytoplasmic pseudogene 11.39  
Dnmt1 DNA methyltransferase (cytosine-5) 1 10.43 X 
Ddx41 DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 8.68  
4933407C03Rik RIKEN cDNA 4933407C03 gene 8.02  
Bcar1 Breast cancer anti-estrogen resistance 1 7.46  
Trim35 Tripartite motif-containing 35 7.18  
Pkm2 Pyruvate kinase, muscle 7.14  
Fyn Fyn proto-oncogene 6.89 X 
Csk C-src tyrosine kinase 6.64 X 
Pex5 Peroxisome biogenesis factor 5 6.26  
Mcm7 Minichromosome maintenance deficient 7 (S. cerevisiae) 6.15 X 
Sars2 Seryl-aminoacyl-tRNA synthetase 2 6.11  
Afg3l1 AFG3(ATPase family gene 3)-like 1 (yeast) 5.34  
Krt2-8 Keratin complex 2, basic, gene 8 5.27  
Mrc2 Mannose receptor, C type 2 5.14  
Tgfbi Transforming growth factor, beta induced 4.98 X 
Zfp162 Zinc finger protein 162 4.94  
Eef2 Eukaryotic translation elongation factor 2 4.92  
B930069K15Rik RIKEN cDNA B930069K15 gene 4.89  
Sfrs2 Splicing factor, arginine/serine-rich 2 (SC-35) 4.84  
Tcfap4 Transcription factor AP4 4.82  
Sgpl1 Sphingosine phosphate lyase 1 4.81  
H2afx H2A histone family, member X 4.77  
Prkaca Protein kinase, cAMP dependent, catalytic, alpha 4.53 X 
Hdac7a Histone deacetylase 7A 4.47 X 
Sec61a1 Sec61 alpha 1 subunit (S. cerevisiae) 4.40  
Ddx6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 4.35  
Pard3 Par-3 (partitioning defective 3) homolog (C. elegans) 4.29  
Rarg Retinoic acid receptor, gamma 4.18 X 
Jarid1a RIKEN cDNA D230014I24 gene 4.12  
Cdkn1a Cyclin-dependent kinase inhibitor 1A (P21) 4.06 X 
Punc Putative neuronal cell adhesion molecule 4.06  
Pard6g Par-6 partitioning defective 6 homolog gamma (C. elegans) 4.03  
1700081L11Rik RIKEN cDNA D030002E05 gene 4.01  
Sall4 Sal-like 4 (Drosophila) 4.01  
Zfp336 Zinc finger protein 336 3.99  
Phgdh 3-phosphoglycerate dehydrogenase 3.98  
F11r F11 receptor 3.96  
Mapkapk2 RIKEN cDNA 8030443L12 gene 3.96 X 
1500041I23Rik RIKEN cDNA 1500041I23 gene 3.95  
Sfrs2ip Splicing factor, arginine/serine-rich 2, interacting protein 3.92  
Kif3a Kinesin family member 3A 3.89  
Tnrc11 Trinucleotide repeat containing 11 (THR-associated protein) 3.87  
Bop1 Block of proliferation 1 3.87  
Itpkb Inositol 1,4,5-trisphosphate 3-kinase B 3.84  
Wasl Wiskott-Aldrich syndrome-like (human) 3.80  
C030025P15Rik RIKEN cDNA C030025P15 gene 3.78  
Herc1 Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 3.78  
5730555F13Rik RIKEN cDNA 5730555F13 gene 3.77  
Matr3 Matrin 3 3.76  
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Table 3.2 Continued 
                    Fold   Putative 
Symbol   Description              change   site(s) 
Copeb Core promoter element binding protein 3.75 X 
C130096N06Rik RIKEN cDNA D130005J21 gene 3.71  
Jarid1a RIKEN cDNA D230014I24 gene 3.70  
Rbm28 RNA binding motif protein 28 3.68  
Polr3d Polymerase (RNA) III (DNA directed) polypeptide D 3.65  
Prp19 PRP19/PSO4 homolog (S. cerevisiae) 3.63  
BC065123 CDNA sequence BC065123 3.62  
Nsf N-ethylmaleimide sensitive fusion protein 3.61  
Brd1 Similar to bromodomain containing protein 1; BR140-like gene 3.60  
Cyp20a1 Cytochrome P450, family 20, subfamily A, polypeptide 1 3.59  
Dyrk3 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 3.59  
Actn4 Actinin alpha 4 3.57  
Mogat2 Monoacylglycerol O-acyltransferase 2 3.55  
Nol5 Nucleolar protein 5 3.54  
Hyou1 Hypoxia up-regulated 1 3.53  
Lims1 LIM and senescent cell antigen-like domains 1 3.50  
Mrps5 Mitochondrial ribosomal protein S5 3.49  
Fgd1 FYVE, RhoGEF and PH domain containing 1 3.48  
Swap70 SWAP complex protein 3.48 X 
Trp53 Transformation related protein 53 3.47 X 
Akt2 Thymoma viral proto-oncogene 2 3.46  
Tyro3 TYRO3 protein tyrosine kinase 3 3.45 X 
 
BY671610 RIKEN full-length enriched, 14.5 days embryo df/df 
Rathke's pouches Mus musculus cDNA clone K820020G11 3', 
mRNA sequence. 
3.44 
 
Prss8 Protease, serine, 8 (prostasin) 3.43  
Csnk1a1 Casein kinase 1, alpha 1 3.41  
Lgtn Ligatin 3.41  
Bbx Bobby sox homolog (Drosophila) 3.40  
Ttn Titin 3.39 X 
A730098D12Rik RIKEN cDNA A730098D12 gene 3.38  
Galnt2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 3.37  
P4ha2 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha II polypeptide 3.36  
Ube2v1 Ubiquitin-conjugating enzyme E2 variant 1 3.35  
A430106J12Rik RIKEN cDNA A430106J12 gene 3.32  
Ptpn11 Protein tyrosine phosphatase, non-receptor type 11 3.30 X 
Scpep1 Serine caroboxypeptidase 1 3.29  
Sfrs2ip Splicing factor, arginine/serine-rich 2, interacting protein 3.29  
Acin1 Apoptotic chromatin condensation inducer 1 3.26  
Mtdh Metadherin 3.25  
 Gene model 293, (NCBI) 3.25  
Nfe2l1 Nuclear factor, erythroid derived 2,-like 1 3.24  
Fstl1 Follistatin-like 1 3.22  
Popdc2 Popeye domain containing 2 3.22  
Elmo2 Engulfment and cell motility 2, ced-12 homolog (C. elegans) 3.21  
2610019N13Rik RIKEN cDNA 2610019N13 gene 3.21  
 AU016710 Mouse two-cell stage embryo cDNA Mus musculus cDNA clone J0728F07 3', mRNA sequence. 3.15  
Smc6l1 SMC6 structural maintenance of chromosomes 6-like 1 (yeast) 3.10  
AW610627 Expressed sequence AW610627 3.09  
Ywhag 3-monooxgenase/tryptophan 5-monooxgenase activation protein, gamma polypeptide 3.09  
Arfgap1 ADP-ribosylation factor GTPase activating protein 1 3.04  
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Table 3.2 Continued 
                    Fold   Putative 
Symbol   Description              change   site(s) 
C730036B14Rik RIKEN cDNA C730036B14 gene 3.03  
Nolc1 Nucleolar and coiled-body phosphoprotein 1 3.03  
Vgll4 RIKEN cDNA A530060M17 gene 3.02  
Txndc7 Thioredoxin domain containing 7 3.02  
Falz Fetal Alzheimer antigen 3.01  
Mbtps1 Membrane-bound transcription factor protease, site 1 3.01  
Eif5a Eukaryotic translation initiation factor 5A 3.01  
Ephb4 Eph receptor B4 3.00 X 
Ppp1r8 Protein phosphatase 1, regulatory (inhibitor) subunit 8 2.96  
1500031N24Rik RIKEN cDNA 1500031N24 gene 2.95  
Dpagt1 
Dolichyl-phosphate (UDP-N-acetylglucosamine) 
acetylglucosaminephosphotransferase 1 (GlcNAc-1-P 
transferase) 
2.95 
 
Ptprf Protein tyrosine phosphatase, receptor type, F 2.94  
Skb1 SKB1 homolog (S. pombe) 2.93  
Tceb3bp1 Transcription elongation factor B polypeptide 3 binding protein 1 2.93  
Cct4 Chaperonin subunit 4 (delta) 2.92  
Itga3 Integrin alpha 3 2.91 X 
Hes3 Hairy and enhancer of split 3 (Drosophila) 2.88  
6330545A04Rik RIKEN cDNA 6330545A04 gene 2.87  
Csnk1g3 Casein kinase 1, gamma 3 2.87  
Tnk2 Tyrosine kinase, non-receptor, 2 2.85  
Nrip1 Nuclear receptor interacting protein 1 2.84 X 
Rps6ka1 Ribosomal protein S6 kinase polypeptide 1 2.82 X 
Zfp292 Zinc finger protein 292 2.81  
2410003B16Rik RIKEN cDNA 2410003B16 gene 2.81  
Ccng1 Cyclin G1 2.78 X 
Ahcyl1 S-adenosylhomocysteine hydrolase-like 1 2.78  
4632412I24Rik RIKEN cDNA 4632412I24 gene 2.78  
Skiip SKI interacting protein 2.78  
2810047L02Rik RIKEN cDNA 2810047L02 gene 2.77  
 Transcribed locus 2.77  
Sbno1 Sno, strawberry notch homolog 1 (Drosophila) 2.77  
Rxrb Retinoid X receptor beta 2.77 X 
 Transcribed locus 2.76  
C78915 Expressed sequence C78915 2.75  
Dhx29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 2.75  
2700069A02Rik Echinoderm microtubule associated protein like 5 2.74  
Pdpk1 3-phosphoinositide dependent protein kinase-1 2.74 X 
Rab11b RAB11B, member RAS oncogene family 2.74 X 
Sumo2 SMT3 suppressor of mif two 3 homolog 2 (yeast) 2.73  
Col2a1 Procollagen, type II, alpha 1 2.72 X 
Pim1 Proviral integration site 1 2.70 X 
Klf3 Kruppel-like factor 3 (basic) 2.70  
Mtdh Metadherin 2.70  
Atp7a ATPase, Cu++ transporting, alpha polypeptide 2.69  
Eif4ebp2 Eukaryotic translation initiation factor 4E binding protein 2 2.68  
Btbd7 BTB (POZ) domain containing 7 2.68  
E430034L04Rik RIKEN cDNA E430034L04 gene 2.67  
Tle3 Transducin-like enhancer of split 3, homolog of Drosophila E(spl) 2.67 X 
Canx Calnexin 2.67  
2310061F22Rik RIKEN cDNA 2310061F22 gene 2.66  
Itm2c Integral membrane protein 2C 2.66  
Zfp219 Zinc finger protein 219 2.66  
Dhcr24 24-dehydrocholesterol reductase 2.65  
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                    Fold   Putative 
Symbol   Description              change   site(s) 
Akt1s1 AKT1 substrate 1 (proline-rich) 2.64  
E430012M05Rik RIKEN cDNA E430012M05 gene 2.64  
1500010G04Rik RIKEN cDNA 1500010G04 gene 2.63  
8430413D17Rik RIKEN cDNA 8430413D17 gene 2.62  
Dpysl3 Dihydropyrimidinase-like 3 2.61  
Fpgs Folylpolyglutamyl synthetase 2.61  
Mns1 Meiosis-specific nuclear structural protein 1 2.61  
Pb1 RIKEN cDNA 2310032M22 gene 2.59  
Sertad2 SERTA domain containing 2 2.59  
Exoc7 Exocyst complex component 7 2.57  
Twistnb TWIST neighbor 2.55  
6330406L22Rik RIKEN cDNA 6330406L22 gene 2.55  
Ddah1 Dimethylarginine dimethylaminohydrolase 1 2.54  
Pcyt2 Phosphate cytidylyltransferase 2, ethanolamine 2.54  
Gcs1 Glucosidase 1 2.54  
Jarid2 Jumonji, AT rich interactive domain 2 2.53  
Eif4g1 Eukaryotic translation initiation factor 4, gamma 1 2.53  
Purb Purine rich element binding protein B 2.53  
5830445C04Rik RIKEN cDNA 5830445C04 gene 2.53  
 
L0029F11-3 NIA Mouse E12.5 Female Mesonephros and 
Gonads cDNA Library Mus musculus cDNA clone L0029F11 3', 
mRNA sequence. 
2.53 
 
Gpd2 Glycerol phosphate dehydrogenase 2, mitochondrial 2.53  
Cldn5 Claudin 5 2.52  
Styx Phosphoserine/threonine/tyrosine interaction protein 2.52  
Hgs HGF-regulated tyrosine kinase substrate 2.51  
Spg7 Spastic paraplegia 7 homolog (human) 2.51  
Hmg20b High mobility group 20 B 2.50  
2610034N03Rik RIKEN cDNA 2610034N03 gene 2.49  
AA960436 Expressed sequence AA960436 2.49  
5830417C01Rik RIKEN cDNA 5830417C01 gene 2.49  
Sympk RIKEN cDNA 1500016F02 gene 2.47  
Smad4 MAD homolog 4 (Drosophila) 2.47  
E330018D03Rik RIKEN cDNA E330018D03 gene 2.47  
Add1 Adducin 1 (alpha) 2.47 X 
0610030E20Rik RIKEN cDNA 0610030E20 gene 2.46  
Fads2 Fatty acid desaturase 2 2.45  
Efnb1 Ephrin B1 2.44 X 
4930470D19Rik RIKEN cDNA 4930470D19 gene 2.44  
B230219D22Rik RIKEN cDNA B230219D22 gene 2.44  
Gna13 Guanine nucleotide binding protein, alpha 13 2.44 X 
2810474O19Rik RIKEN cDNA 2810474O19 gene 2.43  
Il1r2 Interleukin 1 receptor, type II 2.43 X 
BC013667 CDNA sequence BC013667 2.43  
Mcart1 Mitochondrial carrier triple repeat 1 2.42  
Ptbp2 Polypyrimidine tract binding protein 2 2.42  
Pias4 Protein inhibitor of activated STAT, 4 2.42  
6430510M02Rik RIKEN cDNA 6430510M02 gene 2.42  
 Transcribed locus 2.42  
Tmem2 Transmembrane protein 2 2.42  
4921504I05Rik RIKEN cDNA 4921504I05 gene 2.41  
Srprb Signal recognition particle receptor, B subunit 2.41  
A230098A12Rik RIKEN cDNA A230098A12 gene 2.41  
Lztr1 Leucine-zipper-like transcriptional regulator, 1 2.41  
Mbtd1 Mbt domain containing 1 2.40  
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                    Fold   Putative 
Symbol   Description              change   site(s) 
Nxn RIKEN cDNA C230071I02 gene 2.40  
Camkk2 Calcium/calmodulin-dependent protein kinase kinase 2, beta 2.40  
Ppp5c Protein phosphatase 5, catalytic subunit 2.39  
 LL2in12223T7 Hematopoietic Stem Cell Subtracted Library Mus musculus cDNA 5', mRNA sequence. 2.39  
Tcfe3 Transcription factor E3 2.38  
Dek DEK oncogene (DNA binding) 2.38  
Htatip HIV-1 tat interactive protein, homolog (human) 2.38  
Prkcbp1 Protein kinase C binding protein 1 2.38  
1500005K14Rik RIKEN cDNA 1500005K14 gene 2.37  
C330016O16Rik RIKEN cDNA C330016O16 gene 2.37  
Stat3 Signal transducer and activator of transcription 3 2.37 X 
Trio RIKEN cDNA 6720464I07 gene 2.37 X 
Rai1 Retinoic acid induced 1 2.37  
Elp3 Elongation protein 3 homolog (S. cerevisiae) 2.36  
BC035954 CDNA sequence BC035954 2.36  
Dnpep Aspartyl aminopeptidase 2.35  
4833418A01Rik RIKEN cDNA 4833418A01 gene 2.35  
Bat9 HLA-B-associated transcript 9 2.35  
Golgb1 Golgi autoantigen, golgin subfamily b, macrogolgin 1 2.34  
Ablim1 Actin-binding LIM protein 1 2.33  
Ube2d3 Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 2.33  
Rnpc2 RIKEN cDNA B330012G18 gene 2.33  
Ttc3 Tetratricopeptide repeat domain 3 2.33  
Fbxw7 F-box and WD-40 domain protein 7, archipelago homolog (Drosophila) 2.32  
Suhw4 Suppressor of hairy wing homolog 4 (Drosophila) 2.32  
Kif5b Kinesin family member 5B 2.32  
Wdhd1 WD repeat and HMG-box DNA binding protein 1 2.32  
Tbx1 T-box 1 2.31  
Snx27 Sorting nexin family member 27 2.31  
2810403A07Rik RIKEN cDNA 2810403A07 gene 2.31  
Zfp369 Zinc finger protein 369 2.31  
Brd2 Bromodomain containing 2 2.30  
C130052G03Rik RIKEN cDNA C130052G03 gene 2.30  
Etv5 Ets variant gene 5 2.30  
Neo1 Neogenin 2.29 X 
Rad23a RAD23a homolog (S. cerevisiae) 2.29  
5730478M09Rik RIKEN cDNA 5730478M09 gene 2.28  
BC024322 CDNA sequence BC024322 2.28  
Lzf Leucine zipper domain protein 2.28  
Ppap2b Phosphatidic acid phosphatase type 2B 2.28  
Pik3r2 Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 
(p85 beta) 2.28  
Crry Complement receptor related protein 2.28  
Ppil2 Peptidylprolyl isomerase (cyclophilin)-like 2 2.27  
3300001P08Rik RIKEN cDNA 3300001P08 gene 2.27  
Ank3 Ankyrin 3, epithelial 2.27 X 
Baz2a Bromodomain adjacent to zinc finger domain, 2A 2.26  
Ube2e3 Ubiquitin-conjugating enzyme E2E 3, UBC4/5 homolog (yeast) 2.26  
Cd34 CD34 antigen 2.26 X 
Hoxb9 Homeo box B9 2.25  
Igf2bp1 Insulin-like growth factor 2, binding protein 1 2.25  
Peli1 Pellino 1 2.25  
Rgl2 Ral guanine nucleotide dissociation stimulator-like 2 2.25  
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                    Fold   Putative 
Symbol   Description              change   site(s) 
BC025600 CDNA sequence BC025600 2.25  
Dvl1 Dishevelled, dsh homolog 1 (Drosophila) 2.25 X 
AU019823 Expressed sequence AU019823 2.24  
Epb4.1l5 Erythrocyte protein band 4.1-like 5 2.24  
Hcfc1 Host cell factor C1 2.24  
2900016D05Rik RIKEN cDNA 2900016D05 gene 2.23  
Cit Citron 2.22  
Hnrpul1 Heterogeneous nuclear ribonucleoprotein U-like 1 2.22  
Kif2c Kinesin family member 2C 2.22  
Acads Acyl-Coenzyme A dehydrogenase, short chain 2.22  
Cpne3 Copine III 2.21  
4833412N02Rik RIKEN cDNA 4833412N02 gene 2.21  
D330023I04Rik RIKEN cDNA D330023I04 gene 2.21  
Odd1 Oxidative-stress responsive 1 2.21  
Gm1131 Gene model 1131, (NCBI) 2.20  
Pip5k1b Phosphatidylinositol-4-phosphate 5-kinase, type 1 beta 2.20  
Ptprk Protein tyrosine phosphatase, receptor type, K 2.20  
 H4033G10-3 NIA Mouse 7.4K cDNA Clone Set Mus musculus 
cDNA clone H4033G10 3', mRNA sequence. 2.19  
Abcd4 ATP-binding cassette, sub-family D (ALD), member 4 2.19  
Wnt5a Wingless-related MMTV integration site 5A 2.19  
Ccnd3 Cyclin D3 2.19 X 
Siat5 Sialyltransferase 5 2.19  
BC008163 CDNA sequence BC008163 2.18  
Srebf1 Sterol regulatory element binding factor 1 2.18  
Stat3 Signal transducer and activator of transcription 3 2.18 X 
8430422M09Rik RIKEN cDNA C130002M15 gene 2.18  
BC065120 CDNA sequence BC065120 2.18  
Fcmd Fukuyama type congenital muscular dystrophy homolog (human) 2.18  
Mpp5 Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) 2.18  
 
L0910B09-3 NIA Mouse Newborn Kidney cDNA Library (Long) 
Mus musculus cDNA clone NIA:L0910B09 IMAGE:30000980 3', 
mRNA sequence. 
2.18 
 
Glcci1 Glucocorticoid induced transcript 1 2.17  
Armc1 Armadillo repeat containing 1 2.17  
Alkbh AlkB, alkylation repair homolog (E. coli) 2.17  
 Gene model 890, (NCBI) 2.17  
Pja2 Praja 2, RING-H2 motif containing 2.16  
 Transcribed locus, weakly similar to NP_081764.1 Mus musculus 5730493B19Rik gene 2.16  
BC061253 CDNA sequence BC061253 2.16  
Picalm Phosphatidylinositol binding clathrin assembly protein 2.16  
Aup1 Ancient ubiquitous protein 2.16  
U2af2 U2 small nuclear ribonucleoprotein auxiliary factor (U2AF) 2 2.15  
1700023B02Rik RIKEN cDNA 1700023B02 gene 2.15  
Arf4 ADP-ribosylation factor 4 2.14  
Vamp3 Vesicle-associated membrane protein 3 2.14  
6-Sep Septin 6 2.14  
2900073C17Rik 
Mus musculus adult male hippocampus cDNA, RIKEN full-length 
enriched library, clone:2900073C17 product:unclassifiable, full 
insert sequence. 
2.14 
 
Ahcyl1 S-adenosylhomocysteine hydrolase-like 1 2.13  
Dgat2 Diacylglycerol O-acyltransferase 2 2.13  
Ubp1 Upstream binding protein 1 2.13  
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Cnot6l CCR4-NOT transcription complex, subunit 6-like 2.12  
Wrb Tryptophan rich basic protein 2.12  
 Transcribed locus 2.12  
Zfp313 Zinc finger protein 313 2.11  
Cdca5 Cell division cycle associated 5 2.11  
Ppig Peptidyl-prolyl isomerase G (cyclophilin G) 2.11  
Cdh3 Cadherin 3 2.10  
Dlg5 RIKEN cDNA 1700067A10 gene 2.10  
2610318C08Rik RIKEN cDNA 2610318C08 gene 2.10  
Hmga2 High mobility group AT-hook 2 2.10  
2700029M09Rik RIKEN cDNA 2700029M09 gene 2.10  
Gtpbp1 GTP binding protein 1 2.10  
4921506J03Rik RIKEN cDNA 4921506J03 gene 2.10  
Cox15 COX15 homolog, cytochrome c oxidase assembly protein (yeast) 2.09  
Pknox1 Pbx/knotted 1 homeobox 2.09 X 
Mak10 MAK10 homolog, amino-acid N-acetyltransferase subunit, (S. cerevisiae) 2.09  
AW011752 Expressed sequence AW011752 2.08  
Hsd17b7 Hydroxysteroid (17-beta) dehydrogenase 7 2.08  
Mll5 Myeloid/lymphoid or mixed-lineage leukemia 5 2.08  
Efna2 Ephrin A2 2.07 X 
Ddx3x Fibroblast growth factor inducible 14 2.07  
Ahcy S-adenosylhomocysteine hydrolase 2.07  
Sas Sarcoma amplified sequence 2.07  
Fkbp10 FK506 binding protein 10 2.07  
9030408N13Rik RIKEN cDNA 9030408N13 gene 2.07  
2810410D24Rik RIKEN cDNA 2810410D24 gene 2.06  
Mef2a RIKEN cDNA A430081F14 gene 2.06  
Carf RIKEN cDNA A530050O19 gene 2.06  
Dnajc1 RIKEN cDNA D230036H06 gene 2.06  
 
Similar to Polyadenylate-binding protein 4 (Poly(A)-binding 
protein 4) (PABP 4) (Inducible poly(A)-binding protein) (iPABP) 
(Activated-platelet protein-1) (APP-1) 
2.06 
 
Sf3a2 Splicing factor 3a, subunit 2 2.05  
Polr2a Polymerase (RNA) II (DNA directed) polypeptide A 2.05  
1810045K07Rik RIKEN cDNA 1810045K07 gene 2.05  
Csnk1e Casein kinase 1, epsilon 2.05 X 
Siat6 RIKEN cDNA 9530034E10 gene 2.05  
Nvl Nuclear VCP-like 2.04  
Glipr2 GLI pathogenesis-related 2 2.04  
Hist1h3d Histone1, H3d 2.04  
Xrn1 RIKEN cDNA A130001C09 gene 2.04  
Zswim6 Zinc finger, SWIM domain containing 6 2.04  
Pex11a Peroxisomal biogenesis factor 11a 2.03  
1110001A05Rik RIKEN cDNA 1110001A05 gene 2.03  
Mia Melanoma inhibitory activity 2.03  
4631426J05Rik RIKEN cDNA 4631426J05 gene 2.02  
AI839920 Expressed sequence AI839920 2.02  
Rabl3 RAB, member of RAS oncogene family-like 3 2.02  
Basp1 Brain abundant, membrane attached signal protein 1 2.02  
1110014K08Rik RIKEN cDNA 1110014K08 gene 2.02  
Slc31a2 Solute carrier family 31, member 2 2.02  
Wars RIKEN cDNA 5033424D13 gene 2.02  
C130089L09Rik RIKEN cDNA C130089L09 gene 2.02  
Ccm1 Cerebral cavernous malformations 1 2.02  
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Fmr1 Fragile X mental retardation syndrome 1 homolog 2.01  
Nfatc3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 2.01  
Ncoa6ip Nuclear receptor coactivator 6 interacting protein 2.01  
1700024N20Rik RIKEN cDNA 1700024N20 gene 2.01  
Cdc42ep1 CDC42 effector protein (Rho GTPase binding) 1 2.00  
Cpox Similar to Cpo protein 2.00  
*Significant difference between day 8.5 p53 +/+ embryos and p53 -/- embryos. p<0.05. 
 
Examination of Known p53 Target Genes and NTD-related Genes: To verify 
the gene expression data obtained by microarray gene profiling, selected known target 
genes of p53, i.e. cyclin G1 (ccng1), p21 (cdkn1a), Mdm2, Puma (Bbc3), Noxa 
(Pmaip1), and p53 (Trp53) itself, were independently validated using the TaqMan 
quantitative real-time PCR method (Figs. 3.2 and 3.3).  As expected, RT-PCR validated 
that expression of p53 was significantly decreased in expression in p53 +/- and p53 -/- 
embryos (Fig. 3.2).  Well known p53 target genes, cyclin G1 and p21 were also shown to 
be significantly down-regulated in p53 -/- embryos.  In contrast, RT-PCR verified that 
other p53 target genes, Mdm2, Noxa, and Puma, did not show significant alteration in 
p53 -/- embryos.   
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Figure 3.2. RT-PCR verification of p53 gene expression in day 8.5 mouse embryos.  Three 
replicates of pooled embryos were used for each p53 genotype.  * indicates a significant 
difference in p53 gene expression compared to that of p53 +/+.  p<0.05.  
 
 
Figure 3.3. p53 and known p53 target gene expression in day 8.5 mouse embryos using 
microarray and RT-PCR.  * indicates a significant difference in gene expression compared to 
that of p53 +/+.  p<0.05.  
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There are more than 190 genes, including p53, that play a role in the etiology in 
NTDs when deleted.  To determine whether any of these genes are among the 388 genes 
that showed altered expression in p53 -/- embryos compared to p53 +/+ embryos, we 
searched the gene list presented in supplemental Tables 3.1 and 3.2.  Our microarray 
data showed that the expression of six NTD-related genes, Csk, Itga3, Jarid2, Prkaca, 
Rarg, and Sall4, were significantly decreased in p53 -/- embryos.  Similarly, RT-PCR 
data also showed decreased expression of these genes; however, the results did not 
achieve statistical significance (Fig. 3.4).   
 
 
Figure 3.4. Gene expressions of six genes that are known to cause NTDs when deleted in day 
8.5 mouse embryos using microarray and RT-PCR.  * indicates a significant difference in gene 
expression compared to that of p53 +/+.  p<0.05.  
 
Differentially Expressed miRNAs and Comparison of Putative and 
Experimental miRNA Target Genes: To compare the miRNA expression pattern in p53 
+/+ and -/- embryos, miRNA LDAs were utilized.  Of the 368 miRNAs examined, 165 
miRNAs were detected in day 8.5 mouse embryos, and out of these miRNAs, 111 
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miRNAs have mouse homologs (Table 3.3).  This RT-PCR technique further identified 
three miRNAs, miR-1, miR-142-3p, miR-301, that show significantly decreased 
expression and two miRNAs, miR-30e-3p and miR-331, with significantly increased 
expression in p53 -/- embryos compared to p53 +/+ embryos (Table 3.4).       
 With the exception of miR-301, our computational target gene analysis using the 
predicted targets identified by the two algorithms and the experimental data obtained in 
this study have revealed several putative target genes of the selected miRNAs (Table 
3.4).  Table 3.4 lists miRNAs that showed significant alteration in p53 -/- embryos 
compared to p53 +/+ embryos, the fold change and p value for their alteration, as well as 
the predicted target genes that showed a strong correlation with these miRNAs (p<0.05).  
         
Table 3.3 
Detection of miRNA Expressions in Day 8.5 Embryos 
    # of miRNAs     # of miRNAs    Total # of miRNAs 
                  Detected    Not Detected       Investigated 
Mouse miRNAs              111  29   140 
Total miRNAs  (Human)                165  203   368 
 
 
Table 3.4 
miRNA Expression Changes in p53 -/- Day 8.5 Embryos and Putative Targets of the 
miRNAs 
Name         Fold        P    Putative targets* 
  change     Up-regulated     Down-regulated 
miR-1  -1.53   0.040    Fyn      Rev1  
miR-30e-3p  1.41   0.004    Ssx2ip, 4930591A17Rik    Gnai2, Mafg, Rhebl1  
miR-142-3 -2.14   0.024    Arntl 
miR-301 -1.28   0.035    None 
miR-331 1.87   0.006    Vcp, Gnb2, Tbcld10b, Pcbp4, Ppapdc3 Rarg                                                                
*Genes identified by a comparison of the predicted targets identified by two algorithms and the 
genes identified by our regression model. p<0.05.  
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3.5.   DISCUSSION 
Our data show that deletion of only one p53 allele leads to the altered expression 
of only a few genes.  This correlates with our finding that no p53 +/- fetuses exhibit 
exencephaly (section 4), suggesting that at least in the developing mouse embryo loss of 
one p53 allele and the associated changes in gene expression are not sufficient to induce 
NTDs. Other studies, however, have shown that loss of one p53 allele leads to increased 
tumorigenesis in mice and humans (Lynch and Milner, 2006; Varley et al., 1997; 
Venkatachalam et al., 1998, 2001).  These studies and our data indicate that the 
reduction of p53 dosage is sufficient for cancer promotion but not the induction of 
NTDs.  The mechanistic links between p53 and tumorigenesis and NTDs may also be 
different. These differences may relate, in part, to different requirements for p53 in the 
activation of different p53 target gene sets during tumorigenesis and neural tube closure.    
Our data also show that deletion of both p53 alleles results in a significant 
alteration of embryonic gene expression. Moreover, this altered gene expression 
correlates with our finding that 11% of p53 -/- develop NTDs, i.e., exencephaly or spina 
bifida (data found in section 4).  Among the significantly altered genes during the neural 
tube closure, the majority (77%) are down-regulated in the absence of p53 and only 11% 
of the disregulated genes contain putative p53 DNA-binding sites.  A similar study in a 
temperature-sensitive human lung cancer cell line has also shown that the majority of the 
altered genes are down-regulated in p53-deficient cells and less than 20% of the genes 
altered in p53-deficient cells are primary targets of p53 (Kannan et al., 2001), indicating 
that p53 activates pathways and exerts its effect through a diverse network of 
transcriptional changes.  Thus, our data suggest that not only the loss of p53 gene itself 
and the alteration of expression of p53 target genes but also alteration of “downstream” 
genes could well contribute to the mechanisms of NTDs.   
Interestingly, in p53 -/- embryos the expression of several p53 target genes, for 
example, Mdm2, Noxa, and Puma,  was not altered, whereas a few p53 target genes such 
as p21 and cyclin G1 showed decreased expression, indicating that even in normal day 
8.5 developing embryos p21 and cyclin G1 are activated and regulated by p53.  This also 
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suggests that even in day 8.5 embryos without any stress, p53 is activated to regulate 
specific target genes.  Published research has shown that although a high level of 
inactive p53 protein can be observed during embryogenesis, active p53 protein is 
observed in the developing nervous system (Gottlieb et al., 1997; Komarova et al., 1997; 
MacCallum et al., 1996).  Taken together, it is possible that these cell cycle arrest related 
genes, p21 and cyclin G1, are activated by p53 mainly in the nervous system, where cell 
cycle arrest is important for the control of cell numbers at the time of neural tube closure 
(Copp et al., 2003).  In contrast, expressions of pro-apoptotic genes such as Noxa and 
Puma are unchanged, yet these genes are expressed in p53 -/- embryos, suggesting that 
at this embryonic stage, these p53 target genes are not regulated by p53 but could be 
regulated by transcription factors other than p53.  Our data collectively suggest that at 
the time of neural tube closure, p53 tightly controls its specific transcriptional target 
genes to exert particular pathways.   
To assess the possible contribution of the altered genes to NTDs observed in p53 
-/- embryos, we identified six genes (Csk, Itga3, Jarid2, Prkaca, Rarg, and Sall4), 
known to cause NTDs when they are deleted, that were significantly down-regulated 
with analysis by microarray expression profiling.  RT-PCR analysis to confirm the 
expression levels of these six genes showed similar decreases in expression; however, 
these differences were not statistically significant.  Nonetheless, our microarray and RT-
PCR analysis suggest that these six genes may contribute to the NTDs observed in p53 -
/- embryos.  Additional research is necessary to determine whether any or all of these 
genes play a causal role in the etiology of NTDs in p53 -/- embryos.    
Other genes that could possibly contribute to NTDs in p53 -/- embryos were 
selected from Tables 3.1 and 3.2, and grouped into the following categories; cell cycle-
related genes, retinoid-related genes, axon guidance-related genes, and ATM-related 
genes.  For example, our microarray analyses have identified two key cell cycle-related 
genes, p21 and cyclin G1, that are significantly down-regulated in p53 -/- embryos.  
Induction of p21 inhibits cyclin D/cyclin-dependent kinase 4 (CDK4) complex, leading 
to cell cycle arrest at G1 phase (el-Deiry, 1998a).  The function of cyclin G1 is not well 
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known; however, it has been hypothesized that cyclin G1 is a key regulator of the p53-
MDM2 network (Okamoto et al., 2002).  In addition, it has been suggested that cyclin 
G1 plays roles in G2/M arrest after cellular stress (Kimura et al., 2001) given that over-
expression of cyclin G sensitizes cells to apoptosis in mouse cell lines (Okamoto and 
Prives, 1999).  We have also shown that cyclin D3, which promotes cell progression by 
forming a complex with CDKs (Sherr, 1995), showed a significant decrease in p53 -/- 
embryos.  Taken together, our results indicate that the lack of p53 alleles clearly 
disregulates genes involved in cell cycle progression, suggesting that disregulation of 
cell cycle may be one of the mechanisms of NTDs observed in p53 -/- embryos.   
Similarly, we have shown that the expression of retinoic acid receptor gamma 
(Rarg), retinoic X receptor beta (Rxrb), and retinoic acid induced 1 (Rai1) genes are 
also significantly decreased in p53 -/- embryos.  In addition, retinoic acid receptor alpha 
(Rara) also showed 1.5-fold decrease in mRNA expression (data not shown).  Retinoic 
acid receptors (RARs) are known to bind all-trans and 9-cis retinoic acid (RA), to form 
heterodimers with retinoic X receptors (RXRs) and to play critical roles in embryonic 
development, including closure of the hindbrain and antero-posterior patterning of the 
somatic mesoderm and hindbrain neuroectoderm (Chambon, 1996; Leid et al., 1992; 
Mark et al., 2006).  Although Rara- and Rarg-null mutant mice are viable, possibly 
reflecting the existence of functional redundancies between RARs, Rara/g-null embryos 
result in NTDs (Ang and Duester, 1997; Lohnes et al., 1994).  Together, our results 
indicate that decreased expression of these genes may well be involved in the NTDs 
observed in p53 -/- embryos.   
In addition, our microarray analysis identified three key axon guidance-related 
genes, i.e. ephrin A2 (Efna2), ephrin B1 (Efnb1), and ephrin receptor B4 (Ephb4), that 
are significantly down-regulated in p53 -/- embryos.  Published studies show that the 
deletion of ephrin A5 (Efna5) or ephrin receptor A7 (Epha7) leads to NTDs (Holmberg 
et al., 2000), suggesting the important role of ephrins and ephrin receptors in the etiology 
of NTDs.  In the nervous system of developing embryos, a variety of attractive and 
repulsive signals have been identified that guide axonal processes as part of their 
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complex migration pathways (Goldshmit et al., 2006).  Ephrin receptors and their 
ligands are required for repulsive interactions necessary to form the anterior 
commissure, to select spinal cord motor neuron pathways, and to facilitate migration of 
neural crest cells.   
Finally, our analyses have identified two key ATM-related genes, H2AX (H2afx) 
and 53BP1 (Trp53bp1), that are significantly down-regulated in p53 -/- embryos.  53BP1 
is a p53 binding protein that binds to the central DNA-binding domain of p53 
(Derbyshire et al., 2002).  In response to DNA insult, ataxia telangiectasia-mutated 
(ATM) in mammalian cells phosphorylates the C-terminal tail of H2AX protein (Celeste 
et al., 2002; Paull et al., 2000), which then recruits BRCA1 C-terminal (BRCT) domain-
containing proteins including 53BP1 (Wang et al., 2002; Ward et al., 2003).  53BP1 then 
recruits p53 to the site of the DNA damage for the transcriptional activation of p53 target 
genes.  Although statistically significant down-regulation in the expression of H2AX or 
53BP1 was observed, neither gene is a putative target gene of p53.  H2AX and 53BP1 
are clearly involved in the ATM-dependent DNA damage responses and the cellular 
function of p53; however, no study has shown that these genes may be direct p53 target 
genes or that transcription of these genes is somehow regulated by p53.  Further 
experiments are needed to determine whether any of these cell cycle-related, retinoid-
related, axon guidance-related, and ATM-related genes, in fact, play a causal role in 
neural tube closure.           
To investigate whether miRNAs are expressed in early organogenesis-stage 
mouse embryos, whether the expression of miRNAs is altered by deletion of p53 alleles, 
and whether these changes could contribute to NTDs observed in p53 -/- embryos, we 
quantified the expression levels of 368 miRNAs.  In day 8.5 mouse embryos, 111 
mouse-specific miRNAs were expressed, whereas 29 miRNAs were not detected, 
suggesting that the expression of miRNAs is strictly controlled at specific stages of 
mammalian embryonic development.  Our data also showed that three miRNAs, miR-1, 
miR-142-3p, and miR-301 showed statistically significant decrease, and two miRNAs, 
miR-30e-3p and miR-331, showed statistically significant increase in their expression in 
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p53 -/- embryos compared to p53 +/+ embryos, indicating that these miRNAs might be 
regulated by p53.  Precedent for p53-mediated regulation of miRNAs comes from 
studies showing that transcription factors can regulate miRNA expression.  For example, 
p53 has been shown to bind and regulate expression of miR-34 family (Corney et al., 
2007; He et al., 2007) and NFI-A can bind to the promoter of miR-223 and regulate its 
transcription (Fazi et al., 2005).    
The target gene analysis using both our stepwise regression and two publicly 
available computational tools, PicTar and miRBase, further identified putative target 
genes of these miRNAs that are supported by two completely independent approaches.  
Retinoic acid receptor gamma (Rarg), which is a known direct putative target gene of 
p53 that  was significantly down-regulated in p53 -/- embryos, was also shown to be 
regulated by miR-331, which showed increased expression in p53 -/- embryos.  This 
indicates that p53 may synergistically regulate Rarg with miR-331, where the deletion of 
p53 alleles directly up-regulates the expression of miR-331 and down-regulates Rarg, as 
well as the up-regulation of miR-331 contributing further down-regulation of Rarg.  
Similarly, the increased expression of miR-30e was correlated with the down-regulation 
of its putative target genes, guanine nucleotide binding protein alpha inhibiting 2 
(Gnai2), v-maf musculoaponeurotic fibrosarcoma oncogene family protein g (Mafg), and 
ras homolog enriched in brain like 1 (Rhebl1).  In addition, the decreased expression of 
miR-1 with the up-regulation of its putative target gene, Fyn proto-oncogene (Fyn, 
different RefSeq from the one seen in Table 3.2), as well as the decreased expression of 
miR-142 with the increased expression of its putative target gene, aryl hydrocarbon 
receptor nuclear translocator-like (Arntl) were observed.  These results follow the 
conventional understanding of miRNA function in that miRNAs negatively regulate 
gene expression by repressing translation or directing sequence-specific degradation of 
target mRNAs (Meister and Tuschl, 2004; Pillai et al., 2007).  The identification of these 
putative target genes of the selected miRNAs using two completely independent 
methods, computational algorithms and the stepwise regression model of the 
experimental data provides strong support that these genes might be actual miRNA 
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target genes; however, further research is necessary to determine whether any of these 
target genes are directly regulated by these miRNAs.   
In addition to the well-studied function of miRNAs, recent studies have revealed 
another potential function of miRNA in regulating gene expression.  Place et al. (2008) 
provided data showing that miR-373 induces E-cadherin and cold-shock domain-
containing protein C2 (CSDC2), both possessing a putative miR-373 target site within 
their promoter.  Furthermore, two other studies showed that synthetic dsRNAs also 
induce gene expression, referred to as RNA activation (RNAa) (Janowski et al., 2007; Li 
et al., 2006).  In our analysis, decreased expression of miR-1 was correlated with the 
down-regulation of its putative target gene, REV1 homolog (Rev1), as well as the 
increased expression of miR-30e-3p and miR-331 with the up-regulation of their putative 
target genes, suggesting the possible induction of gene expression by these miRNAs.  
Further study and a better understanding of the function of miRNAs and how they 
regulate genes are necessary to understand the roles of miRNAs in the etiology of NTDs 
and development.     
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4.   THE ROLES OF P53 AND P21 IN NORMAL DEVELOPMENT AND  
HYPERTHERMIA-INDUCED MALFORMATIONS 
 
4.1.   OVERVIEW 
Hyperthermia (HS) is a well studied teratogen that induces serious 
malformations, including neural tube defects (NTDs).  Our previous studies have shown 
that HS induces apoptosis by activating the mitochondrial apoptotic pathway.  Prior to 
activation of the mitochondrial apoptotic pathway, HS also activates p53.  Activation of 
p53, in turn, leads to the expression of p53 target genes, e.g., p21.   In the present study, 
we determine whether p53 and/or p21 play a role as teratogen suppressors or inducers of 
HS-induced malformations.  Pregnant mice carrying all three p53 or p21 genotype 
embryos were exposed to HS in a 43 °C water bath for 10 min on day 8.5.   
Subsequently, fetuses were collected on day 15.5 and genotyped.  For p53 fetuses the 
sex of each fetus was also determined using DNA isolated from the accompanying yolk 
sac.  In addition to genotype, (sex for p53 fetuses), we also determined the number of 
resorptions and dead fetuses as well as the number and types of external malformations.  
In the absence of HS exposure, fetuses exhibiting exencephaly, spina bifida, and preaxial 
polydactyly were observed in approximately 11% of p53 -/- fetuses, whereas no 
malformations were observed among p21 -/- fetuses. A female predominance in 
exencephaly and spina bifida, and a male preference in preaxial polydactyly were also 
observed in control p53 fetuses.  Exposure to HS resulted in an increase in exencephaly 
and preaxial polydactyly in fetuses of all three p53 genotypes.  In addition, the incidence 
of these malformations was statistically significantly higher in p53 -/- compared to p53 
+/- and p53 +/+ fetuses.  Interestingly, no fetuses with spina bifida were observed among 
any of the p53 genotypes exposed to HS.  Exencephaly was the only malformation  
 
____________ 
*Reprinted from “The Roles of p53 and p21 in Normal Development and Hyperthermia-
Induced Malformations” by Hiromi Hosako, Liezl E. Francisco, Gail S. Martin, and 
Philip E. Mirkes. Birth Defect Research B. Accepted.  
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observed in p21 fetuses exposed to HS, with an approximately 2-fold increase in 
exencephaly among p21 +/- and a 3-fold increase among  p21 -/- compared to p21 +/+ 
fetuses.  Our study confirms that p53 plays a role in normal development and has shown, 
for the first time, that p53 and p21 function to suppress HS-induced malformations.   
 
 
4.2.   INTRODUCTION 
Each year approximately 3% of babies born in the United States have birth 
defects that are life threatening, require major surgery, or present a significant disability 
(Shepard, 1986).  One of the most common human birth defects, neural tube defects 
(NTDs), represent a group of serious congenital malformations resulting from failure of 
neural tube closure during early development, with a prevalence of approximately 1 in 
1000 live births in the United States (Copp et al., 2003).  Of these, the most common 
NTDs are anencephaly/exencephaly and spina bifida resulting from the failure of neural 
tube closure in the cranial and spinal region, respectively.  The etiology of NTDs is 
complex and is known to involve both genetic and environmental factors.  In humans, 
genetic factors, for example, chromosomal abnormalities and single-gene disorders, 
including Fraser syndrome and Waardenburg syndrome, are associated with NTDs 
(Padmanabhan, 2006).  Although no single gene mutation has been shown to be solely 
responsible for human NTDs, animal studies have identified more than 190 genes that 
cause NTDs when deleted (Harris and Juriloff, 2007).  Examples of environmental 
factors that contribute to NTDs include geographic and temporal variations as well as 
physical and chemical agents, such as maternal hyperthermia, x-irradiation, antiepileptic 
drugs, thalidomide, and folate antagonists (Mitchell, 2005; Padmanabhan, 2006).   
Hyperthermia (HS) is a well recognized teratogen that induces a variety of 
malformations, including NTDs during critical periods of embryo development 
(Edwards, 2006).  The teratogenicity of HS was first recognized in laboratory animals 
(Edwards, 1966), and subsequent epidemiological and clinical studies have shown that 
HS is also a suspected teratogen in humans (Moretti et al., 2005).  The sources of HS in 
humans include febrile illnesses, sauna bathing, and hot tub use (Moretti et al., 2005).  
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Although the central nervous system is especially susceptible to HS-induced damage 
(Edwards et al., 2003; Kline et al., 1985; Shiota, 1982), the mechanisms of HS-induced 
NTDs are not well understood.   
Previously, we showed that HS induces apoptosis in early postimplantation 
rodent embryos by activating the mitochondrial apoptotic pathway, which is 
characterized by the release of cytochrome c and the subsequent activation of caspases, 
cleavage of poly ADP-ribose polymerase, and DNA fragmentation (Little et al., 2003; 
Little and Mirkes, 2002; Mirkes and Little, 1998, 2000).  Subsequent studies, using 
DNA microarray gene expression profiling, identified five candidate “apoptosis-related” 
genes (Mikheeva et al., 2004), three of which were p53-regulated genes.  These data 
implicated p53 in both HS-induced apoptosis and HS-induced malformations.  Our 
research has further shown that HS induced the accumulation and phosphorylation of 
p53 at serine 15 as part of the activation of this transcription factor (Hosako et al., 2007).  
Called “the guardian of the genome”, p53 is a transcription factor that is essential for 
preventing inappropriate cell proliferation, removing damaged cells by apoptosis, and 
for maintaining genomic integrity.  Activation of p53 can lead to apoptosis, cell cycle 
arrest, DNA repair, senescence, or differentiation following a variety of stresses 
(Hofseth et al., 2004; Lane, 1992; Levine et al., 2006).   
Studies using transgenic mice have shown that p53 plays a role in the etiology of 
NTDs (Harris and Juriloff, 2007).  Early studies (Armstrong et al., 1995; Sah et al., 
1995) reported that, although mice lacking p53 are viable, 2-6% of p53 -/- newborn mice 
exhibit abnormal neural tube closure resulting in exencephaly as well as a significant 
increase in mortality in utero or soon after birth.  In addition, these studies revealed that 
the p53 -/- mice exhibiting NTDs are predominantly females, which is also found in 
human exencephaly cases as well as in other mouse mutants, e.g., 1/Hipk2, Efna5, 
Marcks, Nif1, and xn mutants (Harris and Juriloff, 2007; Seller, 1987, 1995).  In mouse 
embryos, both p53 mRNA and protein are ubiquitously expressed until mid gestation 
(Louis et al., 1988; Rogel et al., 1985; Schmid et al., 1991).  At later organogenesis 
stages, however, the expression levels decrease rapidly and only specific differentiating 
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tissues show the expression of p53.  Although p53 is expressed in developing embryos, 
most p53 protein in embryos is relatively inactive, at least with respect to some 
intracellular pathways regulated by p53 (Gottlieb et al., 1997; Komarova et al., 1997; 
MacCallum et al., 1996).  Given the importance of p53 in processes critical to normal 
development, one of the objectives of the present study was to determine whether p53 
functions as an enhancer or suppressor of HS-induced malformations.    
Previous studies have also shown that HS induces the expression of p21 mRNA 
and protein, suggesting a role for p53 in teratogen-induced cell cycle arrest via the up-
regulation of p21 (Hosako et al., 2007).   More recent studies, using p53 deficient mice, 
have confirmed that the expression of p21 is regulated by p53 in day 8.5 mouse embryos 
(section 5).    p21 has the ability to induce cell cycle arrest at both the G1 and G2 
checkpoints.  p21 binds and inactivates CDK4, 6/Cyclin D and CDK2/Cyclin E 
complexes, resulting in pRB hypophosphorylation and cell cycle arrest at G1 phase 
(Stewart and Pietenpol, 2001). p21 arrests cells at G2 checkpoint by inhibiting 
CDK1/Cyclin B1 (Flatt et al., 2000; Innocente et al., 1999).   Given the importance of 
cell proliferation in normal development and the important role of p21 in regulating cell 
division, another objective of the present study was to determine whether p21 acts as an 
enhancer or suppressor of HS-induced malformations.            
 
 
4.3.   MATERIALS AND METHODS 
Experimental Animals: All animals were maintained in accordance with animal 
use protocol approved by the Institutional Animal Care and Use Committee at Texas 
A&M University.  A pair of p53 +/- mice (a gift of Lawrence A. Donehower, Baylor 
College of Medicine) with C57BL6-Tyrc-Brd background (Zheng et al., 2002) and 
highly inbred p21 -/- mice of 129S2 strain from Jackson Laboratory were used for 
breeding.  p21 hybrids were generated by crossing p21 -/- to wild-type males of C57BL6 
strain obtained from a local supplier.  Mice were kept with freely available pellet food 
and water at 21-23 ˚C and 12-h light/dark cycle (6:00-18:00).  Virgin p53 +/- and p21 -/- 
females of 6-17 weeks old were separately cohabited with p53 +/- and p21 +/+ males 
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and checked the following morning for the vaginal plug.  Upon detecting a plug, 12 a.m. 
was designated day 0.   
Hyperthermia Treatment and Fetal Collections: On gestation day 8.5, when the 
embryos are at the most sensitive period for the induction of NTDs (Finnell, 1981), 
pregnant dams were exposed to HS for 10 min at 43 ˚C (or 38 ˚C for a control) in a 
water bath equipped with a thermolegulated heater.  For the HS treatment, each pregnant 
dam was restrained in a 50-ml plastic centrifuge tube with holes drilled on the sides for 
the adequate water circulation and immersed in water up to the lower two-thirds of the 
body as described by Finnell (1986).  Rectal temperature was monitored at 1-second 
intervals by Mini-logger and Mini-mitter reader with a small rectal probe (Respironics, 
Bend, OR) so that the rise in rectal temperatures occurred at approximately the same rate 
for all animals (38 °C at min 0, 39 °C at min 1, 40 °C at min 2, 41 °C at min 3, 42 °C at 
min 4, 42.5 °C at min 5, and 42.8 °C at min 6, and 43 °C for min 7-10).  After exposure 
to HS, treated dams were removed from the centrifuge tube, quickly dried with paper 
towels, and placed in an incubator set at 38 °C to minimize the recovery differences 
among different mice.  Temperature was continually monitored until the baseline 
temperature was reestablished.  The dams were then returned to their cage where they 
remained until day15.5.   
PCR for Genotyping and Sex Identification, and Fetal Examinations: On day 
15.5, fetuses were removed from the uterus and the yolk sac of each conceptus was 
collected in ice-cold Hanks’ balanced salt solution.  Genomic DNA was isolated from 
each yolk sac using PureLink™ Genomic DNA kits (Invitrogen, Carlsbad, CA), and the 
isolated sample was used for p53 or p21 genotyping of its matching fetus.  Primers used 
for p53 PCR genotyping were: p53 forward primer (in the intron 1): 5’-
TTTCCCACCCTCGCATAAGTTTCC-3’, p53 reverse primer (in the intron 2): 5’-
CGCAGGATTTACAGACACCCAACA-3’ (558 bp), puro forward primer: 5’-
ATGACCGAGTACAAGCCCAC-3’, and the puro reverse primer: 5’- 
GCGTGAGGAAGAGTTCTTGC-3’ (166 bp).  Primers used for p21 PCR genotyping 
were: 5’-AAGCCTTGATTCTGATGTGGGC-3’, 5’-
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TGACGAAGTCAAAGTTCCACC-3’, and 5’-GCTATCAGGACATAGCGTTGGC-3’ 
(872 bp for p21 and 700 bp for neo, The Jackson Laboratory). The PCR program for p53 
genotyping consisted of one cycle of 2 min at 95 ˚C, 40 cycles of 40 s at 95 ˚C, 40 s at 
65 ˚C, and 60 s at 72 ˚C, followed by one cycle of 7 min at 72 ˚C.  The PCR program for 
p21 genotyping consisted of one cycle of 3 min at 94 ˚C, 35 cycles of 30 s at 94 ˚C, 60 s 
at 64 ˚C, and 60 s at 72 ˚C, followed by one cycle of 7 min at 72 ˚C.  DNA isolated from 
each p53 fetus was also used for sex determination as described by Sah et al (1995).  All 
samples were visualized on a 1.5% agarose electrophoresis gel after staining with 
ethidium bromide.   
Examination of Fetuses: Day 15.5 fetuses were examined under a microscope 
for neural tube defects as well as other external malformations, and their body length 
was carefully measured using Nikon Digital Sight DS-L (Nikon, Melville, NY).  The 
number of implantation sites, resorptions, and dead fetuses were also recorded.  Dead 
fetuses that showed any degree of degeneration were considered resorptions whereas 
fetuses that retained their integrity but exhibited no blood circulation were counted as 
dead fetuses.   The yolk sac from dead fetuses was used for genotyping.  We were unable 
to genotype resorptions because we were unable to isolate the yolk sac from resorbed 
conceptuses.  For the statistical analyses, we used the Chi-square test to analyze the 
Mendelian distribution ratio of p53 and p21 fetuses. Statistical significance of 
malformations observed in each genotype or/and sex were evaluated by Fisher’s exact 
test, and the t-test was utilized to evaluate the statistical significance of body length of 
each genotype or/and sex (p<0.05).   A total of at least 40 litters per treatment were used 
to collect at least 65-80 fetuses for each genotype. 
Examination of Neonatal p53 Mice: To examine the distribution of genotypes 
among neonatal mice born from p53 heterozygous mice, p53 +/- females were separately 
cohabited with p53 +/- males, and their pups were evaluated for their genotype and 
gender by visual examination (Zheng et al., 2002) upon weaning at 21 days after birth.  
A total of 395 neonatal mice from 86 litters were evaluated. 
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4.4.   RESULTS 
p53 and Normal Growth and Development: In control litters, the number of 
resorptions and dead fetuses on day 15.5 were 16.2% and 1.3%, respectively (Table 4.1).  
Gross examination of the dead fetuses revealed that 20% (1 of 5 fetuses) were 
exencephalic, p53 -/- , and female.  The distribution of genotypes among the collected 
day 15.5 fetuses (+/+: +/-: -/-) approximated the expected 1:2:1 Mendelian ratio 
(26%:50%:24%); however, at weaning the distribution of genotypes was significantly 
skewed (29%: 57%:14%, p=0.0001).  In addition, the number of male and female fetuses 
of each genotype at gestation day 15.5 were equivalent.  Although the ratio of male and 
female pups at weaning was equivalent, 89% of the p53 -/- neonates were male (Table 
4.1 and Table 4.2).  Finally, no statistically significant differences in body size among 
genotypes were observed, although there was a slight but consistent decrease observed in 
both male and female p53 -/- fetuses (Table 4.3).    
External malformations observed in control p53 fetuses include exencephaly 
(1.3%), spina bifida (1.3%), preaxial polydactyly (1.0%), cleft lip (0.3%), and 
microphthalmia (0.3%) (Table 4.1).  As expected, all fetuses with exencephaly were p53 
-/- and female (11%) (Table 4.2).  In addition, all fetuses with spina bifida were also 
identified as p53 -/- and female (11%).  All cases of preaxial polydactyly involved 
thumb duplications and were only observed in males.   All of polydactylous fetuses were 
p53 -/- and involved the hind limb except for one fetus, which had a p53 +/+ genotype 
and involved the fore limb.  Finally, one p53 +/+ female showed cleft lip and 
microphthalmia.   
p53 and HS-induced Malformations: Although no statistically significant 
increase in the number of resorption was observed in the HS-treated group compared to 
control, the number of dead fetuses in the HS-treated group showed a statistically 
significant increase compared to that in control (Table 4.1).  Gross examination of the 
dead fetuses revealed that 20% (3 of 15 fetuses) were exencephalic, p53 -/-, and female.  
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The ratio of genotypes among HS-treated fetuses on day 15.5 (+/+: +/-: -/-) was 
the expected Mendelian ratio of 1:2:1 (24%:54%:22%) and the number of male and 
female fetuses were equivalent among all genotypes.  Finally, no statistically significant 
difference in body size between control and HS-treated fetuses was observed (Table 
4.3). 
An increased number of malformed fetuses was also observed in the HS-treated 
group.  Malformations observed included exencephaly (23.1%), preaxial polydactyly 
(4.1%), cleft lip (0.3%), micropthalmia (0.3%), and hamartomas along the sagittal suture 
of the skull (3.1%).  Fetuses with exencephaly were observed in all genotypes following 
HS treatment, comprising a total of 23.1% of the fetuses collected.  The increase in the 
number of exencephalic fetuses after HS treatment was statistically significant compared 
to control in all three genotypes (indicated as *) and in those with a p53 -/- genotype, 
almost half of the fetuses (46.9%) showed exencephaly.  In addition, the increase in the 
number of exencephalic fetuses in HS-treated p53 -/- group was statistically significant 
compared to the number of exencephalic fetuses observed in HS-treated p53 +/+ and p53 
+/- groups (indicated as†).  The exencephalic fetuses observed after HS treatment 
included both males and females, yet in all genotypes more females were affected, and 
the number of exencephalic females was statistically higher than that of males in p53 -/- 
fetuses as well as in total p53 fetuses collected (indicated as‡).           
Interestingly, spina bifida was observed in control p53 -/- fetuses; however, no 
spina bifida fetuses were observed among HS-treated fetuses.  In addition, the number of 
fetuses exhibiting preaxial polydactyly was statistically significantly increased among 
HS-treated p53 -/- fetuses compared to control.  The increase of preaxial polydactyly in 
HS-treated p53 -/- fetuses was also statistically significant compared to that of p53 +/+ 
fetuses following HS treatment.  Although both males and females exhibit preaxial 
polydactyly after HS exposure, only the increase in HS-treated female is statistically 
significant compared to control.   
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 Interestingly, 42% of the preaxial polydactyly fetuses after HS treatment also 
showed exencephaly, and again all of the polydactyly cases were thumb duplication on 
their hind limb.  In addition, majority of control and HS-treated fetuses exhibited right 
limb preaxial polydactyly.  There was one p53 +/+ female showing cleft lip and one p53 
+/- female with microthalmia following HS treatment.  Finally, we observed 9 cases of 
hamartomas along sagittal suture of the skull in HS-treated fetuses.  These cases were 
found in all three genotypes and both genders.  The increase in hamartomas in total HS-
treated fetuses as well as HS-treated females was statistically significant compared to 
those in control.          
p21 and Normal Growth and Development: No malformations were observed 
among control p21 fetuses, and the distribution of genotypes among day 15.5 fetuses 
(+/+: +/-: -/-) was the expected 1:2:1  Mendelian ratio (24%:49%:27% for control 
fetuses) (Table 4.4).  In addition, there was no significant difference in body size among 
genotypes in control fetuses. 
p21 and HS-induced Malformations: No statistically significant differences in 
the numbers of resorptions and dead fetuses were observed in HS-treated fetuses 
compared to control fetuses (Table 4.4).  Likewise, the distribution of genotypes among 
the day 15.5 fetuses (+/+: +/-: -/-) was the expected 1:2:1 Mendelian ratio (23.4%: 
53.2%: 23.4% for HS-treated fetuses).  In addition, there was no significant difference in 
body size among each genotype of HS-treated fetuses and no significant difference in 
body size between control and HS-treated fetuses. 
 The malformations observed in HS-treated p21 fetuses were exencephaly and 
one case of preaxial polydactyly (Table 4.4).  A statistically significant increase in the 
number of exencephalic fetuses after HS treatment compared to control was observed.  
Fetuses with exencephaly were observed in all genotypes, and the increases in the 
number of p21 -/- exencephalic fetuses were most prominent; however, the increase in 
p21 -/- exencephalic fetuses was not statistically significant compared to p21 +/+ 
exencephalic fetuses.  Finally, one case of preaxial polydactyly (duplication of the 
thumb) was observed on the right hind limb of a p21 +/- fetus after HS treatment. 
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4.5.   DISCUSSION 
 Although we observed the expected Mendelian distribution of p53 genotypes 
(1+/+:2+/-:1-/-) and the expected distribution of males and females (1:1) among control 
day 15.5 fetuses, at weaning p53 null and female pups were underrepresented.  These 
differences are, in part, the result of the increased fetal death in p53 -/- female fetuses 
sometime after organogenesis and before birth.   We observed no differences in neonatal 
death among genotypes (data not shown).   Although we hypothesize that increased 
resorptions also contribute to this difference, we were unable to confirm this due to an 
inability to extract embryonic DNA from resorptions for genotyping.  Nonetheless, our 
results showing increased prenatal death among p53 null fetuses confirm the findings of 
Armstrong et al. (1995).           
Several published studies have examined malformations in p53-deficient mice, 
and the observed malformations included exencephaly, fusion of the upper incisors, 
ocular abnormalities, and preaxial polydactyly of the hind limb (Armstrong et al., 1995; 
Kaufman et al., 1997 ; Pani et al., 2002; Sah et al., 1995).  Our study, in which we 
examined a greater number of litters than in previous studies, basically confirmed the 
spectrum of previously reported malformations.  In addition, we observed fetuses with 
spina bifida, a malformation not reported in previous studies.  Although the percentage 
of fetuses with exencephaly observed in our study was slightly lower compared to that of 
early studies (1.3% compared to 6.2% and 2.1%), this is most likely due to the strain 
differences (Finnell et al., 1986, 2000; Lundberg et al., 2003; Sah et al., 1995).   
The previously described predominance of fetuses with exencephaly in females 
(Armstrong et al., 1995; Sah et al., 1995) was also confirmed by our study.   In addition, 
we showed the female predominance of fetuses with spina bifida.  The biological origin 
of the predominance of NTDs in females, which has also been observed in humans, has 
been debated for decades.  Although the gonads are not yet developed during the neural 
tube closure, possible causes of the female predominance have been investigated, which 
include growth differences and DNA methylation for X-chromosome inactivation 
(Juriloff and Harris, 2000; Seller, 1995).  Research studies have shown that female 
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embryos have a slower embryonic growth rate compared to males (Brook et al., 1994; 
Golding, 1982; Renwick, 1972), although whether the growth rate difference is causally 
linked to the female predisposition to NTDs is not shown (Brook et al., 1994).  X 
chromosome inactivation is a developmental process by which one of the two copies of 
the X chromosome in females is transcriptionally silenced by methylation, thus 
equalizing the expression of X-linked genes between the sexes (Lyon, 1961).  
Methylation regulates X chromosome inactivation as well other processes such as 
embryonic development and genome integrity (Turek-Plewa and Jagodzinski, 2005).   
Methylation of mammalian genomic DNA is mediated by DNA methyltransferases 
(DNMTs).   Mammalian DNMTs, which include DNMT1, DNMT3A, DNMT3B, and 
DNMT3L, are important for methylation pattern acquisition during embryogenesis and 
are divided into two groups according to their functions (Turek-Plewa and Jagodzinski, 
2005).  De novo DNMTs, including DNMT3A and DNMT3B, methylate C to m5C post-
replicatively in unmethylated DNA, whereas maintenance DNMTs such as DNMT1 
attaches a methyl group to DNA during replication (Bestor, 2000; Margot et al., 2003).    
Because an X chromosome must be methylated in every new cell in female embryos 
during X chromosome inactivation, this may lead to a “reduced methylation status” in 
female embryos undergoing rapid embryonic growth (methylation of DNA, protein, and 
lipids (Juriloff and Harris, 2000).  A recent study has shown that the number of copies of 
X chromosomes is associated with the sex differences in neural tube defects observed in 
p53-deficient embryos (Chen et al., 2008).  Our previous microarray study, using the 
same strain of p53 mice, identified 388 genes that were disregulated in p53 -/- day 8.5 
embryos (submitted).   One of these genes was Dnmt1, whose activity is critical for the 
maintenance of DNA methylation and the appropriate histone H3 modification (Turek-
Plewa and Jagodzinski, 2005).  Another study has shown that the deletion of Dnmt3b, 
which is expressed in cranial neural folds, leads to exencephaly (Okano et al., 1999).  
Taken together, these studies suggest that X chromosome inactivation by DNMTs may 
explain the female predominance of exencephaly and spina bifida observed in p53-
deficient embryos.  
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We have observed that p53 -/- fetuses showed increased incidence of NTDs 
whereas no malformations were observed in p21 -/- fetuses in the absence of stress. Our 
previous study has shown that in the absence of cellular stress, p53 target gene, p21, is 
downregulated in p53 -/- embryos compared to that in p53 +/+ embryos, suggesting the 
p53-dependent expression of p21 and a possible contribution of p21 in the induction of 
NTDs observed in p53 -/- embryos.   However, deletion of p21 gene did not lead to 
exencephaly, suggesting that the decreased expression of p21 in p53 -/- embryos is not 
crucial to the induction of exencephaly and spina bifida observed in p53 -/- embryos.       
Interestingly, all the p53 fetuses exhibiting preaxial polydactyly involved 
duplication of the thumb, referred to as preaxial polydactyly type I.  In our study preaxial 
polydactyly type I was observed on the hind limb.  In addition, all of the fetuses with this 
defect were males and p53 -/- except for one p53 +/+ fetus.  Although no previous 
studies have shown the correlation of preaxial polydactyly type I and p53, an extra digit 
on the hind limb of an exencephalic p53 -/- fetus has been also been reported previously 
(Armstrong et al., 1995), suggesting some causal relationship between preaxial 
polydactyly type I and p53.  In humans, the prevalence of preaxial polydactyly type I is 
approximately 0.8-2.5/10,000 (Firth et al., 2005).  The etiology of preaxial polydactyly 
type I is complex, and most cases are sporadic.  Males are more often affected than 
females, at least in certain populations (Bingle and Niswander, 1975; Orioli and Castilla, 
1999).  In our study, all the polydactyly fetuses observed exhibited hind limb preaxial 
polydactyly type I; therefore, p53 deficient mice might be a useful model to study the 
mechanisms of this specific defect.           
Following the HS exposure, we observed an increased incidence of exencephaly 
in all p53 genotypes and in both genders; however, females in all genotypes and p53 -/- 
fetuses were especially susceptible (47% vs. 16% in +/- and 17% in +/+ fetuses).  These 
results suggest that p53 functions as a suppressor of HS-induced exencephaly.   Whether 
p53 plays a role as a teratogen suppressor or inducer has been controversial, although the 
role of p53 as a teratological suppressor has been more favored based on the protective 
role of p53 following a variety of environmental stresses (Choi and Donehower, 1999).  
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However, recent studies have shown that p53 can function as a teratological inducer 
(Boreham et al., 2002; Narai et al., 2006; Wang, 2001), as well as as a teratogen 
suppressor (Baatout et al., 2002; Bekaert et al., 2005; Moallem and Hales, 1998).  For 
example, it has been shown that the loss of p53 alleles increase the incidence of fetal 
resorption and developmental anomalies in mouse embryos exposed to benzo[a]pyrene 
(Nicol et al., 1995).   It was also shown that p53 -/- embryos showed higher incidence of 
structural anomalies and fetal death and a fewer number of apoptotic cells than that of 
p53 +/+ embryos exposed to radiation (Baatout et al., 2002; Norimura et al., 1996).   
Others have also shown that the absence of p53 resulted in the increased limb defects but 
no signs of apoptosis (Moallem and Hales, 1998).   These studies suggest that p53 acts 
as a teratological suppressor.   In contrast, eye defects in mouse embryos exposed to 2-
chloro-2’-deoxyadenosine (2CdA) was mediated by p53-dependent apoptosis, 
suggesting that p53 acts as a teratogen inducer (Wubah et al., 1996).   Other studies have 
also shown that the lack of p53-dependent apoptosis resulted in reduced the incident of 
limb defects and cleft palate (Boreham et al., 2002; Narai et al., 2006; Wang, 2001).   
Close examination of the literature suggests that whether p53 acts as a suppressor or 
inducer is determined by the type of teratogen as well as the type of malformations 
evaluated.  Studies that have identified p53 as a teratological inducer have investigated 
specific malformations such as eye defects, limb malformations, and cleft palate 
(Boreham et al., 2002; Narai et al., 2006; Wang, 2001; Wubah et al., 1996), whereas 
most studies that have identified p53 as a teratogen suppressor have examined multiple 
types of malformations as well as resorptions (Baatout et al., 2002; Bekaert et al., 2005; 
Nicol et al., 1995; Norimura et al., 1996).  In addition, p53 was a teratological inducer of 
limb malformations following irradiation (Boreham et al., 2002; Wang, 2001), whereas 
it was a teratological suppressor of limb malformations following exposure to 4-
hydroperoxycyclophosphamide (Moallem and Hales, 1998).    
The evaluation of p21 fetuses has revealed that p21 -/- mice are developmentally 
normal and no statistically significant increase in the incidence of exencephaly was 
observed following the exposure to HS.  Our previous study has shown that the 
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expression of both p21 mRNA and protein is upregulated in HS-treated day 8.5 embryos, 
suggesting that cell cycle arrest induced by p21 may play an important role in HS-treated 
embryos (Hosako et al., 2007).  Although we observed that there was a slight but 
consistent increase in NTDs in p21 -/- embryos compared to p21 +/+ embryos, the 
increase was not statistically significant.   Therefore, it suggests that other biological 
pathways and proteins may be heavily involved in the induction of NTDs observed in 
p53 -/- embryos.  Taken together, our results indicate that although the statistically 
significant increase in NTDs was not observed, its consistent increase suggest that p21 
may act as a very weak teratogen suppressor.    
Overall, these studies showed that the deletion of both p53 alleles in normal 
embryos leads to NTDs.  In contrast, although p21 is regulated and controlled by p53 
during the normal embryonic development, the regulation of p21 is not causally linked 
to the induction of NTDs.  In the presence of HS exposure, p53 functions as a teratogen 
suppressor.   Following the deletion of p21 alleles, the incidence of exencephaly slightly 
but consistently increased, suggesting that p21 may be a very weak teratogen suppressor, 
although we did not show that the increase was statistically significant.  
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5. THE REGULATION OF APOPTOSIS AND P53 TARGET GENES IN 
P53-DEFICIENT DAY 8.5 MOUSE EMBRYOS EXPOSED TO 
HYPERTHERMIA 
 
5.1.   OVERVIEW 
HS activates the mitochondrial apoptotic pathway and its upstream regulator, 
p53, in day 9 mouse embryos. The activation of p53 results in the upregulation of p21 
mRNA and protein, inducing cell cycle arrest.   The p53 protein also upregulates Noxa 
and Puma mRNAs, but not their proteins.  Although whether these genes play a role in 
the induction of the mitochondrial apoptotic pathway in embryos exposed to HS is not 
clear, these studies suggest that the induction of apoptosis and cell cycle arrest may play 
a critical role in HS-induced NTDs.   Using p53-deficient mice, our previous study 
showed that the deletion of p53 alleles induces the sensitivity to NTDs, therefore p53 
acting as a teratogen suppressor.  To explore the role of p53 in the regulation of 
apoptosis and NTDs, we assessed the induction of apoptosis and p53 target genes in HS-
treated mouse embryos lacking p53 allele(s).    
HS induced a significant increase in p21, Puma, and Noxa mRNAs, transcripts of 
p53 target genes.   In contrast, HS induced no significant increases in these mRNAs in 
p53-deficient embryos, suggesting that the upregulation of p21, Puma, and Noxa in 
embryos exposed to HS are p53-dependent.   Very preliminary results showed that HS 
induced a higher level of caspase-3 activity assay in p53 +/+ embryos compared to p53 
+/- embryos (p53 -/- embryos not available), indicating that the activation of apoptosis in 
embryos exposed to HS is also p53-dependent.   Together with our previous study that 
p53 +/- and p53 -/- embryos exposed to HS exhibited a higher incidence of NTDs, our 
results suggest that the regulation of the p53 target genes as well as the apoptosis is p53-
dependent, although the induction of apoptosis does not causally link to the NTDs 
observed in embryos exposed to HS.    
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5.2.   INTRODUCTION 
Previously, we showed that HS induces apoptosis in early postimplantation 
rodent embryos by activating the mitochondrial apoptotic pathway. Activation of this 
pathway is characterized by the release of cytochrome c and the subsequent activation of 
caspases, cleavage of poly ADP-ribose polymerase, and DNA fragmentation (Little et 
al., 2003; Little and Mirkes, 2002; Mirkes and Little, 1998, 2000).   To begin to identify 
proteins and signaling pathways that regulate cytochrome c release, we compared gene 
expression patterns in HS-treated and –untreated mouse embryos before and during the 
activation of the mitochondrial apoptotic pathway, using DNA microarray gene 
expression profiling.  Our studies identified five candidate ‘‘apoptosis-related’’ genes 
(Mikheeva et al., 2004). Three of these genes, Mdm2, Gtse1, and Cyclin G, are 
coordinately upregulated by HS during the first 5 hr after embryos are exposed to these 
teratogens. Because these three genes are all p53-regulated genes, our microarray data 
suggested that HS activates p53.  The first study of this thesis (section 2) then showed 
that HS induced the accumulation of p53 and phosphorylation of p53 at ser-15, two 
hallmarks of p53 activation.   HS also induced an increase in Noxa and Puma mRNAs, 
transcripts of two known proapoptotic p53 target genes; however, these two teratogens 
did not induce significant increases in NOXA and PUMA proteins, suggesting that p53 
does not activate the mitochondrial apoptotic pathway by transcriptionally upregulating 
the expression of NOXA and PUMA proteins. HS also induced the expression of p21 
mRNA and protein, suggesting a role for p53 in teratogen-induced cell cycle arrest.   In 
the third study (section 4), we determined whether p53 and/or p21 play a role as 
teratogen suppressors or inducers of HS-induced malformations.  The study showed that 
p53 plays a role in normal development and that p53 and p21 function to suppress HS-
induced malformations.   However, these studies did not examine whether the regulation 
of p53 target genes is p53-dependent or p53-independent and whether there is a causal 
relationship among the activation of p53, induction of apoptosis and cell cycle arrest, 
and the induction of serious malformations including NTDs in embryos exposed to HS.   
Therefore, the objective of the current studies were (1) to assess the p53-dependence of 
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p53 target genes in HS-treated embryos and (2) to determine whether the activation of 
p53, induction of apoptosis and cell cycle arrest, and the induction of NTDs are causally 
linked with each other using p53-deficient mouse embryos.   Our preliminary data show 
that the activation of p21, Noxa, and Puma in embryos exposed to HS is p53-dependent.  
In addition, we show that the induction of apoptosis is, at least from our preliminary 
data, p53-dependent; however, the induction of apoptosis was not causally linked to 
NTDs observed after HS treatment.      
 
 
5.3.   MATERIALS AND METHODS 
Experimental Animals: All animals were maintained in accordance with animal 
use protocol approved by the Institutional Animal Care and Use Committee at Texas 
A&M University.  A pair of p53 +/- mice (a gift of Lawrence A. Donehower, Baylor 
College of Medicine) with C57BL6-Tyrc-Brd background (Zheng et al., 2002) was used 
for breeding.  Mice were kept with freely available pellet food and water at 21-23 ˚C and 
12-h light/dark cycle (6:00-18:00).  Virgin p53 +/- females were cohabited with p53 +/- 
males and checked the following morning for the vaginal plug.  Upon detecting a plug, 
12 a.m. was designated GD 0.   
Hyperthermia Treatment and Fetal Collections: On gestation day 8.5, when the 
embryos are at the most sensitive period to the induction of NTDs (Finnell, 1981), 
pregnant dams were exposed to HS for 10 min at 43 ˚C (or 38 ˚C for a control) in a 
water bath equipped with a thermolegulated heater.  For the HS treatment, each pregnant 
dam was restrained in a 50-ml plastic centrifuge tube with holes drilled on the sides for 
the adequate water circulation and immersed in water up to the lower two-thirds of the 
body as described by Finnell et al. (1986).  A rectal temperature was monitored at 1-
second intervals by Mini-logger and Mini-mitter reader with a small rectal probe 
(Respironics, Bend, OR) so that the rise in rectal temperatures is approximately the same 
rate for all animals (38 °C at min 0, 39 °C at min 1, 40 °C at min 2, 41 °C at min 3, 42 
°C at min 4, 42.5 °C at min 5, and 42.8 °C at min 6, and 43 °C for min 7-10).  The 
treated dams were removed from the centrifuge tube, quickly dried with paper towels, 
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and placed in an incubator set at 38 °C to minimize the recovery differences of 
individuals.  Their temperature was continually monitored until the baseline temperature 
was reestablished.   
Embryo Collections and Genotyping PCR: Embryos were explanted 5 hr after 
the exposure, and their yolk sac was separated in ice-cold Hanks’ balanced salt solution 
on GD 8.5.  Each embryo was placed in a separate PCR tube with RNAlater (Ambion, 
Austin, TX) for RT-PCR or quickly flash frozen using liquid N2 for caspase-3 activity 
assay and stored at -80 °C until use.  The yolk sac dissected from each embryo was put 
in a PCR tube with 7.5 µl of tail lysis buffer (25 mM NaOH and 0.2 mM EDTA), and 
heated at 95 °C for 20 min. The same volume of Tris-HCl (40 mM) was added to the 
tube, and 3 µl of the yolk sac sample was used for p53 genotyping of its matching 
embryo.  Primers used for PCR genotyping were: p53 forward primer (in the intron 1): 
5’-GTGTGTGAAATGGTGGATGG-3’, p53 reverse primer (in the intron 3/4): 5’-
AGGTGATGGCTGTGGATG-3’, puro forward primer: 5’-
ATGACCGAGTACAAGCCCAC-3’, and the puro reverse primer: 5’- 
GCGTGAGGAAGAGTTCTTGC-3’.  The expected length of each band was 1147 bp 
for p53 and 166 bp for puro gene.  The PCR program consisted of one cycle of 2 min at 
95 ˚C, 40 cycles of 40 s at 95 ˚C, 40 s at 65 ˚C, and 60 s at 72 ˚C, followed by one cycle 
of 7 min at 72 ˚C.  Samples were visualized on a 1.5% agarose electrophoresis gel after 
staining with ethidium bromide. 
Total RNA Preparation and Quantitative Real-Time PCR: Based on the PCR 
results, 3-7 embryos of similar genotype from multiple litters were pooled in RNAlater 
to obtain quadruplicate samples of each of three genotypes.  Total RNA was extracted 
from each sample using mirVana™ miRNA Isolation Kit (Ambion) according to the 
manufacturer’s instructions.  Concentration and quality of the total RNA were assessed 
using a Nanodrop (Nanodrop, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent 
Technologies, Waldbronn, Germany), respectively.  The RNA samples were stored at -
80 ˚C until analyzed.   Total RNA (1-10 µg) was reverse-transcribed using 25 ng/µl 
oligo(dT)15 primer and 9.6 µM random hexamers by heating at 65 °C for 5 min, 
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followed by cooling on ice.  The mRNA was then copied into cDNA by 300 U 
SuperScript II RNase H¯ reverse transcriptase, 1st strand buffer, 10 mM DTT 
(Invitrogen, Carlsbad, CA), and 30 U RNase block (Qiagen, Valencia, CA) and 
incubated at 37 °C for 1 hr.  The reaction was terminated by placing at 90 °C for 5 min 
and then brought to 4 °C and stored at -80 °C until ready to use.  Subsequently, 1 µl 
cDNA was added to 96-well fast plate with master mix (Applied Biosystems, Foster 
City, CA) and TaqMan probe to carry out fluorogenic 5’ nuclease assays (TaqMan) 
using 7500 Fast Real-Time PCR System (Applied Biosystems).  Pre-designed probes of 
the selected genes were purchased from Applied Biosystems, and relative quantification 
was performed using ∆∆Ct method.   
Preparation of Samples, BCA Protein Assay, and Caspase-3 Activity Assay: 
Ice-cold cell lysis buffer (Biomol, Plymouth Meeting, PA) was added to each embryo 
frozen (10-30 µg per 10 µl buffer) and the tissue was broken up using a Teflon pestle.  
The sample was kept on ice for 5 min and centrifuged 10 min at 10,000 rpm at 4 °C.  
The supernatant was transferred to a new tube.  The protein concentration was measured 
using BCA™ Protein Assay kit (Pierce, Rockford, IL), and Caspase-3 Cellular Activity 
Assay kit plus (Biomol) was used to quantitate caspase-3 activity of each embryo.  The 
caspase-3 activity was measured every 10 min for 8 hr by a plate reader.     
 
 
5.4.   RESULTS 
Examination of Known p53 Target Genes: To determine whether the 
upregulation of known p53 target genes, p21, Noxa, and Puma are p53-dependent, the 
mRNA expression level of these genes were examined using TaqMan quantitative real-
time PCR method.  Figure 5.1 shows that HS induces a significant increase in p21 
mRNA of p53 +/+ embryos.  In addition, it shows that HS did not induce p21 mRNA 
expression in p53 -/- embryos.   Figure 5.2 shows that significant increases in Noxa and 
Puma mRNA levels after the exposure of p53 +/+ embryos to HS were also observed.  
In addition, it shows that HS did not induce Noxa and Puma mRNA expression in p53 -/- 
embryos. 
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Figure 5.1. p21 mRNA expression in day 8.5 p53 +/+ or p53 -/- mouse embryos receiving no 
treatment (CT) or HS (43 °C for 15 min).  * Indicates a significant difference from CT or/and 
p53 -/- (p<0.05). 
 
 
 
Figure 5.2. Noxa and Puma mRNA expression in day 8.5 p53 +/+ or p53 -/- mouse embryos 
receiving no treatment (CT) or HS (43 °C for 15 min).  * Indicates a significant difference from 
CT or/and p53 -/- (p<0.05).  
 
Examination of Apoptosis: Because of the time constraint and sample 
availability, very limited results are shown in Figure 5.3.   Caspase-3 activity assay from 
3 p53 +/+ and 2 p53 +/- embryos showed that increase of apoptosis in p53 +/+ embryos 
exposed to HS compared to p53 +/- embryos exposed to HS. 
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Figure 5.3. Caspase-3 activity assay in day 8.5 p53 +/+ and p53 +/- mouse embryos receiving no 
HS (43 °C for 15 min).  * Indicates a significant difference from p53 +/+ embryos (p<0.05).  
 
 
5.5.   DISCUSSION 
 The cell cycle related gene, p21, and proapoptotic genes, Noxa and Puma, are 
known target genes of p53.   These target genes are regulated and induced by p53 in 
response to a variety of cellular stresses.  However, these p53 target genes are also 
regulated by other transcription factors, suggesting that they may be upregulated both in 
p53-dependent and –independent manner. For example, the induction of p21, 
independent of p53, was observed following the exposure of human hepatocarcinoma 
cells to ceramide (Kim et al., 2000).  Another study showed that p53-independent 
induction of p21 contributes to the activation of caspases in mycophenolic acid-induced 
apoptosis in insulin-secreting cells (Huo et al., 2004).  In response to ischemia the 
induction of Puma, which mediates apoptosis, was observed independent of p53 (Wu et 
al., 2007).  In our study, the expression level of p21, Puma, and Noxa were not altered 
between p53 -/- embryos in the absence and presence of HS, suggesting that the 
induction of these genes are p53-depenent.   Although the p53-dependent upregulation of 
p21 leads to cell cycle arrest in embryos exposed to HS, whether the p53-dependent 
upregulation of Puma and Noxa are associated with the induction of apoptosis is not 
clear.      
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Our very preliminary data have indicated that a decreased level of apoptosis was 
observed in p53 +/- embryos compared to that in p53 +/+ embryos after HS treatment.  
These preliminary results suggest that although the induction of teratogen-induced 
apoptosis is p53-dependent, the induction of teratogen-induced apoptosis appears not to 
be causally linked to the increased incidence of NTDs.        
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6.   CONCLUSION 
 
Over 1,200 chemical and physical agents are known to cause structural and/or 
functional congenital anomalies in experimental animals (Shepard, 2001).   One of the 
most common birth defects, NTDs, represents a group of serious congenital anomalies 
resulting from failure of neural tube closure during early development.  The etiology of 
NTDs as well as other birth defects is complex and is known to involve both genetic and 
environmental factors.   Although the mechanisms by which teratogens disrupt normal 
development are often not well understood, recent studies have shown that many 
teratogens induce cell death in tissues that subsequently develop abnormally and give 
rise to structural malformations (Knudsen, 1997; Scott, 1977).  In addition, teratogens 
often induce cell death in areas of normal PCD such as CNS, suggesting a mechanistic 
link between PCD and teratogen-induced cell death (Menkes et al., 1970; Milaire and 
Rooze, 1983; Sulik et al., 1988).   Mouse mutants, in which genes known to play a role 
in apoptosis have been deleted, also exhibit abnormal levels of apoptosis associated with 
abnormal development often culminating in structural birth defects (Boya and de la 
Rosa, 2005).   Taken together, these studies indicate that the dysregulation of apoptosis 
is consistently correlated with embryo/fetal lethality and/or birth defects.   
Previously, we showed that HS and 4CP, known animal teratogens, induce 
apoptosis in early postimplantation rodent embryos by activating the mitochondrial 
apoptotic pathway.  Activation of this pathway is characterized by the release of 
cytochrome c and the subsequent activation of caspases, cleavage of PARP, and DNA 
fragmentation (Little et al., 2003; Little and Mirkes, 2002; Mirkes and Little, 1998, 
2000).  Using vital dyes and TUNEL staining, we have also shown that teratogen-
induced cell death is cell specific, that is, some cells in the mouse embryo die, 
particularly in areas of normal PCD, while other cells, often neighboring cells, survive 
(Mirkes and Little, 1998; Umpierre et al., 2001). For example, neuroepithelial cells are 
particularly sensitive to teratogen-induced cell death, whereas mesenchymal cells 
surrounding the neuroepithelium are less sensitive (Umpierre et al., 2001). In contrast, 
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cells of the embryonic heart are resistant to cell death induced by a variety of teratogens 
(Gao et al., 1994; Umpierre et al., 2001).  Although teratogens activate the apoptotic 
pathway in sensitive cells, these hallmarks of apoptosis are not activated in cells of the 
heart (Mirkes and Little, 1998, 2000; Umpierre et al., 2001). These results indicate that 
the mitochondrial apoptotic pathway is blocked in heart cells at the level of the 
cytochrome c release from mitochondria or at some point upstream of cytochrome c 
release.  
The rapid induction of the mitochondrial apoptotic pathway in teratogen-
sensitive neuroepithelial cells and the failure to activate this pathway in teratogen-
resistant heart cells suggest that the embryo must possess factors that regulate the efflux 
of cytochrome c and thereby the activation of the mitochondrial apoptotic pathway. To 
begin to identify proteins and signaling pathways that regulate cytochrome c release, we 
previously compared gene expression patterns in HS- or 4CP-treated and –untreated 
mouse embryos before and during the activation of the mitochondrial apoptotic pathway, 
using DNA microarray gene expression profiling. Three genes, Mdm2, Gtse1, and Cyclin 
G, were coordinately upregulated by both HS and 4CP during the first 5 hr after embryos 
were exposed to these teratogens. Because these three genes are all p53-regulated genes, 
our microarray data suggested that HS and 4CP both activate p53.  
p53 is essential for preventing inappropriate cell proliferation and maintaining 
genomic integrity following a variety of stresses (Harris and Levine, 2005). The level of 
p53 is maintained at a low level in unstressed conditions.  Following a cellular damage, 
p53 undergoes posttranslational modifications, which result in the accumulation and 
translocation of p53, enhanced binding to DNA, and transcriptional activation of its 
target genes.  The protein products of p53 target genes subsequently regulate a number 
of cellular processes, the most well studied being cell cycle arrest and apoptosis.   To 
investigate the roles of p53 in normal development, teratogen-induced apoptosis, and 
birth defects, we conducted several studies, which are described in this dissertation. 
First, we have shown that HS and 4CP activate p53, in part at least, by the 
phosphorylation of p53 at ser-15 between 1 and 2.5 hr after exposure to HS or 4CP.  
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Phosphorylation of p53 at serine-15 is correlated with the stabilization and subsequent 
accumulation of p53.  These results indicated that p53 is activated before HS- and 4CP-
induced release of mitochondrial cytochrome c and activation of the caspase cascade, 
which occur between 2.5 and 5 hr after exposure to these two teratogens (Little and 
Mirkes, 2002; Mirkes and Little, 1998, 2000).   
Published data consistently show that teratogens induce apoptosis in some cells 
of the embryos and not others (Gao et al., 1994; Mirkes, 1985; Mirkes et al., 1985, 1991; 
Thayer and Mirkes, 1995).  In the present studies, we now show that heart cell resistance 
is associated with significant attenuation of the activation of p53 in heart cells. Despite 
the attenuated activation of p53 in heart cells in response to teratogenic exposures, our 
data indicate that both HS and 4CP induce increased levels of p21 in heart cells. These 
results suggest that p53 is activated in the heart and when activated subsequently 
upregulates the expression of p21, thereby arresting heart cells. 
To further investigate the mechanisms by which p53 activates the mitochondrial 
apoptotic pathway in the day 9 mouse embryo, we have examined the protein and 
mRNA expression of p53 target genes.  Our results indicate that HS and 4CP both 
induce increased expression of Noxa and Puma mRNAs, transcripts of proapoptotic 
genes belonging to the Bcl-2 family; however, the increased expression of these mRNAs 
was not coupled with an increased expression of these proteins.   Thus, our data suggest 
that p53-mediated upregulation of NOXA and PUMA proteins is not involved in HS- 
and 4CP-induced activation of the mitochondrial apoptotic pathway.   We speculated 
that 1) should Noxa and Puma play a role in the activation of mitochondrial apoptotic 
pathway, these proteins may be sequestered in the absence of an apoptotic stimulus and 
then activated after an appropriate cell death signal, although we are not aware of such 
published data 2) should NOXA and PUMA proteins not play a role in activating the 
mitochondrial apoptotic pathway in teratogen-exposed mouse embryos, other 
proapoptotic target proteins of p53, for example, BAX, p53AIP, and PIGs may be 
upregulated 3) alternatively, p53 may play a transcription-independent role in teratogen-
induced apoptosis in day 9 mouse embryos exposed to HS or 4CP. 
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We have also examined the mRNA and protein expression of cyclin-dependent 
kinase p21.   Our results have shown that HS and 4CP induce the upregulation of both 
p21 mRNA and protein.  Because p21 is a known p53 target that plays a central role in 
arresting the cell cycle after various genotoxic stresses (Harris and Levine, 2005; Taylor 
and Stark, 2001), our results suggest that cells of the day 9 mouse embryo have activated 
the cell cycle arrest arm of the p53 pathway in response to teratogenic exposures. 
Although we have not shown that HS induces cell cycle arrest in early postimplantation 
rodent embryos, we have shown that phosphoramide mustard, the major teratogenic 
metabolite of 4CP, induces alterations in the cell cycle in postimplantation rat embryos 
(Little and Mirkes, 1992; Mirkes et al., 1989).  Together, these results demonstrate that 
4CP induces alterations in the cell cycle in early postimplantation mouse embryos 
exposed in vitro or in vivo.    
To examine the role of p53 in normal and abnormal embryo at the molecular 
level, we next identified genes and miRNAs whose expressions were modified by 
deletion of p53 in day 8.5 mouse embryos.   Our data show that deletion of both p53 
alleles results in a significant alteration in the mRNA expression of 388 genes.   Among 
the significantly altered genes during the neural tube closure, the majority (77%) are 
down-regulated in the absence of p53 and only 11% of the disregulated genes contain 
putative p53 DNA-binding sites.  Thus, our data suggest that not only the loss of p53 
gene itself and the alteration of expression of p53 target genes but also alteration of 
“downstream” genes could well contribute to the mechanisms of NTDs.   
Interestingly, in p53 -/- embryos the expression of several known p53 target 
genes, for example, Mdm2, Noxa, and Puma, was not altered, whereas a few p53 target 
genes such as p21 and cyclin G1 showed decreased expression, indicating that even in 
normal day 8.5 developing embryos p21 and cyclin G1 are activated and regulated by 
p53.  This also suggests that even in day 8.5 embryos without any stress, p53 is activated 
to regulate specific target genes.  Published research has shown that although a high 
level of inactive p53 protein can be observed during embryogenesis, active p53 protein 
is observed in the developing nervous system (Gottlieb et al., 1997; Komarova et al., 
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1997; MacCallum et al., 1996).  Taken together, it is possible that these cell cycle arrest 
related genes, p21 and cyclin G1, are activated by p53 mainly in the nervous system, 
where cell cycle arrest is important for the control of cell numbers at the time of neural 
tube closure (Copp et al., 2003).  In contrast, expression of pro-apoptotic genes such as 
Noxa and Puma are unchanged, yet these genes are expressed in p53 -/- embryos, 
suggesting that at this embryonic stage, these p53 target genes are not regulated by p53 
but could be regulated by transcription factors other than p53.  Our data collectively 
suggest that at the time of neural tube closure, p53 tightly controls its specific 
transcriptional target genes to activate particular pathways.   
To assess the possible contribution of the altered genes to the induction of NTDs 
, we identified by microarray expression profiling six genes (Csk, Itga3, Jarid2, Prkaca, 
Rarg, and Sall4) known to cause NTDs when they are deleted, that were significantly 
down-regulated in p53 -/- embryos.  RT-PCR analysis to confirm the expression levels 
of these six genes showed decreases in expression; however, these differences were not 
statistically significant.  Nonetheless, our microarray and RT-PCR analysis suggest that 
these six genes may contribute to the NTDs observed in p53 -/- embryos.  Additional 
research is necessary to determine whether any or all of these genes play a causal role in 
the etiology of NTDs in p53 -/- embryos.   Our microarray analysis also identified other 
genes that may contribute to NTDs in p53 -/- embryos including cell cycle-related genes, 
retinoid-related genes, axon guidance-related genes, and ATM-related genes.   
Although it is well known that mRNA transcription and post-transcriptional 
processing are key determinants in the regulation of gene expression, miRNAs have also 
been shown to regulate gene expression in mammals, with about 800 miRNAs currently 
predicted to exist in humans (Bartel, 2004; Bentwich et al., 2005).  Recent studies have 
suggested that miRNAs play important regulatory roles in developmental timing and 
patterning, cellular differentiation, proliferation, organogenesis, and apoptosis (Alvarez-
Garcia and Miska, 2005; Ambros, 2004).   In addition, studies have identified p53 as one 
of the gene that regulates particular miRNAs, miR-34 family in response to DNA 
damage and oncogenic stress (Bommer et al., 2007; Chang et al., 2007; Raver-Shapira et 
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al., 2007; Tarasov et al., 2007).  To investigate whether miRNAs are expressed in early 
organogenesis-stage mouse embryos, whether the expression of miRNAs is altered by 
deletion of p53 alleles, and whether these changes could contribute to NTDs observed in 
p53 -/- embryos, we quantified the expression levels of 368 miRNAs.  Our data showed 
that in day 8.5 mouse embryos three miRNAs, miR-1, miR-142-3p, and miR-301 showed 
statistically significant decrease, and two miRNAs, miR-30e-3p and miR-331, showed 
statistically significant increase in their expression in p53 -/- embryos compared to p53 
+/+ embryos, indicating that these miRNAs might be regulated by p53.   The target gene 
analysis using both our stepwise regression and two publicly available computational 
tools, PicTar and miRBase, further identified putative target genes of these miRNAs that 
are supported by two completely independent approaches.  Further study and a better 
understanding of the function of miRNAs and how they regulate genes are necessary to 
understand the roles of miRNAs in the etiology of NTDs and development.   
The target gene analysis using both our stepwise regression and two publicly 
available computational tools, PicTar and miRBase, further identified putative target 
genes of these miRNAs that are supported by two completely independent approaches.  
Retinoic acid receptor gamma (Rarg), which is a known direct putative target gene of 
p53 that  was significantly down-regulated in p53 -/- embryos, was also shown to be 
regulated by miR-331, which showed increased expression in p53 -/- embryos.  This 
indicates that p53 may synergistically regulate Rarg with miR-331, where the deletion of 
p53 alleles directly up-regulates the expression of miR-331 and down-regulates Rarg, as 
well as the up-regulation of miR-331 contributing further down-regulation of Rarg.   
Finally, to further investigate the role of p53 and p21 in teratogen-induced birth 
defects, the incidence of NTDs was investigated in p53 and p21 null mice exposed to 
HS.  In the absence of HS, we observed that 11% of p53 -/- develop NTDs, i.e., 
exencephaly or spina bifida.  This correlates with our earlier finding that deletion of both 
p53 alleles results in a significant alteration of embryonic gene expression. Following 
the HS exposure, we observed an increased incidence of exencephaly in all p53 
genotypes and in both genders; however, females in all genotypes and p53 -/- fetuses 
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were especially susceptible (47% vs. 16% in +/- and 17% in +/+ fetuses).  The 
predominance of fetuses with exencephaly in females has been previously reported, 
although the biological origins of the predominance of NTDs in females are unclear 
(Armstrong et al., 1995; Sah et al., 1995).  Interestingly, all of the fetuses with spina 
bifida cases were also females.  Together, our results suggest that p53 functions as a 
suppressor of HS-induced exencephaly.  Whether p53 plays a role as a teratogen 
suppressor or inducer has been controversial, although the role of p53 as a suppressor 
has been more favored based on the protective role of p53 following a variety of 
environmental stresses (Choi and Donehower, 1999).  Recent studies have shown that 
p53 functions as a teratological inducer (Boreham et al., 2002; Narai et al., 2006; Wang, 
2001), as well as a teratogen suppressor (Baatout et al., 2002; Bekaert et al., 2005; 
Moallem and Hales, 1998).  Examination of this literature suggests that the role of p53 
differs by the type of teratogen as well as the type of malformations evaluated.  Studies 
that have identified p53 as a teratological inducer have investigated specific 
malformations such as eye defects, limb malformations, and cleft palate (Boreham et al., 
2002; Narai et al., 2006; Wang, 2001; Wubah et al., 1996), whereas most studies that 
have identified p53 as a teratogen suppressor have examined multiple types of 
malformations as well as resorptions (Baatout et al., 2002; Bekaert et al., 2005; Nicol et 
al., 1995; Norimura et al., 1996).  In addition, p53 was a teratological inducer of limb 
malformations following irradiation (Boreham et al., 2002; Wang, 2001), whereas it was 
a teratological suppressor of limb malformations following exposure to 4CP (Moallem 
and Hales, 1998).    
 To investigate whether the deletion of p53 leads to the alteration of apoptosis in 
embryos exposed to HS, we examined the induction of apoptosis using caspase-3 
activity assay in p53 +/- mouse embryos exposed to HS.   Our very preliminary data 
have indicated that a decreased level of apoptosis was observed in p53 +/- embryos 
compared to that in p53 +/+ embryos after HS treatment.  These preliminary results 
suggest that although the induction of teratogen-induced apoptosis is p53-dependent, the 
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induction of teratogen-induced apoptosis appears not to be causally linked to the 
increased incidence of NTDs.        
Although p21 -/- mice develop normally, an increased incidence of exencephaly 
is observed following the exposure to HS. Our earlier findings have shown that the 
expression of both p21 mRNA and protein are upregulated in HS-treated day 8.5 
embryos, suggesting that cell cycle arrest induced by p21 may play an important role in 
the etiology of HS-induced malformations.  Taken together, our results indicate that p21 
also acts as a teratogen suppressor and that the activation of cell cycle arrest induced by 
p21 may partially account for the HS-induced exencephaly observed in p53 -/- fetuses.   
Overall, the studies presented in this thesis showed that in normal embryo 
development p53 tightly regulates and controls cell cycle-related genes at the time of 
neural tube closure.   In embryos exposed to teratogens, p53 activates both cell cycle 
arrest and apoptosis and acts as a teratogen suppressor.  However, our results also 
suggested that the activation of mitochondrial apoptotic pathway may not be causally 
linked to the mechanisms of teratogen-induced NTDs.   Published studies and the studies 
presented here using p53 and p21 null mice suggest that both too much or too little 
apoptosis and cell cycle arrest lead to abnormalities and that precise control of these 
biological pathways are critical for normal neural tube development and the prevention 
of teratogen-induced NTDs.  
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